>>I WOULD LIKE TO CALL THE
JOINT BSA/NCAB MEETING TO ORDER.
WELCOME.
I WOULD LIKE TO WELCOME THE
MEMBERS OF BOTH BOARD OF
SCIENTIFIC ADVISERS AND THE
NATIONAL CANCER ADVISER BOARD
ALSO THE MCAB MEMBERS.
AND BELATED HAPPY THANKSGIVING
TO EVERYONE.
THERE ARE SOME REQUIRED
ANNOUNCEMENTS.
MEMBERS OF THE PUBLIC WHO MAY
WISH TO EXPRESS THEIR VIEWS
REGARDING ANY ITEMS DISCUSSED
DURING THIS MEETING MAY DO SO IN
WRITING TO DR. PAULETTE GRAY WHO
IS THE EXECUTIVE SECRETARY.
WITHIN 10 DAYS AFTER THE
MEETING.
ANY WRITTEN STATEMENTS OR
QUESTIONS WILL BE RECEIVED AND
CAREFULLY CONSIDERED.
AS BOARD MEMBERS I WANT TO
REMIND YOU THAT YOU MUST ABSENT
YOURSELVES VIRTUALLY WHEN YOUR
PARTICIPATION AND DELIBERATIONS
ON A PARTICULAR PRODUCT, PROGRAM
OR OTHER SPECIFIC MATTERS WOULD
CONSTITUTE A CONFLICT OF
INTEREST OR CREATE EVEN THE
APPEARANCE OF ONE.
IT IS INCUMBENT UPON YOU BOARD
MEMBERS TO ADVISE THE EXECUTIVE
SECRETARY DR. GRAY TO OBTAIN
FROM ANY ACTION REGARDING THAT
MATTER.
IN LIGHT OF THE CURRENT POLICIES
GOVERNING CONFLICT OF INTEREST
BASED ON FINANCIAL HOLDINGS OF
SPECIAL GOVERNMENT EMPLOYEES
WHICH INCLUDES ALL MEMBERS OF
BOTH BOARDS WE MUST DEPEND ON
YOU TO VOLUNTARILY ABSENT
YOURSELF DURING ANY AND ALL
DISCUSSIONS OF MATTERS THAT
COULD IMPACT THE STATUS OF THOSE
OF HOLDINGS SO WE TRUST YOUR
JUDGMENT IN THESE INSTANCES.
ALSO DURING ANY CLOSED SESSIONS
WHICH ARE NOT EXPECT TODAY ANY
MATERIALS OR DISCUSSIONS OF A
CONFIDENTIALITY NATURE
DELIBERATED ON TODAY ARE
PRIVILEGED INFORMATION.
AND ARE MADE AVAILABLE TO YOU ON
A NEED NO KNOW BASES.
SUCH DELIBERATIONS ARE PRIVATE
AND THE CONTENTS SHOULD NOT BE
DIVULGED.
SO WE WANT TO FIRST DISCUSS
FUTURE MEETINGS.
THE FIRST ORDER OF BUSINESS WILL
BE FOR THE NCAB TO APPROVE THE
NCAB2023 MEETING DATES SO I
WOULD LIKE TO CALL FOR A MOTION
FROM NC AB MEMBERS TO APPROVE
THE MEETING DATES.
>> SO MOVED.
>> SECOND.
>> THANK YOU.
ANY NAYs OR ABSTENTIONS?
I THINK I HAND THE PODIUM OVER
TO KEITH.
>> THANK YOU, JOHN.
GOOD AFTERNOON, EVERYONE OR
MORNING DEPENDING ON YOUR
LOCATION.
SO WE HAVE A BUSY AGENDA AND WE
ARE RIGHT ON SCHEDULE FOR IT
START WITH DR. SHARPLESS'S NIH'S
DIRECTOR'S REPORT.
SO, I'LL HAND THE MICROPHONE
FIRST TO DR. SHARPLESS.
HOPEFULLY YOU HAVE THE AGENDA IN
FRONT OF YOU AND WE WILL --
WE'LL HAVE A SCHEDULED BREAK
COMING AHEAD FURTHER IN THE
PROGRAM.
THAT DOESN'T COME UNTIL
3:45 P.M. AS A BRIEF WARNING BUT
WE HAVE A NUMBER OF
PRESENTATIONS PRIOR TO THAT
TIME.
SOME OPPORTUNITIES FOR
DISCUSSION AFTER EACH AND 4:00
TO 5:30 REVIEWING CONCEPTS AND
OF COURSE RESUME THAT BUSINESS
TOMORROW.
SO DR. SHARPLESS
>> PAULETTE, BEFORE WE GO TO THE
PRESENTATION SHOULD WE ALSO
APPROVE THE MINUTES?
>> YES.
SORRY.
>> SO WE NEED TO APPROVE THE
SEPTEMBER 1,2021 VIRTUAL MEETING
MINUTES.
DO WE HAVE A MOTION TO APPROVE
THOSE MINUTES
>> SO MOVED.
>> SECOND.
>> OKAY.
I THINK NOW WE CAN MOVE ON TO
DR. SHARPLESS'
>> NO.
JOHN.
WE CANNOT.
YOU ASKED FOR A MOTION FOR THE
NCAB -- MEETING DATES AND YOU
GOT UNANIMOUS YEAS.
WE STILL HAVE TO VOTE ON THE
FUTURE MEETING DATES.
>> I'LL TAKE THAT.
SO CIRCULATED TO ALL OF YOU ARE
OUR PROPOSED 2023 MEETING DATES.
ASSUMING THAT YOU'VE HAD A
CHANCE TO REVIEW THOSE.
CAN I ASK FOR A BSA MEMBER TO
MAKE A MOTION FOR THE APPROVAL
OF THE TO 23 MEETING DATES?
>> SO MOVED.
>> SECOND PLEASE
>> SECOND.
>> AND ANY NAYs FROM ANY OF
THE BSA MEMBERS?
>> THEREFORE IT WAS UNANIMOUS.
I NEED YOU TO INDICATE TO THEM
THE QUORUM ETC.
JOHN.
>> OKAY.
SO QUORUM BY LAW A QUORUM OF
BOARD MEMBERS IS REQUIRED FOR
EACH INSTANCE IN WHICH A VOTE
MAY OCCUR WHETHER IN OPEN OR
CLOSED SESSION.
DURING THIS MEETING A MINIMUM OF
18 APPOINTED MEMBERS MUST BE
PRESENT TO VOICE THEIR VOTES.
SINCE WE CANNOT PREDICT THE TIME
NORO CURE ANC OF ANY MOTION YOUR
PRESENCE IN THE VIRTUAL ROOM FOR
ALL SEGMENTS OF THE MEETING IS A
MUST.
THAT MEANS DON'T RUN OFF AND
TAKE A RANDOM BREAK.
MAKE SURE THAT YOU STAY INVOLVED
IN THE MEETING AT ALL-TIMES.
THUS THE QUORUM AT THAT TIME
WILL BE 9 MEMBERS.
OKAY.
SO WHEN A CONCEPT IS DISCUSSED
WHILE BOTH BOARDS CAN
PARTICIPATE IN THE DISCUSSION
ONLY BSA MEMBERS CAN VOTE.
OKAY.
ON THE DISCUSSION TODAY.
OF THE CONCEPTS.
SO THAT WILL BE 9 MEMBERS.
ADDITIONALLY FOLLOWING THE
SUBCOMMITTEE REPORT TODAY ONLY
NCAB MEMBERS WILL BE COUNTED IN
THE VOTE.
ALL BOARD MEMBERS CAN
PARTICIPATE IN THE DISCUSSION.
OKAY.
BUT ONLY BSA MEMBERS CAN VOTE ON
CONCEPTS AND NCAB MEMBERS WILL
VOTE ON THE SUBCOMMITTEE REPORTS
LATER TODAY.
SO THE QUORUM AT THAT TIME WILL
ALSO BENIGN MEMBERS.
-- BE -- NINE
MEMBERS.
DURING THE CONCEPTS ONLY BSA CAN
VOTE: NINE MEMBERS ARE REQUIRED
FOR A FORUM.
PAULETTE, DO WE HAVE A QUORUM?
>> WE HAVE A QUORUM.
OKAY.
>> SO ALSO MAKE SURE THAT YOU'RE
MUTED.
MEETING ETIQUETTE AND WE HAVE
SOMEONE WHO CAN DO THE UNMUTING
FOR US IF NEED BE.
AND SO I THINK NOW WE CAN MOVE
ON TO TH -- THE NCI's DIRECTOR
REPORT
>> GOOD AFTERNOON, JOHN
I MISS MANY THINGS ABOUT DOING
THIS MEETING IN PERSON.
ONE OF THE THINGS IS WHEN YOU'RE
HAVING TROUBLE GETTING THE
ORGANIZATIONAL DETAILS IN PERSON
PAULETTE CAN FOCUS WITH A STICK.
I APPRECIATE EVERYONE PUTTING UP
WITH US AS MOST OF YOU ARE AWARE
THIS REVIEW OF CONCEPTS AND
DISPERSIONMENTS OF FUNDS IS
REQUIRED BY LAW.
THIS IS A VERY IMPORTANT WORKING
MEETING FOR NCI SO THANK YOU FOR
PARTICIPATING AND YOUR HELP.
I HAVE A PACKED TALK AND WE HAVE
A PACKED AGENDA BUT I ALSO WANT
TO MAKE SURE YOUR QUESTIONS ARE
ANSWERED SO FEEL FREE TO SPEAK
UP AND ASK IF THE PROCESS IS
CONFUSING.
OUR NEXT SLIDE.
SO LET ME BEGIN WITH A HEARTFELT
WELCOME TO OUR NEW MEMBERS SHOWN
HERE.
I DO A LITTLE INTRODUCTION BUT
BECAUSE THERE ARE SO MANY NEW
MEMBERS IN THE INTEREST OF TIME
I'LL JUST SHOW THE NAMES.
I WANT TO THANK KEITH FLAHERTY
FOR TAKING ON THE CHAIR ROLE.
THIS IS AN IMPORTANT JOB.
I TRIED TO RECRUIT KEITH TO JOBS
IN THE PAST.
I WANT TO THANK THE OUTGOING
CHAIR WHO DID A WONDERFUL JOB
AND WE APPRECIATE HER COMMITMENT
TO NCI THROUGH THE YEARS.
WELCOME NEW BOARD MEMBERS AND WE
LOOK FORWARD TO YOUR HELP.
NEXT SLIDE.
WE HAVE A NEW NCAB MEMBERS SHOWN
HERE.
WELCOME TO ALL OF YOU HERE AS
WELL.
AS I SAID THIS IS A BUSY AGENDA.
I THINK SOME OF THE PROCESS CAN
BE A BIT OFF-PUTTING BUT THIS IS
VERY IMPORTANT TO THE NCI.
WE TAKE YOUR COMMENTS AND
FEEDBACK SERIOUSLY AND YOUR
QUESTIONS SERIOUSLY.
AND IF YOU HAVE QUESTIONS THAT
WE ARE UNABLE TO ANSWER PLEASE
LET US KNOW.
AS PAULETTE EXPLAINED YOU CAN
ASK THE NCI FOR MORE INFORMATION
IF YOU DON'T FEEL LIKE YOU HAVE
A FULL UNDERSTANDING.
YOU CAN CALL OR E-MAIL ME OR
OTHER NCI STAFF AND WORK THROUGH
PAULETTE.
THE ADVICE AND CONSENT IS VERY
IMPORTANT TO OUR WORK.
LASTLY -- WE HAVE A FEW MEMBERS
ROTATING OFF FROM THE NCAB.
WE'RE GOING TO DO A SEPARATE --
TODAY.
THAT IS A TREMENDOUS BIT OF
SERVICE TO THE NATIONAL CANCER
INSTITUTE AND THESE STRONG
ADVISORS WILL BE MISSED.
SO WE'RE ABOUT TWO WEEKS FROM
THE 50th ANNIVERSARY OF THE
NATIONAL CANCER ACT OF 1971.
DECEMBER 23rd IS THE ACTUAL
SIGNING DATE.
THE NCI HAS TRIED TO LEAD A
NATIONAL EFFORT AMONG
STAKEHOLDERS TO COMMUNICATE
ABOUT THE IMPORTANCE AND WHAT
HAS HAPPENED DURING AS A RESULT
OF THE NATIONAL CANCER ACT AND
WHERE WE HAVE LEFT TO GO.
WHERE WE STILL NEED TO MAKE
FURTHER PROGRESS.
AND I'VE SPOKEN ABOUT THIS A
LOT.
I DID -- THERE WAS A NICE EVENT
AT THE NIXON LIBRARY WHERE WE
TALKED AND IT HAS BEEN A REALLY
IN SOME WAYS GRATIFYING TO SEE
HOW VISIONARY THE NATIONAL
CANCER ACT WAS.
CREATED THESE NEW AUTHORITIES
AND ADDITIONAL FUNDING FOR
CANCER RESEARCH AND THE SEAR
DATABASE AND THE CANCER PROGRAM
AND CLINICAL TRIAL NETWORKS.
HOW THAT WAS ENVISIONED.
IT'S ALSO IMPORTANT TO REALIZE
THAT IT WAS QUITE NAIVE AND TO
THINK WE WOULD HAVE A CURE FOR
CANCER IN FIVE YEARS AND
CERTAINLY IT HAS TURNED OUT TO
BE A MUCH MORE CHALLENGING
PROBLEM.
SO -- IT'S A REALLY GOOD TIME
WHO SAID ENDING CANCER AS WE
KNOW IT IS COMMITTED.
WE STILL HAVE A WAYS TO GO.
WE'VE BEEN DOING A LOT OF
COMMUNICATION AROUND THE NC I-5
0.
HERE A FEW MORE EXAMPLES.
THE FDA IS DOING A NICE EVENT.
SOON TO TALK ABOUT 50 YEARS OF
CANCER PROGRESS.
AND WE REALLY APPRECIATE THE
SUPPORT.
WE DO NOT BELIEVE THIS IS AN NCI
EFFORT BUT EVERYONE WHO'S
INTERESTED IN CANCER PROGRESS TO
TALK ABOUT WHAT THE NATIONAL
CANCER ACT AS -- HAS MEANT.
IT'S VERY MEANINGFUL TO CONGRESS
TO HEAR THIS COMMUNICATION FROM
THE CANCER STAKEHOLDERS.
THERE IS A REALLY IMPORTANT
SOCIAL MEDIA EVENT GOING ON.
WE'RE ASKING EVERYONE WITH AN
INTEREST IN THIS TOPIC WHO'SING
A SOCIAL MEDIA USER TO POST A
SHORT CLIP OF THEMSELVES TO TALK
ABOUT WHAT ENDING CANCER MEANS
TO YOU AND NOTHING WILL STOP US.
SO I HAVE POSTED MINE AND I'VE
SEEN A FEW OTHERS POSTED ON
Twitter.
AND I THINK IT'S A NICE TIME TO
BE TALKING ABOUT THIS IMPORTANT
WORK AND WHERE WE CAN STILL MAKE
MORE PROGRESS FOR PATIENTS.
SO I HOPE YOU WILL TAKE THE TIME
TO DO THAT.
WE HAD RECENT VISIT TO THE NIH
FROM PRESIDENT BIDEN.
THIS VISIT -- WAS WIDELY COVERED
IN THE MEDIA LARGELY FOCUSED ON
THE NIH WORK RELATED TO COVID.
I THINK BEFORE OUR PRIOR BOARD
MEMBERS I TALKED ABOUT THE NCI
PORTFOLIO RELATED TO CORONAVIRUS
RESEARCH INCLUDING THE SCIENCES
NETWORK AND WORK AT FREDERICK
NATIONAL LAB RELATED TO
UNDERSTANDING CANCER OUTCOMES OF
CORONAVIRUS OUTCOMES IN CANCER
PATIENTS.
I WANT TO REMIND YOU THAT IT WAS
SUPPORTED BY A SPECIAL
APPROPRIATION FROM CONGRESS IN
2020.
SO THE WORK THAT WE'VE DONE HAS
BEEN SUPPORTED BY SEPARATE
MONIES.
IT'S NOT THE CANCER SUPPORT THAT
WE GET.
IT'S AN ADDITIONAL FUNDING.
WE LEARNED THAT THE NCI IS BEING
ASKED TO CONTINUE RESEARCH AS
PART OF NEW INITIATIVES FUNDED
BY THE AMERICA'S RESCUE PLAN.
FOR ACTIVITIES TO DETECT
DIAGNOSE AND TRACE AND MITIGATE
THE SPREAD OF COVID-19.
$63 MILLION TO THE NCI TO
ADDRESS TWO ADDITIONAL
PRIORITIES.
-- JUST WILL INCLUDE DEVELOPING
SEAR LOGICAL ASSAYS -- * ALSO
WORK TO DEVELOP REFERENCE
MATERIALS THAT SUPPORT VACCINE
TRIALS AND LICENSING AND OTHER
THERAPEUTIC DEVELOPMENT.
ALSO SURVEILLANCE STUDIES IN
SPECIAL COMPROMISED POPULATIONS
INCLUDING CANCER PATIENTS.
THIS NEW $63 MILLION IS SEPARATE
MONIES.
IT WILL NOT COMPETE WITH
EXTRAMURAL RESEARCH PRIORITIES.
COORDINATING THIS WORK AND
WORKING COLLABORATIVELY WITH
PARTNERS SO THOSE OF YOU WHO
KNOW ABOUT OUR ACTIVITIES
REALIZE THAT THIS IS A
SIGNIFICANT AMOUNT OF WORK.
THE NCI REMAINS CANCER FOCUSED:
THAT IS OUR DAY JOB BUT GIVEN
OUR CAPABILITIES -- WE'RE REALLY
EAGER TO TAKE ON THIS RESEARCH
AND GRATEFUL FOR THE TRUST
PLACED IN US BY CONGRESS AND BY
HHS TO GET THIS IMPORTANT
SCIENCE DONE BUT NOT TO WORRY.
WE REMAIN LASER FOCUSED ON
CONCERT RESEARCH AND ENDING
CANCER AS WE KNOW IT IS A STATED
TOP PRIORITY FOR THIS
ADMINISTRATION AND WE'RE WORKING
CLOSELY ON NEW CANCER PLANS SO
STAY TUNED.
ALONG THOSE LINES WE -- HAVE A
NEW PERSONNEL DEVELOPMENT.
DR. HENRY RODRIGUEZ -- WILL HELP
ADVANCE INNOVATIONS FOR ALL
AMERICANS.
HE HAS MANY YEARS OF PUBLIC
HEALTH AND RESEARCH SERVICE AND
WILL DO A GREAT JOB.
HE IS ON DETAIL AT THE WHITE
HOUSE WHERE HE HAS BEEN AN
IMPORTANT LEADER.
GREAT TO HAVE HENRY HELPING WORK
ON THIS AS WELL.
ONE OF THE THINGS TO BE TALKING
ABOUT IS GIVEN THAT THE
PRESIDENT'S PRIORITY IS TO END
CANCER AS WE KNOW IT WHAT DOES
THAT MEAN?
SO IN THINKING ABOUT THE PAST 50
YEARS AND THE PROGRESS WE'VE
MADE IT'S ALSO USEFUL TO THINK
ABOUT WHERE WE NEED TO GO TO
MAKE FURTHER PROGRESS FOR
PATIENTS AND IT INVOLVES ASKING
OURSELVES HOW DO WE KNOW CANCER
TODAY?
WHAT IT MEANS TO END CANCER AS
WE KNOW IT AND THAT WOULD WOULD
TAKE?
THERE IS NO MENTION OF
ERADICATING ALL CANCER.
WE DON'T THINK THAT IS POSSIBLE.
IN SOME WAYS IT'S A BIOLOGICAL
ACT OF AGING.
HOWEVER WE BELIEVE THAT WE CAN
DO A TREMENDOUS AMOUNT TO
ADDRESS THE TRAGEDY AND BURDEN
OF CANCER AND CHANGE IT TO
SOMETHING THAT IS MUCH MORE
MANAGEABLE PROBLEM FOR US IN THE
FUTURE.
SO THIS IS A WAY THAT WE'VE BEEN
THINKING ABOUT IT WITH THE WHITE
HOUSE AND HERE ARE STATEMENTS
THAT ARE TRUE TODAY ABOUT CANCER
THAT WE WOULD LIKE TO MAKE
UNTRUE AND BY MAKING THEM UNTRUE
WE WOULD BE CHANGING HOW WE KNOW
CANCER AND ENDING CANCER AS WE
KNOW IT TODAY.
I'VE SPOKEN A LOT ABOUT THE
METRIC OF MORTALITY.
ABOUT HOW CANCER KILLS 600,000
AMERICANS IN THE UNITED STATES.
THAT RATE OF MORTALITY HAS BEEN
DECLINING.
FOR MANY YEARS BUT THE RATE HAS
BEEN ACCELERATING IN RECENT
YEARS AND WE BELIEVE IT COULD BE
ACCELERATED FURTHER THROUGH A
NUMBER OF REASONABLE MEASURES.
BUT MORTALITY IS ONLY ONE PRISM.
THERE ARE MANY OTHER WAYS TO
THINK ABOUT CANCER AS WELL SO
HERE ARE SOME OTHER STATEMENTS.
WE HAVE TOO FEW WAYS TO PREVENT
CANCER.
WE HAVE TREATMENTS THAT ARE
EFFECTIVE BUT ARE QUITE TOXIC.
WE HAVE PATIENTS THAT ARE
STYMIED BY THE COMPLICATED
LOGISTICS OF CANCER CARE.
THESE ARE NOT THE ONLY
REPRESENTATIVE STATEMENTS.
THESE ARE JUST A FEW OF THEM.
BUT I THINK THIS LIST IS A GOOD
PLACE TO START AND THIS FRAMING
IS A USEFUL WAY TO IDENTIFY WHAT
WE KNOW ABOUT CANCER TODAY AND
HOW WE WOULD LIKE TO CHANGE THAT
FOR THE BENEFIT OF OUR PATIENTS
IN THE FUTURE.
IT'S A HELPFUL WAY TO LOOK AT
THE PROBLEM.
HOW WOULD WE GO ABOUT THIS?
AND WE BELIEVE THAT WE CAN
APPROACH THIS THROUGH SIX BROAD
THEMES.
THAT WILL BE MORE SENSE, IN THE
YEARS AHEAD.
BUILDING ON THE DECADES OF
PROGRESS.
THE BASIC SCIENCE AND
UNDERSTANDING OF CANCER.
DO ACTIVITIES TO PROMOTE AND
ADVANCE HEALTH EQUITY.
THE PARADIGM OF PERSONALIZING
CANCER CARE.
WE HAVE TO EMBRACE TECHNOLOGY
AND INNOVATION INCLUDING
TECHNOLOGIES THAT INCLUDE US TO
LEARN FROM EVERY PATIENT.
COMMITTED TO TRAINING TO INSPIRE
THE NEXT GENERATION OF CANCER
RESEARCHERS AND PURPOSEFULLY
LOOK AROUND THE CORNERS AND
PREPARE FOR THE CHALLENGES IN
THE FUTURE OF CANCER RESEARCH.
YOU CAN SEE MANY OF THESE
EFFORTS ARE INNER WOVEN AND
OVERLAPPING BUT THIS IS A
FRAMEWORK THAT IS -- INCLUDES
KEY FOCUSES OF THE NCI GOING
FORWARD.
SO THIS IS A SLIDE I SHOW AT
EVERY BOARD MEETING.
IT IS THE NCI APPROPRIATION
TRENDS OVER THE LAST FEW YEARS.
THE NCI HAS ENJOYED ROBUST
SUPPORT FROM CONGRESS IN TERMS
OF INCREASING FUNDING EVERY
YEAR.
THIS REFLECTS A BROAD BIPARTISAN
SUPPORT IN THE U.S. CONGRESS.
A GOOD USE OF FEDERAL MONIES AND
THE RETURN ON INVESTMENT HAS
BEEN QUITE STRONG.
THE ORANGE BARS ARE 2017.
THAT IS THE CANCER MOONSHOT.
THAT IS $1.8 BILLION OVER SEVEN
YEARS.
THE GREEN BAR IN 2020.
THE CHILDHOOD CANCER INITIATIVE.
A $50 MILLION PER YEAR.
TO TRY TO RADICALLY USE DATA
DIFFERENTLY FOR CHILDHOOD
CANCER.
THERE IS ALSO THE WHITE BOX IN
21.
THE SPECIAL APPROPRIATION FOR
COVID RESEARCH DONE AT THE NCI
AND THEN TWO LIGHT BLUE BARS AND
THOSE ARE THE PRESIDENT'S BUDGET
AND THE 2022 HOUSE MARK FOR OUR
APPROPRIATION.
THE SAVVY IF YOU WILL NOTE THAT
WE'RE WELL INTO DECEMBER -- WE
DO NOT HAVE A BUDGET YET FOR
2022.
THE NCI IS OPERATING UNDER A
CONTINUING RESOLUTION.
IT HAS BEEN EXTENDED UNTIL
FEBRUARY 18.
THAT IS A CHALLENGING SITUATION.
WE DON'T HAVE CLARITY SO MAKING
COMMITMENTS ARE DIFFICULT.
LET ME MAKE ONE FINAL POINT.
THE NCI BUDGET IS LARGE.
I THINK MANY OF YOU PARTICULARLY
THOSE OF YOU WHO MAY BE NEW TO
COUNCIL WILL THINK $6.6 BILLION
IS A LOT OF MONEY.
AND IT IS INDEED.
BUT THE RETURN ON INVESTMENT IN
CANCER RESEARCH IS VERY HIGH.
THAT IS A FACT.
IF YOU LOOK AT THE ADVANCES IN
CANCER PROGRESS AND THE
DIAGNOSTICS.
CANCER RESEARCH IS A PUBLIC
INVESTMENT THAT WORKS.
THE BURDEN IS SIGNIFICANT.
600,000 DEATHS PER YEAR.
HUGE COSTS OF TREATMENT.
AND COST IN TERMS OF LOSS OF
PRODUCTIVITY AND OUT OF POCKET
COST TO PATIENTS SO GIVEN THE
TREMENDOUS SOCIETAL COST IT'S A
FAIR QUESTION TO ASK IS IS THIS
THE RIGHT AMOUNT TO BE SPENT.
KEEP THAT IN MIND.
HERE ARE INTERIM PAY LINES FOR
WHILE WE HAVE TO OPERATE UNDER A
CONTINUING RESOLUTION.
CRs COME WITH CERTAIN
CHALLENGES FOR ANY GOVERNMENT
TRYING TO MAKE A BUDGET.
THE FIRST CR WAS FUNDED THROUGH
DECEMBER 3rd AND NOW WE'RE
IN TO A SECOND CR THAT GOES TO
FEBRUARY.
WE WON'T KNOW HOW MUCH FUNDING
WE'LL HAVE UNTIL THE BUDGET IS
PASSED.
IT IS EVEN TECHNICALLY POSSIBLE
THAT WE COULD HAVE A FULL YEAR
CONTINUING RESOLUTION WHICH
MEANS WE WOULD OPERATE UNDER THE
2021 BUDGET.
THAT WOULD BE A SIGNIFICANT
CHALLENGE.
BECAUSE OF THIS UNCERTAINTY WE
HAVE TO BE VERY CONSERVATIVE IN
OUR PLANNING AND THESE PAY LINES
ARE QUITE CONSERVATIVE.
KEEPING IN MIND IT WAS 11th IN
2021.
AND 14th PERCENTILE FOR
ESIs.
NOW I THINK ALL OF US AGREE THAT
A 90% CUT IS TOO HIGH.
AND WE HAVE EVERY HOPE AND
EXPECTATIONS THAT WE WILL BE
ABLE TO INCREASE THAT FURTHER
ONCE WE GET BUDGETARY CLARITY.
BUT IT'S PARTICULARLY COMPLEX
YEAR GIVEN THAT THE BUDGET
CONTROL ACT HAS EXPIRED.
SO BECAUSE OF THAT UNCERTAINTY
WE'RE THEREFORE ADOPTING THIS
CONSERVATIVE APPROACH.
SOME OF YOU MAY BE WONDERING WHY
THEY ARE SO LOW TO BEGIN WITH.
THIS QUITE LOW COMPARED TO OTHER
NIH's.
WE'VE HAD A LOT OF DISCUSSION.
AND THE MAIN LET ME SUMMARIZE BY
SAYING THE MAIN DRIVER HAS BEEN
A MASSIVE INFLUX OF NEW
APPLICATIONS.
THE NCI HAS SEEN A GREATER
INCREASE IN REQUEST FOR FUNDING
THAN THE REST OF THE NIH.
SO, THAT IS IN SOME WAYS A GOOD
PROBLEM.
IT'S A SIGN THAT OUR FIELD IS
VIBRANT.
INDIVIDUALS ARE COME TOGETHER
NCI WITH NEW TECHNOLOGIES AND
APPROACHES AND WAYS TO ADDRESS
CANCER.
BUT THIS INTENSE COMPETITION FOR
FUNDING IS NOT GOOD FOR
LONG-TERM CANCER RESEARCH AND
THE PROSPECTS FOR NEW
RESEARCHERS COMING TO OUR FIELD
AND MAKING A CAREER AS A CANCER
RESEARCHER.
SO PRIORITY HAS BEEN TO IMPROVE
PAY LINES.
WE WERE AS LOW AS 8%.
GOT IT UP TO 11% LAST YEAR.
OUR GOAL IS 15th PERCENTILE.
BUT THE ONLY WAY TO DO THAT IS
WITH ROBUST SUPPORT FROM
CONGRESS.
LET ME UPDATE ON A FEW PRIORITY
ISSUES.
THE CHILDHOOD CANCER INITIATIVE.
WE'RE WELL INTO YEAR TWO OF
THIS.
IT'S CREATING A REAL SET OF
INFRASTRUCTURE FOR DATA SHARING
AND A REAL COMMUNITY COMMITTED
TO DOING THIS.
AND I THINK WHAT WE LEARNED IN
THE CHILDHOOD CANCER SETTING
WILL BE I APPROVING GROUND WITH
HOW WE SHARE AND AGGREGATE DATA
FOR ALL OF CANCER RESEARCH.
WE HELD A SYMPOSIUM.
IT WAS WIDELY ATTENDED AND THE
VIDEO IS ON-LINE AND QUITE
IMPRESSIVE FOR THOSE OF YOU WHO
WANT TO SEE THE DISCUSSION.
WHERE THIS INITIATIVE HAS MADE
PROGRESS AND THINGS THAT WE'RE
STILL IN THE WORKS.
I WANTED TO HIGHLIGHT TWO PARTS.
THE FIRST IS MOLECULAR CARIBBEAN
PROTOCOL.
* MOLECULAR CHARACTERIZATION FOR
ALL CHILDREN WITH CANCER.
MANY PATIENTS ARE ALREADY
GETTING SEQUENCING DONE AT
ACADEMIC CENTERS AND MANY DON'T
REQUIRE SEQUENCING BUT FOR THOSE
WHO ARE NOT GETTING SEQUENCING
DONE WE WANT TO SET A MINIMUM
FLOOR FOR WHAT WE THINK IS THE
ANALYSIS.
THAT PROJECT IS WELL UNDERWAY.
WHERE THE NCI WOULD SUPPORT THE
SEQUENCING OF THESE PATIENTS IN
AN A CREDITED WAY.
IT COULD BE RETURNED TO THE
PATIENT AND PHYSICIAN AND BE
USED FOR CLINICAL DECISION
MAKING.
THE PROJECT WILL BEGIN WITH A
FEW DISEASE TYPES BUT OUR GOAL
IS TO EXPAND THIS BEYOND JUST
THOSE TUMOR TYPES TO ANY TYPE OF
CANCER.
WE HAVE A VENDOR SELECTED.
WE EXPECT WE WILL BE ABLE TO
LAUNCH THIS THE FIRST CHILD THIS
SPRING.
PERHAPS AS SOON AS APRIL.
WE'RE GEARING UP TO IMPLEMENT
THE HANDLING OF THESE SPECIMENS.
WE'VE AMENDED THE PROJECT -- TO
INCLUDE THE MOLECULAR PROTOCOL.
ALSO THINKING ABOUT WAYS THAT WE
CAN ACCEPT SAMPLES FROM CHILDREN
NOT TREATED HERE.
AND WE WILL BE TARGETING UP TO
3,000 PATIENTS A YEAR STARTING
THIS SPRING.
THE NATIONAL CHILDHOOD CANCER
REGISTRY.
THIS IS AN INNOVATIVE IDEA THAT
WE CAN COLLECT AND LINK
INFORMATION ON CHILDREN WITH
CANCER FROM DISPARATE SOURCES
AND MAKE THOSE DATA AVAILABLE TO
THE RESEARCH COMMUNITY IN A WAY
THAT IS VALUABLE.
SEAR MEDICARE HAS BEEN VERY
SUCCESSFUL.
FOR THAT REASON WE HAVE A NEW
EFFORT THAT WE'RE FOCUSED ON
REGISTRY INFORMATION AND
NATIONAL CHILDHOOD CANCER.
IT'S RECENTLY LAUNCHED A TOOL
THAT IS A WEB BASED APPLICATION
PRESENTING CHILDHOOD CANCER
STATISTICS.
IT'S BASED IN MANY WAYS ON NCCR
DATA.
IT PROVIDES ACCESS TO THESE DATA
AND WAYS TO VISUALIZE THEM AND
THIS IS AN AREA WHERE WE ARE --
HAVE GRAND PLANS TO LINK FURTHER
DATASETS AND MAKE MORE DATA
AVAILABLE FOR RESEARCH.
TO SEE WHAT HAPPENS TO CHILDREN
WITH CANCER IN THE REAL WORLD
WHO MAY BE TREATED BY TRIALS.
>> ABOUT THREE WEEKS AGO
REPRESENTATIVES OF BOTH NATIONS
HAD A GREAT MEETING TO VIRTUALLY
IDENTIFY OPPORTUNITIES FOR
COLLABORATIVE EFFORTS AIMED AT
THIS GOAL OF ENDING CANCER AS WE
KNOW IT.
THE SIX TOPICS ARE THE
STATEMENTS THAT WE WOULD LIKE TO
MAKE UNTRUE.
CANCER PREVENTION.
DISPARITIES AND HEALTH EQUITY.
THE NEED FOR BETTER INFORMATION.
A QUEST FOR BETTER PATIENT
OVER-ALL SURVIVAL SO A REALLY
INTERESTING SET OF DISCUSSIONS.
I FOUND SOME OF THE TOPICS
FASCINATING.
THE DISCUSSION OF HEALTH
DISPARITY RESEARCH.
THERE IS SOME PROBLEMS THAT ARE
SIMILAR.
SOME THINGS THAT ARE DIFFERENT.
I THINK THIS IS A REAL
OPPORTUNITY TO LEARN AND DO SOME
GREAT SCIENCE GOING FORWARD.
THE PLAN IS TO HAVE A LEADERSHIP
SUMMIT THIS SPRING AND IN THE
MEANTIME WE'RE GOING TO WORK ON
DELIVERABLES TO DEVELOP THOSE
AND ANNOUNCE THAT IN THE SPRING.
ONE AREA WHERE THERE HAS BEEN
INVOLVEMENT A LOT OF DISCUSSION
GOING ON IS THE TOPIC OF
ENVIRONMENTAL CAR CERTAIN
BEGINS.
-- * CAR CERTAIN BEGINS.
-- -- AND SO IT SEEMS TO ME LIKE
THIS PROBLEM IS MORE CHALLENGING
AND MORE COMPLEX AND THERE IS A
REAL PUBLIC HEALTH RESEARCH NEED
IN THIS AREA BECAUSE OF NEW DATA
AND NEW APPROACHES BUT ALSO NEW
TOXIC CHEMICALS IN THE
ENVIRONMENT THAT MAY BE
SIGNIFICANT TO AMBIENT
ENVIRONMENT IN DIET AND DRINKING
WATER.
BREAST CANCER REMAINS A COMMON
CAUSE -- A COMMON CANCER IN
WOMEN.
AND RECENT EVIDENCE POINTS TO --
RACIAL -- AND WE THINK THAT
ENVIRONMENTAL CAR CERTAIN AGAIN
ENVIRONMENT -- CAR SIN BEGINS.
-- THERE ARE NEW AND EXCITING
TECHNOLOGIES THAT WE NEED TO BE
FURTHER STUDIED.
WE NEED NEW THINKING IN THIS
AREA AND I AGREE WITH THAT.
THE STUDIES HAVE SERVED US WELL
BUT WE CAN DO MORE NOW WHERE WE
HAVE THINGS LIKE MUTATIONAL
SIGNATURES AND THE ABILITY TO
AGGREGATE BIG DATA AND OTHER
SYSTEMS THAT THIS NEW SCIENTIFIC
POSSIBILITY NEEDS TO BE
CONSIDERED AND NONE OF THIS
DISCUSSION WAS UNIQUE TO BREAST
CANCER.
THIS APPLIED TO ANY CANCER WHERE
THERE IS AN INTEREST IN
ENVIRONMENTAL CARCINOGENS AND
THIS IS A TOPIC OF INTEREST.
STAY TUNED.
THERE WILL BE MORE INFORMATION
COMING OUT OF THE NIH SOON.
THIS YEAR THE LUNG CANCER
SCREENING RECOMMENDATIONS.
THIS IS AN INTERESTING PAPER.
TO EVALUATE THE EFFECT OF THOSE
REVISIONS AND IT MAKES AN
INTERESTING POINT IS THAT LUNG
CANCER SCREENING IS FAR UNDER
UTILIZED.
THERE IS ALSO A REAL POSSIBILITY
TO COUPLE TOBACCO SESSION SAYS
PROGRAMS WITH LUNG CANCER
SCREENING THAT COULD BE
IMPACTFUL.
EVEN IF WE DON'T GET LUNG CANCER
SCREENING UP TO A 40-50
PERCENTILE BUT COUPLE IT THAT
COULD MAKE AN IMPACT.
HOW FAR TO ADD IN TOBACCO
CESSATION AND COUPLE THAT.
I WANT TO POINT OUT IN THIS
APPROVAL -- FOR RENAL CELL
CARCINOMA.
THIS IS WORTH MENTIONING FOR
LOTS OF REASONS.
IT'S A QUITE ACTIVE DRUG IN
ADVANCED RENAL CANCER.
BUT ONE IMPORTANT POINT TO MAKE
ABOUT THIS AGENT IS THAT THE
BACK GROUND SCIENCE FOR THIS WAS
HEAVILY SUPPORTED BY THE
NATIONAL CANCER INSTITUTE.
THEY'VE BEEN WORKING ON RENAL
CANCER AND MADE PARADIGM
CHANGING DISCOVERIES IN THIS
FIELD AND OUR EXTERNAL FUNDIES
-- WON THE NOBEL PRIZE -- SO
THIS IS A STORY THAT IS ELEGANT
BASIC SCIENCE THAT TRANSLATES
INTO AN AGENT FOR PUBLIC GOOD.
I TELL THESE SORTS OF STORIES
ALL THE TIME.
HOW -- DRUGS -- WHICH CAN CURE
SOME PEOPLE.
AND I TALK ABOUT HOW THE WORK
LED TO APPROACHES AND HOW
VALUABLE THEY'VE BEEN.
THEY START WITH A -- R01.
WE HAVE TO CAN BE THE CRITICAL
ROLE OF BASIC SCIENCE.
IT'S SOMETIMES A HARD ARGUMENT
TO MAKE TO CONGAS TO WHY WE
STILL NEED THE SUPPORT AT NCI.
* AND THAT LEADS TO A NEW GREAT
APPROACH TO CANCER IN HUMANS.
NEXT SLIDE.
VERY INTERESTED IN THE TOPIC OF
TUMOR VACCINES.
A LOT OF DISCUSSION ABOUT
PREVENTIVE CANCER VACCINES
ACROSS THE FEDERAL GOVERNMENT.
THIS IS SOMETHING THAT CAME UP
IN THE U.S./UK CALL.
WE HAVE TWO TRIALS NOW GOING.
THE FIRST IS A TRIAL IN LYNCH
SYNDROME.
IT CREATES CHARACTERISTIC
ANTIGENS.
AND THOSE CAN THEN BE THE
SUBSTRATE FOR A VACCINE.
A PREVENTIVE VACCINE FOR
INDIVIDUALS AT HIGH RISK FOR
COLON CANCER AND THIS IS A TRIAL
THAT HAS RECENTLY I THINK IT WAS
EXPECT TO START THIS QUARTER.
ADDITIONALLY HERE IS A MORE
TARGETED TRIAL FOR PATIENTS AT
HIGH RISK OF PANCREATIC CANCER.
LIZ IS THE PI OF THE TRIAL AND
ALSO AN EXCITING APPROACH.
THE TOPIC OF PREVENTIVE RACK
SCENES FOR CANCER IS ONE THAT
WE'RE INTERESTED IN EXPLORING.
PEDIATRIC MATCH IS WELL
UNDERWAY.
THIS IS AFTER DECEMBER 31.
THE PROCESS WILL CHANGE AND
SCREENING WILL BE DONE THROUGH
COMMERCIAL LABS.
SO UP UNTIL THAT PERIOD NCI HAD
BEEN DOING A LOT OF THE
SEQUENCING FOR MATCH.
ADULT MATCH IS NOW LARGELY
CLOSED AND WE'RE THINKING ABOUT
WHAT COMES NEXT FOR THE ADULT
MATCH TRIAL BUT PEDS MATCH IS
STILL GOING ON AND THERE ARE SIX
STUDY ARMS GOING ON.
AND NOW THE SEQUENCING IS MORE
AVAILABLE THROUGH COMMERCIAL
SOURCES.
THE LAST THING IS WITH THE
SUPPORT OF THE NCI EQUITY
COUNCIL WE'RE LAUNCHING AN EARLY
INVESTIGATOR PROGRAM TO BECOME
INDEPENDENT RO1 SUPPORTED
INVESTIGATORS.
THE NEED FOR CANCER RESEARCH
ENTERPRISE FOR CONTINUOUS FLOW
OF TALENT THROUGH THE PIPELINE.
EACH YEAR THE EIAP WILL SUPPORT
THE CAREER DEVELOPMENT OF
QUALIFIED INVESTIGATORS.
PROVIDE ACCESS TO MENTORING.
APPLICATIONS MUST BE SUBMITTED
BY DECEMBE 31,2021.
THIS IS ONE OF MANY INITIATIVES
THAT HAS COME OUT OF THE EQUITY
AND INCLUSION PROGRAM.
I THINK AS I SAID PROMOTING
HEALTH EQUITY THROUGH EVERYTHING
THAT WE DO IS A TOP PRIORITY.
SO THAT CONCLUDES MY PREPARED
REMARKS AND LET AND SEE IF THERE
ARE ANY QUESTIONS AND THANK YOU
FOR THE OPPORTUNITY TO SPEAK
TODAY.
>> PLEASE USE --
>> QUICK QUESTION FOR YOU ABOUT
THE PAY LINISH.
9% VERY DISCOURAGING.
WILL YOU BE ABLE TO GO BACK TO
RBGs THAT ARE FUNDED BETWEEN 9
AND 11% WHEN THE BUDGET IS
PASSED
>> 9 IS TEMPORARY.
SO AS MK WILL DESCRIBE THE 2022
BUDGET IS THE MOST CONFUSING IN
MY TIME IN GOVERNMENT.
WE -- THE TWO NUMBERS THE
PRESIDENT'S NUMBER AND THE HOUSE
NUMBER ARE LIKE $200 MILLION
APART.
A SUBSTANTIAL DIFFERENCE.
SO WE HAVE A LOT OF UNCERTAINTY
ABOUT WHAT IS GOING TO HAPPEN
THIS YEAR SO THE 9% IS A VERY
CONSERVATIVE NUMBER.
BUT WE HOPE AND EXPECT TO DO
BETTER THAN THAT ONCE WE KNOW
WHAT OUR APPROPRIATION WILL BE
FOR CONGRESS.
WE CAN SAY OUR NUMBER ENDS UP
BEING 11 OR 12 THEN WE CAN PICK
UP THOSE GRANTS THAT WERE IN THE
INTERVAL AND WE WILL DO THAT.
BUT YOU CAN SEE WHY THIS CAUSES
A PROBLEM FOR THE NCI.
THE NCI PAYS A LOT OF GRANTS
THROUGH SELECT PAY.
SO WHAT DO YOU DO TODAY IF
YOU'RE SITTING ON A 10%.
IT PROVIDES THIS BUDGETARY
UNCERTAINTY FROM US.
I'M SURE THE PIs WHO ARE
WAITING TO HEAR FROM US IF THEY
ARE GOING FOR GET FUNDED OR NO.
WE HOPE THE GEARS OF CONGRESS
WILL SPIN QUICKLY.
>> BUT YOU WILL REVISIT THOSE
GRANTS THAT ARE BELOW 11.
>> AND ABOVE 11.
WHEN WE KNOW WHAT OUR PAY LINE
IS WE'LL LOOK AT ALL OF THEM.
AND MOST OF THEM WILL BE FUNDED
EXCEPT FOR THE OCCASIONAL
REASONS THAT WE DON'T FUND THEM.
IT'S GENERALLY THE WAY THEY GET
FUNDED.
BY THE WAY WE RECENTLY REVISED
PAY LINES AND THE PROCESS IS
DESCRIBED ON THE WEB AND IS
AVAILABLE IF YOU ARE INTERESTED.
>> THANK YOU.
>> QUICK QUESTION.
IN TERMS OF OUR 15th
PERCENTILE GOAL IS THIS GOING TO
BE IMPACTED DO YOU THINK AND THE
SECOND IS AND WHERE ARE WE ON
ARPA-H?
>> TWO GOOD QUESTIONS.
I THINK -- THE GOAL -- WOULD BE
THE NUMBER W -- WE SUGGESTED UP TO
THE 15th PERCENTILE.
TO GET THERE 2022 WOULD HAVE TO
BE 12%.
IT WOULD REQUIRE VERY ROBUST
SUPPORT FROM CONGRESS.
WE WOULD NOT BE ABLE TO DO THAT
WITH ONE OF THE LOWER NUMBERS.
THIS IS A REALLY CRITICAL TIME.
THE LARGER NUMBERS DISCUSSED IN
CONGRESS WE WOULD BE ABLE TO DO
THAT -- THE LOWER NUMBERS WE
MIGHT HAVE TO PAUSE IN OUR GOAL.
WE WOULD NEVER GIVE UP ON OUR
GOAL FOR INCREASING PAY LINES
FOR NCI INVESTIGATORS.
BUT WE WON'T KNOW.
THERE IS NO WAY OF DOING IT BY
MOVING MONEY AROUND.
SO THE ORIGINAL WAY TO MEET THAT
PAY LINE GOAL PROPOSED IS WITH
INCREASED SUPPORT FROM CONGRESS.
CONGRESS HAS HEARD ABOUT OUR PAY
LINE CRISIS FROM MANY OF YOU IN
FACT.
GIVING ADVICE TO THE CONGRESS
AND HAVE MADE CLEAR THAT AT
NUMBERS PAY LINES LIKE 9% PEOPLE
ARE GOING TO GO TO OTHER FIELDS
THE LAST THING IS TO NOT FUND
THE FOUNDATIONAL SCIENCE.
>> AND ARPA-H.
>> ARPA-H -- THE PROPOSED NEW
AGENCY THAT WOULD HAVE SPECIAL
CAPABILITIES FOR BIOMEDICAL
RESEARCH.
IT HAS BEEN THERE HAS BEEN SOME
DISCUSSION -- IT APPEARS IN BOTH
THE HOUSE AND THE SENATE BUDGET.
THE NUMBER IN THE FUNDING IS
$3 BILLION AND IN THE SENATE
BILL $2 BILLION.
THERE IS SOME DISCUSSION WHERE
ARPA-H WOULD LIVE AND EXIST.
THE MAJORITY OPINION IS --
POSITIONED IN THE NIH AND IT
WOULD DO BIOMEDICAL RESEARCH
THAT WOULD BE DIFFERENT.
MAYBE BEING EXEMPT FROM OUR
USUAL PROCESS LIKE PEER REVIEW.
IT IS TASKED TO WORK ON CANCER
AND OTHER DISEASES.
IT WOULD REQUIRE AN INDEPENDENT
DIRECTOR BUT WE DON'T KNOW THE
BUDGET AND WHO THE DIRECTOR IS
GOING TO BE AND WHAT IT'S GOING
TO WORK ON.
WE'RE VERY MUCH INTERESTED IN
FURTHER DEVELOPMENTS.
THE IT'S A TOP PRIORITY OF THE
BIDEN ADMINISTRATION.
SO I THINK IT'S GOING TO HAPPEN
BUT THERE ARE STILL A LOT OF
DETAILS TO BE FILLED IN
>> WE'LL LEARN MORE ABOUT IT IN
THE COMING MONTHS.
THANK YOU SO MUCH.
WE DO HAVE TO MOVE ON.
>> I'VE BEEN PATIENTLY WAITING
WITH MY HAND RAISED
>> WE'VE GOT TO MOVE ON BECAUSE
WE'RE ABOUT 15 MINUTES BEHIND.
>> I WANT TO SAY A 10% CUT IS
NOT GOOD.
>> I APOLOGIZE FOREGOING OVER
BUT THANK YOU JOHN FOR KEEPING
US ON TRACK
>> FEEL FREE TO TYPE IT
DIRECTORY INTO THE CHAT.
AND WE CAN STILL EFFECTIVELY
ADDRESS YOUR QUESTION.
BUT I JUST WANT TO MOVE ON
BECAUSE WE'RE RUNNING A FEW
MINUTES BEHIND.
SO NEXT IS THE LEGISLATIVE
REPORT FROM MK HOLOHAN.
>> THANK YOU FOR THIS
OPPORTUNITY TO SPEAK.
I'M GOING TO BE BRIEF.
AS I REMIND MEMBERS EVERY
MEETING THERE IS A DETAILED
LEGISLATIVE UPDATE THAT IS PART
OF YOUR MEETING MATERIALS AND
PLEASE FEEL FREE TO CONTACT ME
OR MY TEAM.
WE'RE HAPPY TO HEAR FROM NEW
MEMBERS.
RETURNING MEMBERS.
YOUR STAFF.
IF YOU HAVE ANY QUESTIONS PLEASE
REACH OUT.
I WASN'T GOING TO SHOW POLITICAL
HEADLINES.
BECAUSE THEY WERE JUST TOO DIRE.
THE ONE ARTICLE THAT HAD AN
OVER-ALL SUMMATION OF WHERE
THINGS STAND -- ALONG THE LINES
OF SENATE SINKS DEEPER IN
DYSFUNCTIONAL QUAGMIRE.
BIG NEWS OVERNIGHT -- LOTS OF
DEVELOPMENTS.
CHUCK SCHUMER SHOWS HOW RETIRING
THINKS JOB IS THESE DAYS.
I DON'T KNOW WHAT IS IN THE BAGS
BUT I THINK THE MAN NEEDS A
STAFFER TO HELP HIM.
SENATOR McCONNEL AND SOME OF
THE REPUBLICANS ARE -- NO ONE IS
HAPPY WITH SENATOR McCONNEL
AND THE DEBT CEILING.
THEY'VE BEEN PLAYING CHICKEN.
AND IT HAS TO BE RAISED OR
SUSPENDED BY DECEMBER 15th.
DEMOCRATS HAVE BEEN TRYING TO
GET REPUBLICANS TO AGREE THAT
THIS IS A BIPARTISAN
RESPONSIBILITY.
DEMOCRATS ROSE TO RAISE IT WHEN
IT WAS NECESSARY AND THEY WANT
THE REPUBLICANS TO DO IT NOW.
YOU CONTROL THE HOUSE AND SENATE
AND WHITE HOUSE YOU CAN DO IT ON
YOUR OWN AND SINCE YOU'RE
PURSUING A RECONCILIATION BILL
WITHOUT OUR VOTES THAT IS THE
WHOLE BEAUTY OF THAT
RECONCILIATION PROCEDURE IS THAT
THEY CAN PASS WITH A SIMPLE
MAJORITY IN THE SENATE THEN YOU
CAN DO IT YOURSELF.
YOU RAISE THE DEBT LIMIT.
YOU OWN IT AND WE'LL TALK ABOUT
IT IN THE MID-TERMS.
COMING UP IN NOVEMBER AS YOU
REALIZE THAT PERMEATES ALL OF
THE CALCULATIONS GOING ON RIGHT
NOW.
WHAT THEY ARE ABLE TO DO IS
STRIKE A DEAL WHERE THEY WOULD
ALLOW A ONE TIME EXEMPTION --
ONE TIME RULE CHANGE WHERE
DEMOCRATS CAN PASS -- DEMOCRATS
REFUSING TO ADD IT TO
RECONCILIATION.
THEY CAN PASS IT AND REPUBLICANS
INSISTED THAT THEY DO IT ON
THEIR OWN.
THAT THEY CLARIFY A SPECIFIC
DOLLAR AMOUNT.
NOT JUST SUCH AS NECESSARY BUT
TO CLAIM A SPECIFIC DOLLAR
AMOUNT TO GET THEM -- THEY WOULD
LIKE TO RAISE THE DEBT LIMIT AND
GET IT STAYING WHERE IT NEEDS TO
BE UNTIL THEY GET PASSED THE
MID-TERMS IN NOVEMBER.
THAT IS WHERE THE ESTIMATES ARE
AS HIGH AS $2 TRILLION.
AND IT'S REALLY BIG NEWS AND
McCONNEL FEELS LIKE HE IS
STICKING WITH HIS POLICIES THAT
Rs DO NOT NEED TO VOTE FOR THE
INCREASE.
BUT THIS IS A ONE TIME WORK
AROUND.
ALSO LAST NIGHT WE SAW SOME
AGREEMENT ABOUT THE HOUSE PASSED
THE DEFENSE AUTHORIZATION BILL
WHICH IS A VERY BIG DEAL FOR A
FEW REASONS.
IT HAS BEEN A BIPARTISAN
PRIORITY.
THEY PASSED IT FOR 60 YEARS.
IT HAS NEVER NOT PASSED AND IT
WAS RUNNING INTO A LOT OF
PROBLEMS THIS YEAR.
ONE THING THAT IS IMPORTANT IS
THAT IT TRIGGERS -- IT CONNECTS
TO A DISAGREEMENT ABOUT
APPROPRIATIONS AND DEFENSE
FUNDING.
THESE ARE REALLY POSITIVE SIGNS
OF WHAT HAPPENED IN THE PAST 24
HOURS.
SO CONGRESS HAS TO ADDRESS A LOT
OF FISCAL DEADLINES.
THE DEBT CEILING.
FY22 APPROPRIATIONS.
WE'RE IN OUR SECOND CONTINUING
RESOLUTION GOING TO FEBRUARY 18.
THERE IS A LOT OF CONCERN AS
DR. SHARPLESS MENTIONED WHEN
THEY CANNOT AGREE WEEKEND UP IN
A SITUATION WITH A FULL YEAR CR.
I DON'T THINK THAT IS GOING TO
HAPPEN.
AND THERE IS REALLY NO ONE
BENEFITS FROM THAT.
AND THIS IS KIND OF A UNIQUE
YEAR.
APPROPRIATIONS HAS BEEN SORT OF
AN INNOCENT BYSTANDER.
APPROPRIATIONS HAS NOT BEEN ABLE
TO BE THE SUBJECT OF THE KIND OF
LEADERSHIP NEGOTIATION THAT IT
TYPICALLY WOULD BECAUSE OF THESE
MAJOR LEGISLATIVE PACKAGES AND
REALLY AGAIN WITH MID-TERMS
LOOMING IN NOVEMBER THIS IS A
WINDOW THAT THE ADMINISTRATION
HAS TO ADVANCE THESE PROGRAMS
AND GETTING THE BIPARTISAN
INFRASTRUCTURE BILL DONE WAS A
REALLY BIG DEAL.
THIS NEXT THE BBB IS VERY
IMPORTANT TO THE ADMINISTRATION.
AND SO, THAT IS GOING TO BE
WHERE THE ENERGY IS AND
APPROPRIATIONS IS IN A SECOND
PLACE PRIORITY.
SO THE INFRASTRUCTURE PACKAGE
HAVING THIS PASSED A HUGE
VICTORY.
HERE IS OUR ROSE GARDEN
CEREMONY.
IT PASSED THURSDAY EVENING AND
THE PRESIDENT WAITED TO SIGN IT
UNTIL THE FOLLOWING WEEK SO HE
COULD ASSEMBLE SOME MEMBERS OF
CONGRESS WHO WORKED SO HARD TO
GET THIS DONE.
THIS IS YOUR TRADITIONAL
INFRASTRUCTURE BILL.
IT DOES INCLUDE SOME INNOVATIVE
APPROACHES FOR HIGH SPEED
INTERNET ACCESS.
ON TO THE NEXT NOW.
SOMETIMES THEY CALL THE BUILD
BACK BETTER ACT THE HUMAN
INFRASTRUCTURE ACT.
THIS IS AN ENORMOUS PRIORITY FOR
THE PRESIDENT.
ALL OF THE DEMOCRATIC LEADERS
ARE WORKING VERY HARD TO TRY TO
MAKE THIS HAPPEN.
IT HAS BEEN SHRUNK IN TERMS OF
SIZE AND SCOPE.
IT STARTED OUT AT $3.5 TRILLION.
SENATOR MAN CHEN AND SENATOR
CINEMA MADE IT CLEAR THEY WERE
NOT GOING TO GO WITH THAT.
*.
WE DON'T KNOW WHEN THE SENATE IS
GOING TO VOTE ON IT.
SENATOR SCHUMER SENT OUT A
LETTER SAYING EXPECT WEEKEND
VOTES.
LATE OF NIGHTS.
DON'T PLAN VACATION.
HE WOULD LIKE TO GET IT PASSED
BEFORE CHRISTMAS.
THERE ARE A LOT OF DEMOCRATS WHO
ARE SAYING DON'T SET A DEADLINE.
BECAUSE THAT IS GOING TO WORK
AGAINST US SO WE'LL SEE HOW THAT
HAPPENS.
ARPA-H.
THERE WAS LANGUAGE IN THE
RECONCILIATION PACKAGE.
IT CAME OUT OF THE
RECONCILIATION PACKAGE.
7 SOME OF THE LEADERS SAID IT
WAS NOT APPROPRIATE FOR
RECONCILIATION WHICH IS SUPPOSED
TO HAVE A NEXUS WITH THE BUDGET.
IN ADDITION TO THE DEADLINE
BEING SOMEWHAT A LITTLE BIT TOO
TIGHT TO GET THAT DONE BY THE
25th.
SENATOR MANCHIN SAID HE WAS
URGING A SLOW DOWN IN TERMS OF
MOVING THE RECONCILIATION BILL.
CURES 2.0.
WE SAW A DRAFT VERSION AND THIS
WAS INTRODUCED.
HR6,000 SPONSORED BY DIANE -- OF
COLORADO AND FRANK UPTON.
THIS WOULD ESTABLISH ARPA-H
WITHIN THE NIH.
WE EXPECT THIS BILL TO PICK UP
SOME STEAM OVER THE NEXT COUPLE
OF MONTHS.
MOST OF THE CONGRESSIONAL
WATCHERS THINK IT'S GOING TO
MOVE WHEN THE FDA USER FEE
AUTHORIZATION PASSED.
AND THAT IS SOMETHING THAT IS
WHERE PEOPLE ARE AIMING HERE
BECAUSE OF SOME OF THE SUBJECT
MATTER.
SO FY22 APPROPRIATIONS.
WE HAVE THE PRESIDENT'S BUDGET
REQUEST WHICH STARTS THE
PROCESS.
THE HOUSE MOVED QUICKLY.
THEY PROVIDED THE PRESIDENT'S
BUDGET REQUESTED THIS.
THE HOUSE CAME THROUGH WITH
$3 BILLION FOR ARPA-H.
THE SENATE WAS UNABLE TO GET
THEIR BILL OUT OF SUBCOMMITTEE.
A 50/50 SENATE MEANS THE RULES
ARE 50/50 SENATE IN THIS
CONGRESS WOULD BE 50/50 ON
COMMITTEE SO THEY DON'T HAVE THE
VOTES TO SWAY IT.
THIS IS NOT THE THING THAT GOES
TO YOU WHOLE SENATE AND THE VICE
PRESIDENT COMES TO BREAK THE
TIE.
THEY RELEASED THEIR DRAFT BILL.
BOTH SIDES HAVE DONE IT WHEN
THEY'VE BEEN IN THE MAJORITY.
SO WHAT THAT MEANS IS HERE IS
WHAT THE MAJORITY IS THINKING.
7 DOES NOT NECESSARILY REPRESENT
BIPARTISAN AGREEMENT ON THE
SENATE SUBCOMMITTEE SO THE
NUMBERS WE SAW WHEN THOSE BILLS
WERE POSTED WAS $2.4 BILLION
ALLOCATION FOR ARPA-H WHICH HAS
NOT YET BEEN AUTHORIZED.
THIS IS AN APPROPRIATION.
AND FOR NCI $6.77 BILLION
APPROPRIATION.
THE HOUSE BILL IS A BIGGER
INCREASE FOR NCI.
WE'RE IN OUR SECOND CR.
THAT GOES THROUGH
FEBRUARY 18th.
IN FY21 THERE WERE FIVE CRs
FAIRLY SHORT-TERM.
THEY LASTED 88 DAYS.
CRs ARE NORMAL.
IT'S REGULAR ORDER.
ESSENTIALLY.
SO THERE IS NOTHING TO READ INTO
ABOUT THE CRs THAT WE'VE HAD
SO FAR.
THE FACT THAT THIS LAST CR A
MORE STANDARD PLAY WOULD HAVE
BEEN TO TAKE IT UP TO CHRISTMAS
TO PUT PRESSURE ON CONGRESS TO
GET THE APPROPRIATION DONE.
8 THEY CHOSE TO GO TO
FEBRUARY 18 BECAUSE THERE ARE
TOO MANY OTHER BIG HIGH-PROFILE
PACKAGES THAT ARE SERVING THAT
PURPOSE OF THAT PRESSURE.
HERE IS ONE OF THE REASONS WHY I
THINK -- WE'LL NOT SEE A FULL
YEAR CR.
THIS IS THE FIRST THAT EARMARKS
OUR BACK.
WHICH ARE SPECIFIC PROJECTS.
THEY CALL THEM COMMUNITY PROJECT
FUNDING REQUESTS.
NONE OF THOSE GET DONE IF WE
DON'T HAVE A REAL APPROPRIATION
BILL.
IN THE SENATE 646 SENATORS
SUBMITTED THESE SPENDING
REQUESTS.
THEY ARE CALLING THEM SOMETHING
DIFFERENT IN THE SENATE AND THEY
HAVE TWO DIFFERENT SYSTEMS FOR
TRACKING THEM.
THIS REPRESENTS A SIGNIFICANT
NUMBER OF PROJECTS.
ONE RETIRING MEMBER FROM ALABAMA
-- ALSO THE HIGHEST RANKING
DEMOCRAT SENATOR LEAHY IS
RETIRING AS WELL.
IF WE DO NOT HAVE THE BILL THOSE
EARMARKS DON'T HAPPEN.
ALSO THE DEFENSE COMMUNITY HAS
BEGUN TO BE VERY VOCAL ABOUT
DEFENSE NEEDS AND FY22
APPROPRIATION.
THEY CANNOT CONTINUE BASED ON
THEIR FY20 IN A FEW YEAR CR.
THEY PASSED IT WITH A
$25 BILLION INCREASE IN
AUTHORIZATION FOR DEFENSE OVER
THE PRESIDENT'S BUDGET REQUEST.
ONE OF THE ISSUES THE TWO BIG
ISSUES -- ABOUT MOVING FY22
APPROPRIATIONS ARE POISON PILL
WRITERS.
THE REPUBLICANS SAY THE
DEMOCRATS HAVE PUT IN.
-- THAT HAS BEEN PART OF
APPROPRIATION BILLS FOR DECADES.
THE DEMOCRATS TOOK IT OUT THIS
TIME.
I ASSUME IT'S GOING BACK IN BUT
THIS IS A REAL POINT OF
CONTENTION.
THE OTHER ISSUE WAS DEFENSE.
THERE IS NO BUDGET CONTROL ACT
IN PLAY RIGHT NOW WHICH IN THE
PAST REQUIRED PARITY FROM
DEFENSE AND NONDEFENSE ACCOUNTS.
SO A LOT OF REPUBLICANS HAVE
SAID THEY WANT HIGHER NUMBER OF
DEFENSE.
NOW THEY HAVE THE OPPORTUNITY TO
MAKE THAT HAPPEN.
BUT ONLY IF THERE IS AN FY22
APPROPRIATION.
A FULL YEAR CR WOULD NOT BUDGE
THOSE NUMBERS.
WE SAW THIS WEEK THE DEATH OF
SENATOR BOB DOLE WHO IS ONE OF
THE LONGEST SERVING SENATORS IN
THE HISTORY OF THE SENATE AND I
THINK IT'S SORT OF APPROPRIATE.
IF YOU HAVE AN OPPORTUNITY TO
READ HIS LAST OP-ED -- IT'S IN
THE WASHINGTON POST.
HE WAS KNOWN AS A DEAL MAKER AND
SOMEONE WHO WORKED WITH THE
OTHER SIDE OF THE AISLE.
HE WORKED WITH SENATOR MOYNIHAN
OF NEW YORK AND HE WORKED WITH
TED KENNEDY TO PASS THE
AMERICANS WITH DISABILITY ACT IN
1990.
I THINK THE FACT THAT HE IS
GOING TO BE HIS SERVICE STARTS
TOMORROW.
HE WILL BE LYING IN STATE AT THE
CAPITOL.
THAT HAS PUT A LITTLE FIRE UNDER
THE LEGISLATIVE ACTIVITY IN THE
SENATE TO GET THINGS DONE WOULD
PLEASE HIM AS HE WAS ALL ABOUT
MAKING PROGRESS.
ALSO WHEN HE WAS DIAGNOSED WITH
LUNG CANCER IN FEBRUARY OF 2021
-- EVIDENTLY PRESIDENT BIDEN
VISITED HIM FOR A COUPLE OF
HOURS.
THEY WORKED TOGETHER FOR ALMOST
25 YEARS IN THE SENATE.
FORMER SENATOR DOLE GAVE HIM A
LITTLE BIT OF FEEDBACK ABOUT
SOME THINGS THAT HE DIDN'T FEEL
LIKE HE WAS DOING RIGHT SO HE
WAS TRYING TO MAKE DEALS UP TO
THE END.
I'M HAPPY TO TAKE ANY QUESTIONS.
I'M GOING TO IMAGINE THEY ARE
GOING TO ASK TO DO THOSE
OFF-LINE.
>> FANTASTIC.
A LOT BURIED IN THE SLIDES.
WE DO DEFINITELY -- WE'RE ABOUT
10 OR 11 MINUTES OVER TIME.
AND UNLESS THERE ARE ANY BURNING
QUESTIONS.
WE COULD MOVE ON TO THE NEXT
AGENDA ITEM.
AND THAT ACTUALLY IS
DR. SHARPLESS AND HIS
RECOGNITION OF RETIRING NCAB
MEMBERS.
>> WE'RE GOING TO PROJECT THOSE
NAMES.
CORRECT?
>> WE NEED THE RETIRING NCAB
MEMBER SLIDE.
>> I APOLOGIZE.
>> THIS IS ANOTHER REASON WHY
IT'S TOUGH DOING THESE THINGS
NOT IN PERSON.
>> LET ME SEE.
>> I HAVE A CHEAT SHEET.
OKAY.
HERE WE GO.
APOLOGIZE.
AS I MENTIONED BEFORE WE HAVE
SOME RETIRING BOARD MEMBERS WHO
AS I SAID HAVE BEEN ON SOME OF
THE NCAB FOR QUITE SOME TIME AND
WE WANT TO THANK THEM FOR THEIR
SERVICE.
PETER ADAMSON AND YUA N SPACE
CHANG ARE NOT HERE.
DEB IS THE SENIOR VICE PRESIDENT
OF RESEARCH AT EMORY UNIVERSITY
AND HAS BEEN A GREAT ASSET TO
THE NCI IN THINKING THROUGH LOTS
OF ISSUES RELATED TO HEALTH
SERVICES RESEARCH.
THE NRG AND A WEALTH OF GOOD
ADVICE.
THANK YOU FOR YOUR SERVICE.
NEXT IS TIM LEY.
HE IS THE PROFESSOR OF MEDICINE
AND GENETICS AT WASU IN ST.
LOUIS.
A PASSIONATE DEFENDER OF BASIC
SCIENCE AND HE HAS GIVEN ME A
LOT OF GREAT ADVISE.
MAX WICHA.
PLAQUE HAS BEEN A STALL WART *
SUPPORTER OF THE NCI.
THANK YOU, MAX.
PETER HAS GIVEN US GREAT ADVICE.
SO I WANT TO THANK ALL OF THESE
RETIRING BOARD MEMBERS FOR THEIR
SERVICE.
AS I SAID I WISH WE COULD HAVE
DONE THIS IN PERSON SO I COULD
GIVE YOU ALL OF THE OBLIGATORY
HUGS.
>> THANK YOU.
DO YOUR VIRTUAL HAND COLLAPSES
AND THANKS TO ALL OF THE MEMBERS
WHO ARE RETIRING.
WISH YOU THE BEST OF LUCK.
SO MOVING RIGHT ALONG.
THE NEXT AGENDA ITEM IS A
PRESENTATION ON CANCER MOONSHOT
LOOKING AHEAD.
IF YOU CAN PULL THAT
PRESENTATION UP.
WHICH ACTUALLY WAS REQUESTED BY
THE BOARD.
THIS WILL BE PRESENTED TO US BY
DANA SINGER.
A DEPUTY DIRECTOR FOR SCIENTIFIC
STRATEGY AND DEVELOPMENT.
>> THANK YOU.
CAN YOU HEAR ME?
>> YES.
>> AND THE SLIDES ARE UP?
>> YES.
>> THANK YOU AND GOOD AFTERNOON
OR GOOD MORNING AS THE CASE MAY
BE AND THANK YOU FOR THE CHANCE
TO GIVE YOU AN UPDATE ON THE
CANCER MOONSHOT AND THE PROGRESS
THAT HAS BEEN MADE OVER THE PAST
FIVE YEARS.
IN THE NEXT FEW MINUTES I'D LIKE
TO DESCRIBE SOME OF THE MOONSHOT
ACHIEVEMENTS AND THEN LOOK AHEAD
TO HOW WE SUSTAIN AND BUILD ON
THOSE ACCOMPLISHMENTS IN A WAY
THAT ENCORPORATES THEM INTO THE
LARGER CANCER RESEARCH EFFORT.
THE LEGISLATION THAT ENACTED THE
CANCER MOONSHOT IDENTIFIED THREE
SPECIFIC GOALS.
ONE TO ACCELERATE OUR
UNDERSTANDING OF CANCER.
TWO, TO ENHANCE DATA SHARING AND
THREE, TO ENCOURAGE GREATER
COLLABORATION.
TO ACHIEVE THE FIRST GOAL A BLUE
RIBBON PANEL WAS CONVENED AND
CHARGED WITH IDENTIFYING THOSE
AREAS OF RESEARCH THAT WERE
POISED FOR ACCELERATION.
THEIR RECOMMENDATIONS ARE LISTED
HERE.
I'M GOING TO USE THIS TEMPLATE
TO HIGHLIGHT JUST A FEW OF THE
MOONSHOT INITIATIVE THAT'S
RESPOND TO THE RECOMMENDATIONS.
THE PATIENT ENGAGEMENT
RECOMMENDATION CALLED FOR
NETWORKS TO ASSIST CANCER
PATIENTS IN FINDING CLINICAL
TRIALS.
AND CONVERSELY TO HELP
RESEARCHERS ENROLL PATIENTS FROM
DIVERSE POPULATIONS.
NCI CONNECT AND MY PART WERE
STARTED IN 2018.
THESE TW TWO -- PROGRAMMED HAVE
FORMED PARTNERSHIPS THAT ARE
AIMED AT UNDERSTANDING AND
TREATING RARE TUMORS.
THROUGH THESE PROGRAMS A NUMBER
OF CLINICAL TRIALS HAVE BEEN
STARTED.
PECGS IS A PATIENT ENGAGEMENT
INITIATIVE STARTED IN 2020.
ENCOURAGING CANCER PATIENTS AND
SURVIVORS TO BE ACTIVE
PARTICIPANTS IN CANCER RESEARCH
AND ADDRESS GAPS IN OUR
KNOWLEDGE AND CANCER GENOMICS OF
RARE OR HIGHLY LETHAL CANCERS.
PEDIATRIC CANCER WAS CALLED OUT
IN TWO OF THE RECOMMENDATIONS.
FOCUSES ON UNDERSTANDING THE
STRUCTURE AND FUNCTION OF FUSION
-- PROTEIN COMPLEXES TO INFORM
THE DEVELOPMENT OF SMALL
MOLECULE DISRUPTORS.
I'M R IMMUNO THERAPY.
WE ALL KNOW THAT WHILE THESE
HAVE SHOWN INCREDIBLE PROMISE *
FOR SOME TYPES OF CANCER IN
OTHER CANCERS CURRENT APPROACHES
STILL HAVE LIMITED EFFICACY.
THE PI-DDN -- DEVELOPING NOVEL
THERAPEUTIC APPROACHES FOR
PEDIATRIC CANCER AND IT HAS BEEN
ENORMOUSLY SUCCESSFUL.
ONE OF THE PROGRAMS THAT HAS
GENERATED A CLASS OF T CELLS --
BY RECOGNIZING SURFACE --
PEPTIDE -- COMPLEXES.
PEDIATRIC CITN SUPPORTS
MULTI-INSTITUTIONAL PHASE I AND
EARLY PHASE II PEDIATRIC IMMUNO
THERAPIES.
UNDERSTANDING THE IMMUNE
MECHANISMS THAT CONTRIBUTE TO
TUMOR RESISTANCE AND AMONG ITS
ACCOMPLISHMENTS IS THE
DEVELOPMENT OF A CAR T-CELL THAT
KILLS CANCER CELLS EXPRESSING
LARGE AMOUNTS OF ANTIGEN BUT
DOESN'T KILL NORMAL CELLS THAT
EXPRESS LOWER LEVELS OF THE SAME
PROTEIN AND ADDRESSING THE
IMPORTANT ISSUE OF ON TARGET OFF
TUMOR KILLING.
IMPLEMENTATION SCIENCE HAS BEEN
A MAJOR FOCUS OF THE MOONSHOT
WITH MANY PREVENTION AND SYMPTOM
MANAGEMENT.
PROGRAMS LIKE IMPACT THAT
FOCUSES ON REDUCING SYMPTOM
BURDEN AND OPTIMIZING
THERAPEUTIC OUTCOME BOTH IN
CHILDREN AND ADULTS.
THE C3I PROGRAM HAS LED TO A
BETTER UNDERSTANDING OF WHAT
CONSTITUTES A SUCCESSFUL SMOKING
CESSATION PROGRAM.
TWO OF THE PROGRAMS ARE
INCREASING COLORECTAL CANCER
SCREENING, FOLLOW-UP AND
REFERRER IN UNDERSERVED GROUPS.
DURING THE PANDEMIC THESE TEAMS
CONTINUE TO WORK IMPLEMENTING
NOVEL TELEHEALTH SERVICES THAT
LED TO INCREASED SCREENING UP
TAKE.
I SHOULD POINT OUT THAT WHILE
THESE PROGRAMS ADDRESS HEALTH
DISPARITIES, HEALTH DISPARITIES
WAS A FIND AS A CROSSCUTTING
THEME IN THE RECOMMENDATIONS.
ALL MOONSHOT PROGRAMS ARE
REQUIRED TO CONSIDER HEALTH
DISPARITIES.
THE HUMAN TUMOR ATLAS NETWORK IS
DEVELOPING ATLASES THAT
VISUALIZE THE 3-D ARCHITECTURE.
THE COMPETENT SINCE AND
MULTI-SCALE INTERACTIONS OF THE
TUMOR AS THE TUMOR PROGRESSES
AND METASTASIZES.
THERE ARE DATA FROM 8 INITIAL
ATLASES INCLUDING PEDIATRIC THAT
ARE AVAILABLE THROUGH THE PORTAL
WITH MORE TO BE DEPOSITED SOON.
SO IN TOTAL THE MOONSHOT HAS
LAUNCHED OVER 70 NEW PROGRAMS
AND SUPPORTED OVER 240 PROJECTS.
CLEARLY I'VE ONLY HAD TIME TO
HIGHLIGHT A SMALL FRACTION OF
THESE BUT I HOPE I'VE GIVEN YOU
A SENSE OF THE BREATH AND DEPTH.
WE HAVE NOT NEGLECTED THE OTHER
TWO GOALS.
TO ENHANCE DATA SHARING NCI HAS
DEVELOPED THE CANCER RESEARCH
DATA COMMONS WHICH HOUSES AND
WILL MAKE AVAILABLE ALL OF THE
MOONSHOT DATA. IN ADDITION ALL
PUBLICATIONS AND THE UNDERLYING
DATA ARE REQUIRED TO BE MADE
FREELY AND PUBLICLY AVAILABLE
IMMEDIATELY UPON PUBLICATION.
WITH RESPECT TO THE THIRD GOAL
MANY OF THE MOONSHOT PROGRAMS
ARE NETWORKS WHERE COLLABORATION
IS INTEGRAL TO AND EMBEDDED
WITHIN THEM.
MEETINGS HAVE BROUGHT TOGETHER
MOONSHOT INVESTIGATORS FROM
MULTIPLE VARIOUS PROGRAMS TO
DISCUSS RESEARCH AND TO SPARK
CROSS INITIATIVE COLLABORATIONS.
THE NCI HAS ESTABLISHED
PARTNERSHIPS WITH THE DOE, THE
DoD AND THE VA AS WELL AS WITH
OTHER NIH INSTITUTES.
AND THE MONTHLY MOONSHOT SEMINAR
SERIES IS DESIGNED TO INFORM
BOTH THE RESEARCH COMMUNITY AND
THE PUBLIC OF MOONSHOT RESEARCH
ACCOMPLISHMENTS.
SO AS THE MOONSHOT IS WINDING
DOWN WE'VE ALREADY STARTED TO
ASSESS ITS CONTRIBUTIONS USING A
TWO PHASE APPROACH.
THE FIRST PHASE IS COLLECTING
AND ANALYZING DATA TO MONITOR
PROGRESS.
IT WILL CONTINUE THROUGH 2026
WHEN ALL OF THE INITIAL MOONSHOT
FUNDED GRANTS WILL END.
SINCE THE PROGRAM'S IMPACT ONLY
BECOMES APPARENT OVER TIME A
FINAL ASSESSMENT WILL BE ONGOING
OVER THE FOLLOWING FEW YEARS IN
PHASE II.
BUT WE CAN ALSO TAKE AN EARLY
LOOK AT THE ANALYSIS OF MOONSHOT
ACCOMPLISHMENTS AND WE CAN SEE
THAT IT'S ALREADY BEEN
PRODUCTIVE LEADING TO A LARGE
NUMBER OF PUBLICATIONS OF
PATENTS AND TRIALS.
IF WE FOCUS JUST ON MOONSHOT
PUBLICATIONS WE SEE THAT ON
AVERAGE THEY ARE MORE HIGHLY
CITED WHEN COMPARED TO
PUBLICATIONS FROM THE NCI BASE
INDICATING THAT THEY HAVE A HIGH
OVER-ALL IMPACT.
THE MOONSHOTS ALSO SERVE TO
EXPAND THE CANCER RESEARCH
WORKFORCE.
A QUARTER WERE NEW INVESTIGATORS
AND OVER 10% HAD NO PRIOR NC
ISSUES FUNDING.
WOMEN REPRESENT ABOUT A THIRD OF
ALL OF THE INVESTIGATORS.
WHICH REFLECTS THE
REPRESENTATION IN THE APPLICANT
POOL.
SO I HOPE IT'S EVIDENCE FROM
THESE INITIAL ANALYSIS THAT THE
MOONSHOT HAS LAID CRITICAL
FOUNDATIONS.
WE'RE BEGINNING TO LOOK AHEAD TO
THINK ABOUT HOW DO INCORPORATE
THE SCIENTIFIC ADVANCES MADE
THROUGH THE MOONSHOT INTO THE
OVER-ALL NCI PORTFOLIO AND HOW
TO TRANSITION MOONSHOT FUNDING
TO STANDARD APPROPRIATED FUND
FUNDING.
NCI NEEDS TO BUILD ON THE
ADVANCES WHILE MAINTAINING AND
ENHANCING INVESTIGATOR
INITIATIVE RESEARCH AND OTHER
NCI MISSION CRITICAL OBJECTIVES.
ALSO PURSUE NEW AREAS AND
OPPORTUNITIES THAT HAVE EMERGED
AS A RESULT OF MOONSHOT
RESEARCH.
IT HAS PROMOTED A CULTURE OF
COLLABORATION OF DATA SHARING
AND OF OPEN ACCESS PUBLICATION.
ALL OF WHICH WILL WANT TO
CONTINUE TO INCORPORATE ACROSS
ALL OF OUR FUNDED RESEARCH.
SO AS WE PLAN FOR THE TRANSITION
WE HAVE TO DETERMINE WHICH OF
THE MOONSHOT PROGRAMS NEED
CONTINUED SUPPORT TO ACHIEVE
THEIR GOALS AND WHICH HAVE
ALREADY ACHIEVED THEIR GOALS.
WE HAVE ALSO WANT TO SUPPORT NEW
PROGRAMS THAT EMERGE FROM THE
SUCCESS OF THE MOONSHOT
PROGRAMS.
YOU'RE GOING TO SEE AN EXAMPLE
OF THAT TOMORROW.
IT'S A DIRECT OUTGROWTH OF THE
SUCCESS OF PIDDN.
AS WE PLAN THE TRANSITION AN
IMPORTANT CONSIDERATION IS TO
BALANCE THE NEEDS OF MOONSHOT
PROGRAMS WITH NONMOONSHOT
PROGRAMS AND TO THAT END WE'RE
IN THE PROCESS OF ESTABLISHING A
BUDGET PLAN TO HELP EASE THE
TRANSITION OF CONTINUING
MOONSHOT PROGRAMS INTO THE
APPROPRIATED BUDGET.
SO THE TRANSITION PLANNING HAS
STARTED WITH EACH OF THE
MOONSHOT PROGRAMS OUTLINING
THEIR PLANS FOR THE FUTURE.
THIS SLIDE SUMMARIZES THOSE
PROGRAMS THAT WOULD LIKE TO
CONTINUE BEYOND THE APPROPRIATED
MOONSHOT FUNDING AND THEIR A
ASSOCIATED TIME LINES.
SO ABOUT TWO-THIRDS OF THE
PROGRAMS HAVE EXPRESSED AN
INTEREST IN CONTINUING IN SOME
FORM AND WOULD NEED TO BE
SUPPORT THROUGH STANDARD
APPROPRIATED FUNDS.
THE IMPACT ON THE BUDGET IS
SPREAD OUT BETWEEN FY22 AND FY27
AS YOU CAN SEE HERE WITH THE
MAJOR IMPACT IN FY23 AND 24.
SO I WANT TO SHOW YOU THE BUDGE
TEARY CHALLENGE.
*.
IT IS $1.8 BILLION.
THAT $1.25 BILLION HAS BEEN
OBLIGATED.
THE REQUEST FOR CONTINUATION
THAT I JUST SUMMARIZED IN THE
LAST SLIDE TOTAL $884 MILLION.
SO THAT WOULD BRING THE TOTAL
MOONSHOT INVESTMENT TO
$2.3 BILLION AND RESULT IN WHAT
WE CAN CALL A NOMINAL DEFICIT OF
$564 MILLION.
SO IN ANTICIPATION OF NEEDING TO
CONTINUE TO SUPPORT SOME OF THE
MOONSHOT PROGRAMS WE HAVE
RESERVED ABOUT $280 MILLION OF
MOONSHOT NO YEAR FUNDS TO EASE
THE TRANSITION OF MOONSHOT
PROGRAMS INTO APPROPRIATED
FUNDING AND HAVE BEEN MODELING
VARIOUS WAYS IN WHICH IT COULD
HELP -- THOSE MOONSHOT FUNDS
COULD HELP OFFSET THE IMPACT ON
THE BUDGET.
IF ALL OF THE TRANSITION
REQUESTS THAT I SHOWED YOU
BEFORE WERE TO BE APPROVED WE
ESTIMATE THAT ON AVERAGE IT
WOULD TAKE $100 MILLION
ADDITIONAL ADDED ANNUALLY TO THE
NCI BUDGET.
BUT I WANT TO POINT OUT THAT
THESE REQUESTS FOR CONTINUATION
WILL STILL HAVE TO GO THROUGH
THE NORMAL APPROVAL PROCESS AND
IT'S LIKELY THAT NOT ALL OF
THOSE REQUESTED CONTINUATIONS
WILL BE APPROVED.
SO THE BUDGET MODELING IS STILL
GOING TO BE ADJUSTED DYNAMICALLY
AS PROGRAMS BRING CONCEPTS
FORWARD AND WE'LL CONTINUE TO
TRY TO OPTIMIZE THE MODELING TO
EQUAL THIS TRANSITION.
SO IN THE EARLIER SLIDES I
SHOWED YOU THE SCIENCE.
THIS WORK CLOUD IS INTENDED TO
ILLUSTRATE AT A HIGH LEVEL HOW
THE MOONSHOT FUNDS THEMSELVES
HAVE BEEN INVESTED ACROSS THE
DIFFERENT SCIENTIFIC AREAS.
WE'VE MADE MAJOR INVESTMENT IN
PREVENTION AND EARLY DETECTION.
IN IMMUNO THERAPY AND CHILDHOOD
CANCERS AND INFRASTRUCTURE.
WITH THE REQUEST THAT WE HAVE
FOR CONTINUATION WE CAN DO A
SIMILAR ANALYSIS TO SEE HOW
THOSE ARE SPREAD OUT.
SO THIS NOW ILLUSTRATES THE
DISTRIBUTION OF MOONSHOT FUNDING
REQUESTS.
THE $844 MILLION THAT I REFERRED
TO BEFORE.
AND WHEN YOU SEE THAT ALL OF THE
REQUESTS REPRESENT A MIX OF BOTH
RESEARCH AND INFRASTRUCTURE
THERE IS A GREATER EMPHASIS HERE
ON INFRASTRUCTURE AND SO THAT
REALLY TELLS US AND I THINK IT'S
A MAJOR CONSIDERATION IS TO WHAT
EXTENT WE PRIORITIZE CONTINUED
SUPPORT FOR INFROM A STRUCTURE
RELATIVE TO ONGOING RESEARCH.
SO DESPITE THE BUDGETARY
CHALLENGES WE'LL HAVE TO
CONTINUE TO DEVELOP NEW EMERGING
PROGRAMS WHILE BALANCING THEM
WITH THE NEEDS OF MOONSHOT AND
NONMOONSHOT PROGRAMS.
IN PARALLEL WE'LL COMMENT TO
DYNAMICALLY MODEL WAYS IN WHICH
TO EASE THESE PROGRAMS FROM
MOONSHOT FUNDING INTO
APPROPRIATED FUNDING AND MAKING
DECISIONS WILL BE INFORMED BY
THE ONGOING ASSESSMENT OF THE
MOONSHOT PROGRAMS.
BASED ON THE INITIAL ASSESSMENT
IT'S CLEAR THAT MOONSHOT HAS
BEEN SUCCESSFUL IN ACHIEVING ITS
PRIMARY GOALS BUT GOING FORWARD
OUR GOAL WILL BE TO MAINTAIN AND
BUILD ON THOSE ACHIEVEMENTS.
SO IN CLOSING I WANT TO THANK
ALL OF THE MANY NCI STAFF ON THE
MOONSHOT IMPLEMENTATION TEAM.
THIS HAS BEEN AN ENORMOUS
ONGOING PROJECT ON THEIR PART
AND I'M HAPPY TO ANSWER ANY
QUESTIONS.
FOR THE CLEAR PRESENTATION AND
BEING CONCISE AND GETTING US
CLOSE TO BEING ON TRACK.
THERE ARE A NUMBER OF QUESTIONS
IN THE CHAT.
BUT WE DO HAVE TIME I THINK FOR
A COUPLE OF QUESTIONS.
I COULD READ A FEW IN THE CHAT.
ONE FROM DR. AZAD.
GREAT TO SEE THE PUBLICATIONS
PATENTS.
BUT WANTED TO SEE WHETHER OR NOT
YOU HAVE STARTED WORKING TOWARDS
DEVELOPING TANGIBLE OUTPUTS AS
WE CONSIDER QUANTIFIABLE IMPACT.
HOW ARE WE IMPACTING PATIENTS
THROUGH MOON SHOT OF ACTIVITIES
AND WHAT ARE THE PLANS FOR
CREATING THAT IMPACT MODEL?
>> YEAH.
THAT IS A VERY GOOD QUESTION.
AND I THINK AS WE ASSESS THE
SUCCESS OF THE MOONSHOT AND THE
RETROSPECTIVE ANALYSIS WE WILL
BE ABLE TO DO A MUCH BETTER JOB
OF DEVELOPING AN IMPACT MODEL
BUT WHAT WE CAN SEE IS THAT MANY
OF THE RESEARCH ACCOMPLISHMENTS
THAT WERE SUPPORTED BY THE
MOONSHOT HAVE MOVED INTO
CLINICAL TRIALS NOW.
SO THE CLINICAL TRIALS ARE NOT
NECESSARILY SUPPORT BY MOONSHOT
BUT HAVE BEEN ENABLED BY THE
MOONSHOT AND WE EXPECT OVER TIME
THAT WE'LL SEE MORE AND MORE
CLINICAL TRIALS EMERGING AS A
RESULT OF THE MOONSHOT SUPPORT.
AND SO I THINK THAT AS WE GET
FURTHER BEYOND THE MOONSHOT WE
WILL BE ABLE TO HAVE A MUCH
BETTER IDEA OF WHAT KIND OF
IMPACT THE MOONSHOT HAS HAD.
>> SURE AND ANOTHER I THINK
IMPORTANT CONSIDERATION IS AS WE
THINK ABOUT TRAINING AS WE THINK
ABOUT DIVERSITY A QUESTION ABOUT
WHAT PERCENTAGE OF THE MOONSHOT
PRINCIPLE INVESTIGATOR ARE UNDER
REPRESENTED MINORITIES AND IS
THAT BEING TRACKED AS WELL?
>> YEAH.
CURRENTLY THE UNDER REPRESENTED
MINORITY SUPPORTED THROUGH THE
MOONSHOT IS LESS THAN 10%.
SO IT'S OBVIOUSLY SOMETHING THAT
WE'RE CONCERNED ABOUT AND
WATCHING BUT HAVE AN EMPHASIS
FOR OUR TRAINEES TO TRY TO
RECRUIT MORE UNDER REPRESENTED
MINORITIES BUT RIGHT NOW IT'S
LESS THAN 10%.
AND I SHOULD POINTED OUT THAT
IT'S HARD TO DO A LOT OF
SPECIFIC DATA ANALYSIS IN
REPORTING BECAUSE THE NUMBERS
ARE SO SMALL WE'RE CONSTRAINED
BUT WE'RE TRYING TO TRACK IT AS
MUCH AS POSSIBLE TO KNOW HOW TO
TARGET TO IMPROVE THE
REPRESENTATION.
>> GREAT.
I THINK AMY HAS A QUESTION.
WOULD YOU LIKE TO POSE YOUR
QUESTION.
UNMUTE YOUR MIC
>> I WAS THINKING IT WOULD BE
INTEREST TO LOOK AT THE SAME
METRICS WITH THE OVER-ALL NCI
PROGRAM TO SEE IF THIS STRATEGY
IS EFFECTIVE RELATIVE TO THE
MORE STANDARDIZED WAY.
>> YES.
SO WE HAVE BEEN USING THE NCI
BASE AS A COMPARER AND SOME OF
THE DATA I SHOWED YOU IN TERMS
OF THE IMPACT OF THE
PUBLICATIONS IS USING THAT.
THE PROBLEM IS IT'S NOT REALLY
AN IDEAL COMPARER.
MOONSHOT FUNDING WAS WEIGHTED
VERY HEAVILY ON NETWORKS AND
COOPERATIVE AGREEMENTS WHEREAS
THE NCI BASE IS MUCH MORE
HEAVILY WEIGHTED ON INVESTIGATOR
INITIATIVE RESEARCH ON RO1s
AND PO1s SO WE'RE STRUGGLING
TO IDENTIFY WHAT THE RIGHT
METRICS ARE.
WE'RE TRYING TO FIGURE OUT THE
BEST WAY TO ANALYZE THESE DATA.
THANK YOU FOR THAT.
>> ADDITIONAL QUESTIONS?
WE MAY HAVE TIME FOR ANOTHER ONE
OR TWO.
>> THERE ARE COMMENTS ABOUT THE
HOW MUCH THE MOON COUNT AND THE
IMPACT -- -- ON PAY LINES IN THE
FUTURE.
DO YOU WANT TO TALK ABOUT THAT
ISSUE?
>> YEAH.
CLEARLY WE'RE VERY AWARE OF THE
IMPACT THAT IT MIGHT HAVE.
THAT IS ONE OF THE REASONS WE
HAVE SET ASIDE SOME OF THE
MOONSHOT FUNDS TO HELP WITH THAT
TRANSITION TO MINIMIZE THE
IMPACT ON THE RPG AND THE PAY
LINE.
I SHOULD ALSO NOTE THAT MUCH OF
THE MOONSHOT INVESTMENT IS NOT
IN THE RPG.
EVEN THOUGH THE TOTAL AMOUNT
THAT WILL MOVE INTO APPROPRIATED
FUNDS IS EVERYTHING IS APPROVED
WOULD BE SUBSTANTIAL.
NOT ALL OF THAT WOULD GO INTO
THE RPG.
IN OUR MODELING WE'RE TRYING
REALLY TO PROTECT THE RPG AND
THE PAY LINE SO THAT WE DON'T
HAVE A MAJOR DISTORTION IN THE
PAY LINE AS A RESULT OF THE
MOONSHOT
>> A QUICK QUESTION.
YOU'RE GOING TO KNOW THE ANSWER
TO THIS I KNOW.
SO IT'S HARD TO STOP DOING
THINGS AT THE NCI.
I'M CURIOUS THE MANY MOONSHOT
INVESTIGATORS THAT HAVE COME IN
AND THE NUMBER OF PRIORITIES
THAT WE HAVE DO THESE
INVESTIGATORS REALLY UNDERSTAND
THAT THESE PROGRAMS ARE FINITE.
AND IN FACT -- MANY OF THEM ARE
GOING TO END.
>> ANNA THAT IS A GREAT QUESTION
AND A QUESTION THAT APPLIES TO
ALL NCI PROGRAMS.
>> ALL OF WHICH ARE HARD TO
STOP.
>> BUT WE DO STOP THEM.
I THINK THIS ONE IS CLEARER AND
I WILL POINT OUT THAT MANY OF
THEM IN A NUMBER OF CASES THOSE
PROGRAMS CAN NOW -- NOT THE
PROGRAMS BUT THE INVESTIGATORS
CAN NOW ENTER THE RPG POOL AND
SUBMIT APPLICATIONS THAT DON'T
NECESSARILY NEED CONCERTED
PROGRAMS.
NOW REMEMBER I SAID ABOUT A
THIRD OF THE PROGRAMS HAVE
ALREADY DECIDED THAT THEY ARE
NOT GOING FOR CONTINUE AND ARE
WORKING WITH THEIR INVESTIGATORS
TO TRANSITION.
SO IT'S NEVER EASY.
IT'S USUALLY PAINFUL ON THE SIDE
OF THE INVESTIGATOR BUT WE DO
HAVE TO CONTINUE TO EVOLVE OUR
PROGRAMS TO ADDRESS THE NEWEST
OPPORTUNITIES.
>> SURE.
THANK YOU
>> THIS IS MIKE.
VERY NICE PRESENTATION.
SINCE ONE OF THE GOALS WAS WHAT
DATA -- GIVE ME AN IDEA OF THE
PIPELINE.
I GET THIS IMPRESSION THAT MANY
OF THE PROGRAMS AND CENTERS HAVE
THEIR OWN DATA PLAN AND THE
UPLOADS HAVE BEEN SLOW SO WHAT
IS YOUR IMPRESSION OF HOW MUCH
IS IN THE CANCER DATA COMMONS
AND WHAT CAN WE EXPECT BEFORE
FUNDING IS DONE WITH THE FUNDED
PROGRAMS OF GETTING THAT ALL
HARMONIZED AND INTEGRATED INTO
THE DATA COMMONS AS THERE WAS A
CENTRAL PART OF THE PROGRAM AND
IT SEEMS TO BE LAGGING.
7
>> YEAH.
SO A NUMBER OF THE PROGRAMS AS
YOU SAID DO HAVE THEIR OWN DATA
COORDINATING CENTERS.
THEY ARE AS I UNDERSTAND IT
DESIGNED TO BE ABLE TO DIRECTLY
FEED INTO THE CANCER RESEARCH
DATA COMMONS.
AS THE DIFFERENT DATA COMMONS
ARE STOOD UP.
AND THAT HAS BEEN HAPPENING AT
VARIOUS SPEEDS BUT THERE IS A
COMMITMENT TO ENSURING THAT ALL
OF THE DATA THAT WERE GENERATED
THROUGH THE MOONSHOT WILL BE
BROUGHT INTO THE CRDC.
I DON'T KNOW IF TONY IS ON THE
CALL TODAY.
AND WOULD WANT TO COMMENT ON
THAT.
>> COULD I ASK -- THAT THIS
ISSUE BE ADDRESSED AND GIVE US
AN IDEA OF THE PIPELINE.
THERE IS NO DOUBT THAT IT HAS
BEEN EARTH SHATTERING SUCCESS.
I REMAIN CONCERNED THAT ALL OF
THE COMMONS HAS ALL OF THIS
WONDERFUL DATA -- THERE ARE
FIVE, SIX TIMES -- INVESTIGATORS
HAVE TO GET THE DATA.
THE QUICKER IT IS IN THE COMMONS
-- ANYTHING THAT WE CAN DO TO DO
THIS WILL HAVE A TREMENDOUS
IMPACT.
WITH THE PROGRAM WINDING DOWN
THAT THIS MAJOR GOAL WILL NOT BE
FULFILLED.
THE DATA MAY BE LOST IF THIS IS
NOT DONE AS A PRIORITY.
SO I MIGHT SUGGEST THAT WE FOCUS
ON THAT ASPECT OF IT IN A FUTURE
NCI -- BSA -- NCAB MEETING
>> THERE ARE TWO COMMONS THAT
ARE UP.
THE CANINE AND THE IMMUNO
ONCOLOGY COMMONS THAT ARE
ACCEPTING DATA.
I CANNOT TELL YOU HOW
EFFICIENTLY THAT IS.
BUT GIVING A PRESENTATION HERE
WOULD BE A GOOD IDEA.
>> I WAS GOING TO MAKE THAT
SUGGESTION.
IT'S BEEN A SIGNIFY TOUR PART --
-- SIGNATURE PART.
I THINK IT'S PRETTY ROBUST.
WE SHOULD HEAR MORE ABOUT IT AND
TEEN IS NOT HERE TO TALK ABOUT.
A MAJOR INVESTMENT BEYOND THE
MOONSHOT AND AN AREA WHERE WE
NEED ADVICE ABOUT WHERE TO G -- GO
IN THE FUTURE
>> DATA SHARING AND DATA
MANAGEMENT.
WE SHOULD PUT THAT ON ONE OF THE
FUTURE AGENDAS.
THANK YOU.
IT WAS A GREAT DISCUSSION.
AND THANK YOU.
>> THANK YOU.
>> NEXT WE HAVE A PRESENTATION
ENTITLED THE NIH COMMON FUND,
FACULTY INSTITUTIONAL
RECRUITMENT FOR SUSTAINABLE
TRANSFORMATION OR THE NIH FIRST.
BY DR. SPRINGFIELD.
>> THANK YOU.
>> I JUST WANT TO TAKE LIBERTY.
DON'T GET MAD AT ME.
BUT I WANT TO ACKNOWLEDGE THIS
HISTORIC DAY.
HAVING JOHN CARPTEN -- THE FIRST
AFRICAN-AMERICAN -- -- WE THANK
YOU PAULETTE.
WE THANK YOU,ED IN FOR
NOMINATING JOHN TO THIS VERY I
PLUS STRAWS * POSITION.
JOHN REPRESENTS THE KIND OF
FACULTY THAT WE'RE LOOKING FOR
IN THESE FIRST AWARDS.
HE HAS BEEN A GREAT MENTOR.
A STRONG SUPPORTER.
THE FIRST AFRICAN-AMERICAN TO DO
THE AACR ANNUAL MEETING SO JOHN
REPRESENTS A WONDERFUL ROLE
MODEL FOR US IN CANCER AND
CANCER HEALTH DISPARITIES SO
THANK YOU JOHN FOR JOINING THE
NCAB AND WELCOME.
SO LET ME START -- LET ME DISPEL
A MYTH.
HE HAS BEEN GOING OUT AND A A
CHAMPION OF THE PROGRAM.
HE HAS DONE SUCH A GREAT JOB OF
PROMOTING THIS PROGRAM.
THAT MANY PEOPLE THINK THIS IS
AN NCI PROGRAM.
AND IT'S NOT.
AND HE JUST SAID.
THE NCI FIRST IS GOING TO BE
PRESENTED.
LET ME DISPEL THIS MYTH.
WE STILL GET QUESTIONS ABOUT
THIS.
WHILE WE WOULD LOVE TO TAKE
CREDIT FOR THE FIRST THIS IS NOT
AN NCI PROGRAM.
IT'S A COMMON FUND PROGRAM.
THIS PROGRAM SUPPORTED BY THE
NIH COMMON FUND AND FOR THOSE OF
YOU WHO MAY HAVE BEEN AROUND IN
2004 IT STARTED AT THE NIH ROAD
MAP AND THIS PROGRAM HAS AGAIN
BEEN UNANIMOUSLY REAUTHORIZED AT
THE NIH LEVEL.
THERE IS A DIVISION THAT REALLY
HOUSES THESE DEDICATED SOURCES
OF FUNDING TO ENABLE GOAL DRIVEN
TRANS NIH RESEARCH.
SO ALL COMMON FUND PROGRAMS MUST
HAVE THESE FIVE CRITERIA EVEN TO
BE CONSIDERED OR ELIGIBLE TO BE
PROPOSED FOR FUNDING.
THEY MUST BE TRANSFORMATIVE.
THEY MUST HAVE A HIGH IMPACT.
TO DRAMATICALLY AFFECT THE
BIOMEDICAL AND BEHAVIORAL
RESEARCH OVER THE NEXT DECADE.
THEY MUST BE CATALYTIC.
THEY MUST ACHIEVE THESE DEFINED
SETS OF HIGH IMPACT GOALS WITHIN
5-10 YEARS.
SO ALL OF YOU SITTING OUT HERE
THAT HAVE RO1s THAT HAVE THE
NUMBER 25 OR THE P30 WITH THE
NUMBER 20 ATTACHED TO THEM YOU
WON'T FIND THEM HERE.
THESE ARE SHORT-TERM HIGH IMPACT
PROGRAMS.
THEY MUST BE SYNERGISTIC.
THEY MUST PROMOTE THE MISSION.
OF THE NIH INSTITUTES AND
CENTERS TO BENEFIT HEALTH.
THEY HAVE TO BE CROSSCUTTING.
THEY MUST CUT ACROSS SEVERAL
MISSIONS, MULTIPLE IC MISSIONS
THAT ARE RELATIVE TO MULTIPLE
DISEASE OR CONDITIONS AND THEY
HAVE TO BE SUFFICIENTLY COMPLEX
TO REQUEST A COORDINATED
APPROACH AND THESE PROGRAMS MUST
BE UNIQUE.
SOMETHING THAT NO ONE ENTITY IS
LIKELY TO DO ON ITS OWN.
THIS SLIDE DEMONSTRATES FOR YOU
THE SPECTRUM OF RESEARCH AND
RESEARCH CATEGORIES THAT ARE
CURRENTLY FUNDED BY THE COMMON
FUND PROGRAM.
AND I WANT TO POINT OUT THAT NCI
LEADERSHIP AND STAFF ARE
INVOLVED IN MANY, MANY OF THESE
INITIATIVES AND PROBABLY YOU AS
PIs HAVE BENEFITED AND
RECEIVED AWARDS SUPPORTED BY THE
COMMON FUND.
THE ONE THAT I'M GOING TO TALK
BUT IS THE FACULTY INSTITUTIONAL
RECRUITMENT FOR SUSTAINABLE
TRANSFORMATION.
8 SO WHY FIRST?
I KNOW JUST ABOUT EVERYBODY
AROUND THIS TABLE AND YOU KNOW
THE PROBLEMS WE'VE BEEN FACED
WITH THESE PROBLEMS.
IT'S NOT NEW AND THE FACT THAT
UNDER REPRESENTED MINORITIES ARE
BEING GRANTED PhDs BUT THEY
ARE NOT BEING HIRED AT THE
ACADEMIC INSTITUTIONS AND ONCE
THEY ARE HIRED TYPICALLY ONE AT
A TIME OR TWO AT BEST THEY FEEL
A SENSE OF ISOLATION AND THEY
DON'T FEEL THAT THEY HAVE TRUST
OR THE RELATIONSHIPS COMPARE TO
NONMINORITY COUNTERPARTS ARE NOT
THE SAME AND THEN THE OTHER
PROBLEM IS INSTITUTIONAL.
RIGHT?
THESE REALLY LACK THE NECESSARY
ELEMENTS OF INCLUSION AND EQUITY
AND THAT SEND A HORRIBLE MESSAGE
TO PEOPLE OF COLOR UNDER
REPRESENTED MINORITIES THAT THEY
JUST DON'T BELONG IN SCIENCE.
AND BELIEVE ME IF WE DO NOT DO
ANYTHING ABOUT THIS WE KNOW THAT
THIS PROBLEM WOULD ONLY HAVE
BEGUN TO GET WORSE.
SO UNDER THE LEADERSHIP OF
DR. HANNAH VALENTINE WHO WAS THE
CHIEF OPERATING DIVERSE TEASE
OFFICER.
SHE FELT THAT NIH HAD TO DO
SOMETHING ABOUT THIS.
SHE DEVELOPED A CONCEPT AND
PRESENT EDIT TO THE ADVISORY
COUNCIL, THE DIRECTOR
DR. COLLINS.
IT WAS APPROVED AND A LARGER
WORKING GROUP WAS CONVENED TO
CONCEIVE AND DEVELOP AND
IMPLEMENT THIS PROGRAM.
AND SO ON THIS SLIDE YOU SEE THE
CURRENT STRUCTURE.
IT'S COMPOSED OF TWO OF LIMITS.
A U54 WHICH IS A FACULTY COHORT.
AND THAT IS THE PROGRAM THAT NCI
MANAGES.
AGAIN THIS IS NOT AN NCI PROGRAM
SO DON'T ASKED IN FOR MORE
MONEY.
AND THE OTHER COMPONENT IS A
COORDINATING AND EVALUATING
CENTER.
IT'S HOUSE ENDS AT THE NATIONAL
INSTITUTE OF MINORITY HEALTH AND
HEALTH DISPARITIES AND THIS
EVALUATION CENTER WILL CONDUCT A
COMPREHENSIVE EVALUATION OF THE
FIRST COHORT PROGRAM.
THE INITIAL PROGRAM BUDGET
ALLOCATION IS AT $241 MILLION
AND THIS IS A NINE-YEAR PROGRAM.
SO AGAIN THE PURPOSE OF THE
FIRST COHORT -- IS TO TRANSFORM
CULTURE AT NIH FUNDED EXTRAMURAL
INSTITUTIONS.
AND WHAT THIS PROGRAM WILL DO IS
PROVIDE SUPPORT FOR THESE
INSTITUTIONS TO IMPLEMENT,
ENHANCE, SUSTAIN CULTURES OF
INCLUSIVE EXCELLENCE THAT HAVE
TO BE TRANSFORMATIONAL NOT AT
JUST THEIR OWN ACADEMIC
INSTITUTION BUT BEYOND AND WHAT
DOES THAT MEAN?
WE WANT THESE INSTITUTIONS YOUR
INSTITUTIONS TO CREATE
ENVIRONMENTS WHERE ALL
INDIVIDUALS ARE WELCOME AND NOT
ONLY SURVIVE BUT WILL THRIVE.
ALSO PROVIDING SUPPORT FOR THESE
INSTITUTIONS TO RECRUIT AND HIRE
A DIVERSE COHORT OF EARLY CAREER
FACULTY AND THE COHORT IS A
WHOLE GROUP OF INDIVIDUALS NOT
ONE, NOT TWO BECAUSE THE
ISOLATIONS DETRIMENTAL TO THE
SUCCESS.
SO THIS COHORT MODEL IS ONE THAT
HAS BEEN USED BY THE NIH AND
OTHER ICs AND EVEN US THE IQ
WE USE A COHORT MODEL.
WE KNOW THE IMPORTANCE OF
BRINGING INDIVIDUALS IN A GROUP
WHERE WE SEE EACH OTHER.
WE CAN TALK TO EACH OTHER.
WE TALK THE SAME LANGUAGE.
WE HAVE THE SAME PROBLEMS.
WE EAT THE SAME FOOD.
WE DRESS THE SAME WAY.
WE WEAR THE SAME -- AND WE'RE
MORE COMFORTABLE.
THE ADDITIONAL ADVANTAGE IS THAT
WE'RE ASKING INDIVIDUAL
INSTITUTIONS TO HIRE NOT JUST IN
A COHORT BUT IN RESEARCH
CLUSTERS.
THAT WILL AID IN THESE FACULTY
-- ESTABLISHING NETWORKS FOR
COLLABORATIONS, RIGHT SO THAT
THEY IN FACT CAN BE MORE
SUCCESSFUL.
SO THE FACULTY THAT ARE
RECRUITED AND HIRED MUST HAVE A
COMMITMENT TO PROMOTING
DIVERSITY AND INCLUSION AND THEY
MUST BE COMPETITIVE FOR
ADVERTISED RESEARCH TO ATTRACT
EQUIVALENT POSITIONS.
THEY MUST BE COMPETITIVE.
WHY?
BECAUSE THE GOAL IS TO HAVE
THESE FACULTY APPLY FOR RO1
FUNDING WITHIN A VERY SHORT
PERIOD OF TIME WHICH IS THE
DURATION OF THE AWARD.
SO THE PROGRAM OVERVIEW IS AS
FOLLOWS.
WE HAVE PLAN TO MAKE 12
STAGGERED AWARDS.
FOUR AWARDS EACH YEAR.
WE'RE RELEASING THREE 4 PHASE.
EACH AWARD IS FIVE YEARS.
THE FIRST YEAR IS A LAUNCH YEAR.
A PLANNING YEAR.
FOR KEY PERSONNEL AND CORE
LEADERS.
PLANNING STRATEGIES.
CLUSTER HIRING.
FACULTY AND PROFESSIONAL AND
RESEARCH DEVELOPMENT AND SEARCH
COMMITTEES.
THIS IS A YEAR WHERE THEY ARE
PLANNING SO WE'RE GIVING THEM
THIS YEAR TO GET IT TOGETHER.
THE SECOND THROUGH THE FOURTH
YEAR IS WHERE THE FACULTY ARE
BEING RECRUITED AND HIRED.
ALL FACULTY HAVE TO BE HIRED BY
THE THIRD YEAR OF THIS AWARD.
SO WE PROVIDE FUNDS FOR START UP
PACKAGES.
WE PROVIDE FUNDS FOR
PROFESSIONAL DEVELOPMENT AS WELL
AS INCLUSIVE ACTION TO
ACTIVITIES.
SO HERE IS THE FIRST COHORT
STRUCTURE.
ALL PROGRAMS MUST HAVE THESE
REQUIRED CORES.
ADMINISTRATIVE CORE.
FACULTY DEVELOPMENT CORE.
EVALUATION CORE.
AGAIN THE ADMINISTRATIVE CORE IS
THE POWER HOUSE OF THIS PROGRAM.
THIS IS WHERE THE ACTIVITY THE
ENERGY THE LEADERSHIP ALL OF
THESE THINGS ARE TAKING PLACE.
KEY PERSONNEL.
CORE LEADERS.
IF YOU HAVE LARGE INFRASTRUCTURE
PROGRAMS THIS IS NO DIFFERENT
FROM OTHER PROGRAMS THAT YOU
HAVE MANAGED IN THE PAST.
THE FACULTY DEFINITELY CORE IS
THIS CORE THAT IS RESPONSIBLE
FOR DEVELOPING THESE ACTIVITIES.
AGAIN THESE ARE EARLY CAREER
FACULTY.
WE HAVE TO PROVIDE PROFESSIONAL
DEVELOPMENT, MENTORING.
SPONSORSHIP.
ACTIVITIES TO MAKE SURE THAT
THEY ARE IN FACT COMPETITIVE FOR
THESE RO1 SUBMISSIONS AND THE
EVALUATION CORE IS TO ESTABLISH
THE INDIVIDUAL MILESTONES FOR
INDIVIDUAL PROGRAMS AS WELL AS
WORKING IN PARTNERSHIP WITH THE
CEC TO DEVELOP COMMON METRICS
AND COMMON MEASURES AND OUTCOMES
THAT CAN BE EVALUATED AT THE END
OF THIS PROJECT PERIOD.
SO YOU HAVE TO BE ABLE TO
CONDUCT RESEARCH AND YOU HAVE TO
PROVIDE EVIDENCE FOR COMMITMENT
TO DIVERSITY AND INCLUSION.
IT HAS TO APPLY EITHER AS A
LIMITED RESOURCE, HIGH RESOURCE
INSTITUTION OR IN PARTNERSHIP.
AND SO THIS SLIDE REALLY LETS US
KNOW WHAT IS A LIMITED RESOURCE
INSTITUTION.
IT IS AN INSTITUTION THAT
RECEIVES LESS THAN $50 MILLION
AND LESS THAN $25 MILLION IN RO1
SUPPORT.
AND THE LAST THREE YEARS BEFORE
SUBMITTING THE GRANT.
AND YOU CAN ALSO APPLY AS A
PARTNERSHIP.
AND YOU CAN APPLY WITH A HIGH
RESOURCE INSTITUTION.
A LIMITED RESOURCE INSTITUTION.
VICE VARSHA -- *.
CAVEATS IS THEY MUST RECRUIT NO
LESS THAN 10 FACULTY.
LIMITED RESOURCE INSTITUTIONS
MUST RECRUIT NO LESS THAN SIX.
SO IF YOU COMBINE AN HRI WITH AN
LRI YOU HAVE TO RECRUIT NO LESS
THAN 10.
7 IF TWO LRIs ARE PARTNERED NO
LESS THAN 6 FACULTY HAVE TO BE
RECRUITED.
SO AS I POINTED OUT IN THE FIRST
COUPLE OF SLIDES STATING THAT
THESE COMMON FUND INITIATIVES
HAVE TO HAVE MEASURABLE GOALS
AND OBJECTIVES WITHIN A SHORT
PERIOD OF TIME THIS PROGRAM HAS
THIS AS WELL.
EACH OF THE GOAL AREAS FOR
INSTITUTIONAL CULTURE CHANGE,
HIRING THE FACULTY,
PROFESSIONAL MeSH P --
DEVELOPMENT.
* THESE ARE GOING TO BE REFINED
AS WE BEGIN TO WORK WITH THE
CEC.
BUT THE CAVS NET HERE IS THAT
THE APPLICANT MUST PROVIDE
BASELINE DATA FOR EACH OF THESE
GOALS.
IN ORDER NOR US TO EVALUATE ON A
YEARLY BASES AS WELL AS AT THE
END OF THE PROJECT PERIOD.
THIS IS A BUDGET SLIDE AND I
WANT TO POINT YOU TO THE BOTTOM
LEFT HAND WHICH REALLY GIVES US
THE BUDGET PER AWARD.
EACH AWARD WILL GET AN AVERAGE
OF ABOUT $10 MILLION.
NOW YOU MAY SAY OH, MY GOODNESS.
THIS IS NOT ENOUGH MONEY AT ALL
TO DO ALL OF THE THINGS THAT YOU
HAVE WANT US TO DO.
IN THIS PROGRAM.
RIGHT.
AND IT'S NOT.
AGAIN COMMON FUND PROGRAMS ARE
CATALYTIC.
THESE INSTITUTIONS HAVE TO PUT
SOME SKIN IN THE GAME.
THEY HAVE TO COMMIT TO MAKING
THESE FACULTY WHOLE BECAUSE WE
KNOW THE FUNDS THAT WE'RE
PROVIDING FOR THESE START UP
PACKAGES MAY NOT BE EQUIVALENT
TO WHAT YOU'RE OFFERING OTHER
FACULTY SO YOU HAVE TO PUT SKIN
IN THE GAME.
THE FUNDS THAT WE'RE PROVIDING
ARE INSUFFICIENT.
YOU HAVE TO PUT SOME SKIN IN THE
GAME.
INSTITUTIONAL COMMITMENT IS
ABSOLUTELY PARAMOUNT TO THE
SUCCESS OF THESE PROGRAMS
BECAUSE YOU'RE TRANSFORMING YOUR
INSTITUTIONAL CULTURE AS WELL AS
BRINGING IN A DIVERSE COHORT
THAT YOU WANT TO RETAIN AND
PROMOTE SO THAT WE CAN ANSWER
THESE QUESTIONS ABOUT DIVERSITY
OF FACULTY ON SOME OF OUR LARGE
STANDING PROGRAMS WHERE WE DON'T
SEE THEM EXIST.
THIS REPRESENTS AN INITIAL GREAT
START IN PROVIDING THE CATALYTIC
EFFORT.
THE FUNDS, THE VENTURE CAPITAL
IF YOU WILL TO SUPPORT THESE BUT
YOU AS INSTITUTIONS HAVE TO
COMMIT TO THESE PROGRAMS.
AND INSTITUTIONAL COMMITMENT IS
SOMETHING THAT WE TAKE SERIOUSLY
WHEN MAKING RECOMMENDATIONS.
NEXT SLIDE.
SO HERE WE ARE.
WE'VE GONE THROUGH THE FIRST
YEAR.
IT'S BEEN A BANNER YEAR.
IT'S BEEN A WONDERFUL YEAR.
WE RECEIVED A TREMENDOUS OUT
POURING OF SUPPORT FROM THE
COMMUNITY AND THAT MEANS WE HAD
A LOT OF APPLICATIONS FOR THE
FIRST FISCAL 21.
AND THIS IS WHERE WE'VE COME UP
WITH IN TERMS OF OUR
RECOMMENDATIONS.
7 IT TOOK US A LONG TIME TO VET
THESE APPLICATIONS.
THE REVIEWERS DID A GREAT JOB.
THESE APPLICATIONS WERE ALSO
OUTSTANDING.
SO IT MADE OUR JOB VERY
DIFFICULT TRYING TO IDENTIFY
THESE FIRST COHORT AWARDEES.
AND YOU CAN SEE THERE IS A GOOD
DIVERSITY HERE.
WE HAVE ONE FROM UAB IN
TUSKEGEE.
A HIGH RESOURCE AND LIMITED
RESOURCE INSTITUTION.
WE HAVE TWO LRI SAN DIEGO STATE
UNIVERSITY AND FLORIDA STATE
UNIVERSITY.
WE HAVE THREE HRI & DREXEL,
MOUNT SINAI AND SAN DIEGO.
NOW THIS PROGRAM IS STILL
ONGOING AND WHAT I CAN TELL YOU
IS THE PLANS THEY HAVE IN PLACE
ARE PHENOMENAL.
I CAN'T GIVE YOU DETAILS AT THIS
POINT AND CERTAINLY WE'RE GOING
TO COME BACK TO DO THAT BECAUSE
WE HAVE ONE MORE ROUND.
INSTITUTIONAL SUPPORT HAS BEEN
FABULOUS.
THE FACULTY DEVELOPMENT
ACTIVITIES ARE VERY UNIQUE FOR
THESE DIVERSE COHORTS.
I WAS JUST BLOWN AWAY BY THESE
APPLICATIONS AND THIS --
REPRESENTS SIX BUT THERE WERE SO
MANY MORE.
THESE ARE AREAS THAT THERE IS A
NATIONAL CONCERN.
IN ADDITION TO LOOKING AT THE
MERIT OF THE APPLICATION AND
GEOGRAPHY, THE TYPE OF
INSTITUTIONS AND THE NUMBER OF
FACULTY BEING RECRUITED WE ALSO
LOOKED AT THE BIOMEDICAL
RESEARCH AREAS AND THE NEXT
SLIDE SHOWS YOU THAT THERE IS A
VERY DIVERSE -- -- RESEARCH THAT
IS TAKING PLACE THAT WILL BE
FUNDED THROUGH THESE PROGRAMS.
SO THE MISSION OF THE BIOMEDICAL
RESEARCH AND BEHAVIORAL RESEARCH
EFFORTS ARE HIGHLIGHTED HERE.
THREE OF THE STATION ARE GOING
TO BE RECRUITING FACULTY AND
CANCER.
THE OTHER THING THAT WE NOTICED
IS THAT HEALTH EQUITY OR HEALTH
DISPARITY RESEARCH IS COMMON
AMONG ALL OF THESE APPLICATIONS.
SO, IT'S REALLY GRATIFYING TO
SEE THAT WE'RE DEALING ALSO WITH
THE DISPARITY RESEARCH AND
BUILDING UP AN AREA THAT IS
DESPERATELY NEEDED ACROSS THE
NIH.
SO THESE AWARDS WERE MADE IN
SEPTEMBER.
WE HAD OUR FIRST KICK OFF
MEETING.
THE PIs ATTENDED.
THE CORE LEADERS ATTENDED.
WE HAD A WONDERFUL KEYNOTE
ADDRESS BY FRANCIS AND WONDERFUL
REMARKS FROM THREE OF OUR
COCHAIRS
AND THE PROGRAM MANAGEMENT IS
UNDER WAY.
THESE PROGRAMS ARE STANDING UP.
WE'RE MEETING WITH THEM ON A
MONTHLY BASES PROVIDING INPUT
AND FEEDBACK ON THE FIRST YEAR.
WE'RE GOING TO BE IDENTIFYING
PROJECT SCIENTISTS BECAUSE THE
RESEARCH AREAS ARE VERY DIVERSE
SO WE'RE EMPLOYING SUBJECT
MATTER EXPERTISE FROM ACROSS THE
NIH SO THEREFORE IT'S REALLY AN
EXCITING TIME.
LOOKING FORWARD TO NEXT YEAR.
THE OTHER THING IS OUR FIRST CEC
EXECUTIVE STEERING COMMITTEE HAS
MET.
AND THIS AWARD WAS MADE TO
MOOREHOUSE SCHOOL OF MEDICINE.
ANOTHER LIMITED RESOURCE
INSTITUTION.
SO WE'RE VERY EXCITED ABOUT
THIS.
WE'RE EXCITED ABOUT THE
DIVERSITY OF THE APPLICATIONS
AND THE AWARDS AND ALSO THAT THE
CEC IS GOING TO BE MANAGED BY
MOOREHOUSE COOL OF MEDICINE
UNDER THE LEADERSHIP.
SO HERE WE ARE.
WE MADE THE 6 AWARDS FOR FISCAL
21.
WE'RE IN FISCAL 22 NOW.
THE APPLICATIONS HAVE COME IN
FOR 22.
THEY CAME IN -- IN SEPTEMBER.
THE REVIEW IS ABOUT TO TAKE
PLACE IN FEBRUARY.
WE'RE RECRUITING REVIEWERS IF
YOU'RE INTERESTED IN LEARN ABOUT
THIS PROGRAM -- SEND YOUR NAME
TO ME.
I WILL PASS IT FORWARD.
WE ANTICIPATE MAKING FOUR AWARDS
AGAIN IN 22.
FOR THE LAST -- THE COCHAIRS
HAVE APPROVED.
WE'RE MAKING FINAL CHANGES IN
THE RFA AND HOPEFULLY THAT THIRD
RFA WILL BE RELEASED IN JANUARY
OF EARLY 22.
SO I DON'T KNOW IF YOU GOT IT.
OUR PLAN WAS TO MAKE FOUR AWARDS
ORIGINALLY.
BUT IN 21 WE MADE SIX.
AND I HAVE TO TELL YOU THE IC
COCHAIRS LED BY NED, MARIE,
ELISSAO DID A GREAT JOB.
BECAUSE WE RECEIVED A LOT OF
APPLICATIONS.
A LOT OF APPLICATION ESCORTED
GREAT -- * THEY WERE WONDERFUL
AND IT WAS DIFFICULT TRYING TO
IDENTIFY THE FOUR.
WE WENT BACK TO THE COMMON FUND
AND WENT BACK TO THE IC
DIRECTORS AND ASK HEY CAN YOU
CONTRIBUTE TO THIS EFFORT AND WE
WERE DELIGHTED THAT THE COMMON
FUND -- AND AGAIN NED AND MARIE
AND ELISSO AND OTHER ICs AS
YOU CAN SEE HERE AND THAT
ALLOWED US TO MAKE TWO
ADDITIONAL AWARDS THIS YEAR.
I'M REALLY HOPING THAT THIS
HAPPENS AGAIN EACH FISCAL YEAR.
BUT THIS REALLY -- IS A
TESTAMENT TO THE COMMITMENT AT
THE NIH LEVEL FOR ALL OF THE
ICs FOR THIS PROGRAM.
SO I'M VERY HAPPY ABOUT THAT.
THE NCI FIRST TEAM HAS BEEN
AMAZING.
KUDOS TO THEM.
KUDOS TO OGA GIVING THESE AWARDS
OUT THIS YEAR.
AND OUR PROGRAM MANAGEMENT TEAM
THROUGHOUT THE COURSE OF THIS
HAS BEEN AMAZING.
BUT -- NEXT SLIDE -- NCIs
EFFORT PALE IN COMPARISON TO THE
WORK OF THIS TRANS NCI FIRST
WORKING GROUP.
THE COCHAIRS ARE COMMITTED,
PASSIONATE.
THEY ARE FIGHTING FOR WAR AND
IT'S BEEN A PLEASURE ALSO TO
WORK WITH THE WORKING GROUP
LEADER TEAM.
AND I HAVE TO SAY THAT WE ALL
BEGAN THIS WORK WHEN COVID HIT.
AND DURING THE TIME WHEN WE WERE
SEEING RACIAL AND SOCIAL IN
JUSTICE IN FRONT OF OUR FACE
DAILY AND SO THIS WAS A BEAM OF
LIGHTED FOR US WORKING THROUGH
THOSE DARK DAYS AND WE WOULD SEE
THIS EVERY DAY.
WE HAVE NEVER MET FACE TO FACE.
ALL OF OUR WORK HAS BEEN
VIRTUAL.
AND IT'S JUST BEEN SUCH A
REWARDING EXPERIENCE.
AND I AM SO HOPEFUL THAT THE
WORK THAT WE PUT INTO THIS
PROGRAM WILL TRANSFORM THE
CULTURES AT OUR ACADEMIC
INSTITUTIONS SO THANK YOU.
APPRECIATE YOUR TIME.
AGAIN THIS IS NOT AN NCI PROGRAM
SO DO NOT ASKED IN FOR MORE
MONEY
>> TREMENDOUS.
TREMENDOUS.
THANK YOU SO MUCH SONIA FOR THAT
PRESENTATION ABOUT THIS NEW
PROGRAM.
AND I'M SPEECHLESS.
SO EXCITED ABOUT THE OUTCOMES.
YET ANOTHER AMAZING NCI
INITIATIVE.
>> NO.
NIH INITIATIVE.
>> NIH --
>> MAY I MAKE ONE COMMENT?
>> YES.
BUT JUST A COMMENT
>> I APOLOGIZE -- BUT IT'S ONLY
BECAUSE I'M SO PROUD OF IT.
I THINK SONIA HAS BEEN A LITTLE
COY.
THIS WAS A CAT HERDING EXERCISE.
AND IT WAS AMAZING THAT SONIA
PULLED THIS OFF ALSO WORKING
WITH THE COLLABORATORS AND I'M
EXCITED THAT SONIA MENTIONED
HANNAH VALENTINE.
HER ROLE WAS SIGNIFICANT.
GREAT PRESENTATION.
>> THERE ARE A LOT OF QUESTIONS
I'M SURE.
I THINK IT'S DEFINITELY WORTH AT
LEAST ONE OR TWO QUESTIONS.
>> WE'RE GOING TO COME BACK WITH
THE OUTCOMES.
>> A COUPLE OF PEOPLE HAVE
QUESTIONS IN THE CHAT.
DOES ANYONE WANT TO ASK A
QUESTION AT THIS POINT?
>> JOHN.
THIS IS CHASE.
THIS IS A GOOD PROGRAM.
I SHARE THE ENTHUSIASM.
IT'S A LONG TIME IN THE MAKING.
WE ALL KNOW THIS.
BUT THERE IS NO SUCH THING AS A
FREE LUNCH AND WE DON'T HAVE
THAT BIG OF A POOL OF PEOPLE
ACROSS THE COUNTRY TO DRAW ON.
SO MY GET WAS TO WHAT EXTENT ARE
WE LOOKING AT POTENTIAL NEGATIVE
IMPACTS IN INSTITUTIONS --
[ INDISCERNIBLE ]
>> I'M SORRY.
I DON'T UNDERSTAND THE QUESTION.
>> I THINK THE QUESTION IS THERE
A THREAT THAT SOME INSTITUTIONS
MAY LOSE SOME OF THEIR TALENT TO
NIH FIRST FUNDED INSTITUTIONS?
>> OR ARE -- LESS EQUIPPED LESS
RESOURCED INSTITUTIONS THAT
WE'RE TRYING TO SHORE UP.
SO I CAN SEE A NEGATIVE FLOW
OUTFLOW FROM THESE INSTITUTIONS
AS THESE PROGRAMS ARE LED
ELSEWHERE.
>> AGAIN WE SEPARATED OUT THE
HIGH RESOURCE FROM THE LIMITED
RESOURCE.
THE SEPARATE REVIEW FOR THOSE
INSTITUTIONS.
SO WE'RE TRYING TO AGAIN EQUIP
THE LIMITED RESOURCE
INSTITUTIONS AS WELL.
THIS ISSUE OF BRAIN DRAIN OR
HAVING UNDER REPRESENTED
MINORITIES BEING STOLEN AWAY
INTO MAINSTREAM INSTITUTION IS
SOMETHING THAT WE'VE BEEN
DEALING WITH FOREVER.
I DON'T THINK IT'S ALL TO
AUTOMATICALLY GO AWAY BUT AS
MORE OF THE PROGRAMS ARE
IMPLEMENTED AND DIVERSITY
BECOMES THE FACE OF THE
INSTITUTIONS WE'LL SEE LESS OF
THAT.
THAT IS THE HOPE.
>> THAT IS GREAT.
ANY OTHER QUESTIONS FOR
DR. SPRINGFIELD.
I'M SURE THERE ARE BUT BE GREAT
TO HEAR THE UPDATES AND TO SEE
THE NEXT GROUP AND TO EVEN SEE
WHO THAT COHORT IS.
AND TO WATCH THEIR CAREER
TRAJECTORIES.
THANK YOU SO MUCH SONIA FOR THAT
PRESENTATION.
>> THANKS.
>> OUR FINAL PRESENTATION WILL
BE BROUGHT TO US BY DR. ROBERT
CROYLE WHO'S THE RETIRING
DIRECTOR OF THE DIVISION OF
CANCER CONTROL AND POPULATION
SCIENCES.
>> THANK YOU, JOHN.
TERRIFIC TO SEE YOU.
AND JUST FOR CONTEXT AND RELATED
TO THE NATIONAL CANCER ACT I
WANT TO MAKE SURE THAT THE BOARD
MEMBERS ARE AWARE THAT NCI IS
THE ONLY INSTITUTE OF THE NIH
WHO WHERE THE CHAIR OF THE
ADVISORY COUNCIL IS NOT THE
INSTITUTE DIRECTOR.
BECAUSE OF THE NATIONAL CANCER
ACT THE BOARD IS CHAIRED BY
SOMEBODY OUTSIDE THE NCI.
AND BECAUSE OF THE PROVISIONS
AND OTHER REASONS NCI HAS MORE
OVERSIGHT MORE ACCOUNTABILITY
AND MORE TRANSPARENCY I CAN SAY
NOW I'M ABOUT TO RETIRE FROM NIH
AND AFTER ATTENDING A LOT OF
ADVISORY MEMBERS WHERE INSTITUTE
DIRECTORS CAN BE VERY DIRECTIVE
IN WHAT HAPPENS AT A COUNCIL
MEETING I THINK -- JUST TO
APPRECIATE THAT THE
ACCOUNTABILITY THAT NCI HAS.
WE HAVE MORE ADVISORY BOARDS
THAN ANYBODY ELSE AND OUR
COUNCIL IS NOT CHAIRED BY OUR
INSTITUTE DIRECTOR.
SO I'M GOING TO TALK ABOUT IN A
VERY QUICK SUPERFICIAL WAY
BECAUSE IT'S HARD TO REFLECT AND
SUMMARIZE 19 YEARS AS DIVISION
DIRECTOR AND 23 YEARS AT NCI AND
SUMMARIZE CHALLENGES MOVING
FORWARD IN A SHORT AMOUNT OF
TIME.
SO I'M GOING TO HIT SOME
HIGHLIGHTS ABOUT WHERE WE'VE
BEEN IN TERMS OF CANCER CONTROL
AND SOME OF THE CHALLENGES
MOVING FORWARD.
I'M GOING TO TALK ABOUT THE
LAUNCH OF THE DIVISION AND SOME
OF THE MAJOR PROGRAMS AND
MECHANISMS FOR FUNDING RESEARCH
THAT WE'VE UTILIZED IN THE
DIVISION.
AND THEN AGAIN JUST TOUCH ON A
FEW ISSUES OF CURRENT CHALLENGES
AND ALSO MENTION OUR TRANSITION
TO OUR NEW DEVELOPMENT DIRECTOR
WHO HAS ALREADY STARTED.
SO THIS SLIDE HIGHLIGHTS A FEW
OF THE MAJOR EVENTS IN THE
HISTORY.
WHICH WAS FORMED THE DIVISION
WAS FORMED IN RESPONSE TO BOARD
CRITICISM OF NCI.
SO WHEN RICK WAS DIRECTOR HE
COMMISSION ENDS FIVE PROGRAM
REVIEW GROUPS AND THERE WAS THE
BISHOP -- REPORT WHICH LED TO A
MAJOR REORGANIZATION OF NCI.
SO WHAT I OFTEN CALL THE BRAIN
REORGANIZATION UNDER RICK -- AND
ALSO AT THE SAME TIME THE OFFICE
OF CANCER SURVIVORSHIP WAS
CREATED SO I WANTED TO SHOUT OUT
-- BECAUSE WE'RE CELEBRATING THE
25th ANNIVERSARY OF OCS WHICH
IS LED BY DR. EMILY -- BUT AGAIN
THE RESULT OF ADVOCACY AND INPUT
FROM ADVISORS.
AND ENGAGEMENT FROM THE WHITE
HOUSE.
AGAIN IN PART DUE TO THE CANCER
ACT.
BARBARA -- IS THE GIANT WHOSE
SHOULDER I'VE STOOD ON.
SHE WAS APPOINTED AS THE
ORIGINAL DIVISION DIRECTOR AND
SHE HAD THE CHARGE OF SITTING
DOWN WITH BOB HYATT THE DEPUTY
ORIGINALLY AND MYSELF WITH A
BLANK SHEET OF PAPER CREATING A
NEW DIVISION AT NCI.
IT WAS AN EXCITING TIME AND A
HUGE OPPORTUNITY AND A HUGE
RESPONSIBILITY.
WE THEN FORMED A NUMBER OF NEW
PROGRAMS AND CONTINUED TO EVOLVE
INVOLVE OVER THE YEARS.
A WHOLE NEW PROGRAM WHEN HEALTH
CARE DELIVERY RESEARCH WHICH AT
THE TIME WAS A BIT
CONTROVERSIAL.
BUT ALSO SOME SIGNATURE RESEARCH
PROGRAMS.
SO THERE IS NO WAY I'LL GO
THROUGH ALL OF THE RFAs AND
SPECIAL INITIATIVES.
I'M GOING TO AS WE WILL MAIL YOU
THE LAST -- OUR DIVISION'S LAST
ANNUAL REPORT UNDER MY TENURE SO
YOU WILL BE GETTING IN THE MAIL
A HARD COPY OF OUR LAST ANNUAL
REPORT WHICH ALSO INCLUDES A BIT
OF A RETROSPECTIVE REVIEW ON THE
MAJOR INITIATIVES OVER THE
YEARS.
ONE OF THE STRATEGIES THAT WE
USE WHICH HAS BECOME MORE COMMON
AT NCI NOW BUT WAS NEW AT THE
TIME WAS CENTERS OF EXCELLENCE
AS A RESEARCH FUNDING MECHANISM
TO PROVIDE REALLY AMBITIOUS
RESEARCH GOALS IN A COMPLEX
CHALLENGING AREA OF GREAT
IMPORTANCE TO CANCER CONTROL.
THE FIRST OF THESE BEING THE
TRANTRANSDISCIPLINARY TOBACCO USE.
IT WAS COLLABORATIVE WITH OTHER
INSTITUTES AND FUNDERS.
HNIDA AND -- WOOD FOUNDATION.
THESE ARE THE LARGEST RFAs
THAT WE'VE LAUNCHED ALL OF WHICH
WERE DISCUSSED AND REVIEWED BY
THE BSA OF COURSE.
AND ALSO I THINK THIS IS ONE WAY
TO HIGHLIGHT SOME OF THE HIGHEST
RESEARCH PRIORITIES THAT WE'VE
HAD IN CANCER CONTROL.
WE WERE THE FIRST INSTITUTE AT
NIH TO PUT AN EFFORT IN
COMMUNICATION RESEARCH.
AND THAT IS REALLY COME BACK
AROUND TO THE NIH AND I THINK
NIH CLEARLY HAS RECOGNIZED THAT
THE AGENCY AS A WHOLE COULD HAVE
AND SHOULD HAVE MADE A BROADER
COMMITMENT AS WE'VE SEEN IN
COVID IN THE EXISTENCE OF
VACCINE HESITANCY.
HOPEFULLY MOVING FORWARD A
GREATER EFFORT ON HEALTH
COMMUNICATION AND UNDERSTANDING
PERSUASION AND HOW TO COUNTER
MISINFORMATION
SO WHAT IS NEXT?
ONE THAT THE BSA YOUR GROUP
BEING REVIEWED -- WE JUST HAD
THE REVIEW FOR THE NEW CENTERS
OF EXCELLENCE IN TELEHEALTH
RESEARCH.
IN CANCER RELATED CARE SO I
THINK NCI IS PLAYING A SIGNIFY
TOUR LEADERSHIP ROLE.
WE WERE TRACKING POLICY AND
DEVELOPMENTS AND SAW THE GREATER
INTEREST IN CONGRESS AND ALSO
HOW TELEHEALTH BECAME SO VITAL
DURING COVID AND IN THE SPRING
OF NEXT YEAR WE WILL BE DECIDING
ON AND FUNDING OUR FIRST
RESOURCE CENTERS ON TELEHEALTH
AND THIS WILL BE CRITICAL MOVING
FORWARD.
ONE OF THE THINGS THAT WE'VE
BEEN CAREFUL TO DO -- IN THE
CASE OF THE MOONSHOT AS YOU
HEARD AND ALSO ALL OF US WHO
HAVE LED MAJOR INITIATIVES HAVE
BEEN MINDFUL ABOUT EVALUATION
AND LESSONS LEARNED.
IT HAS BEEN MORRI MORE -- RIGOROUS.
UNDERSTANDING HOW TO IMPROVE THE
FUNCTIONING OF TEAM SCIENCE.
AND PROJECTS.
AND WE CREATED A NEW FIELD NOW
KNOWN AS THE TEAM SCIENCE.
AND I RECENTLY PUBLISHED A BOOK.
SO I THINK THIS ISSUE.
EVALUATION IS GOING TO BE
IMPORTANT GOING FORWARD.
YOU CANNOT TALK ABOUT CANCER
CONTROL IN ANY CONTEXT WITHOUT
TALKING ABOUT TOBACCO CONTROL
AND IT'S STILL THE CASE THAT
CANCER CONTROL'S MOST IMPORTANT
CHALLENGE IS TOBACCO CONTROL.
WE DON'T DISCUSS IT ENOUGH.
IT'S STILL THE LEADING CAUSE OF
PREVENTED ANNUAL DEATH IN THE
UNITED STATES.
AND * AND THE LEADING CAUSE OF
CANCER DEATH.
TOBACCO CONTROL -- HAS BEEN AN
AREA -- BUT WILL CONTINUE TO BE
IMPORTANT.
WE OFTEN TAKE IT FOR GRANTED.
BECAUSE IT IS STILL WIDESPREAD
AND BECAUSE IT'S STILL A
CHALLENGE.
BUT I THINK ONE OF THE MOST
REMARKABLE PUBLIC HEALTH STORIES
IS THE PROGRESS WE'VE MADE IN
TOBACCO CONTROL AND MANY OF YOU
HAVE SEEN THIS SLIDE BEFORE IN
VARIOUS FORMS AND OVER THE
YEARS.
BUT THIS SHOWS TOBACCO
CONSUMPTION CIGARETTE
CONSUMPTION IN ADULTS IN THE
U.S. OVER THE LAST MANY YEARS
AND ITS ASSOCIATION WITH A
NUMBER OF EVENTS P. ALL OF WHICH
WERE VERY HARD FOUGHT AND HARD
WON.
THRILLED THAT THE DOCTOR HAS
JOINED OUR BOARD BECAUSE THIS
CONTINUES TO BE A HUGE
CHALLENGE.
IT'S IMPORTANT TO NOTE THAT ONE
OF THE OUR BIGGEST AREAS OF
PROGRESS AGAINST CANCER IS THE
RESULT OF OUR PROGRESS IN
REDUCING TOBACCO USE.
AND THIS IS JUST PART OF THE PAY
OFF.
OFTEN TIMES WE TALK ABOUT THE
REDUCTION OF LUNG CANCER
MORTALITY.
AGAIN REDUCTION OF TOBACCO USE
BEING THE MAJOR DRIVER.
IMPROVEMENTS IN SURVIVAL AS A
RESULT OF THE ADVANCEMENTS IN
THERAPY.
BUT ALSO IMPORTANT TO SAY THAT'S
A NOT JUST A CANCER ISSUE.
MANY DIFFERENT CHRONIC ISSUES
ARE ASSOCIATED WITH TOBACCO USE.
FDA HAS PLAYED A KEY ROLE.
THE DEPARTMENT OF HEALTH AND
HUMAN SERVICES AND MANY OTHER
AGENCIES AS WELL.
I'VE GOT TO GIVE A SHOUT OUT TO
THE CDC ON SMOKING ON HEALTH.
THEY'VE BEEN CLOSE AND TIGHT
COLLABORATORS OVER THE YEARS AND
DONE REMARKABLE WORK AT THE CDC.
KEY CHALLENGES MOVING FORWARD.
QUICK AND SIMPLISTIC.
MOVING FORWARD AND GENERATING
THE EVIDENCE THE FDA NEEDS.
THERE ARE MANY AUTHORITIES AND
WE'VE WORKED CLOSELY WITH THEM
AND WE'VE BEEN THE BENEFICIARY
BECAUSE IT'S BEEN UNPRECEDENTED
THE AMOUNT OF MONEY THAT FDA HAS
TRANSFERRED OVER THAT FUND MANY
OF OUR GRANTS.
SO THERE HAS BEEN A SIGNIFICANT
INFLOW OF RESEARCH FUNDS NOT
PAID FOR BY NCI BUT BY THE FDA
AND THAT IS REALLY IMPORTANT TO
ACKNOWLEDGE.
BUT ONE OF THE AUTHORITIES THAT
THEY HAVE IS TO REDUCE NICOTINE
LEVELS IN TOBACCO PRODUCTS AND
THIS IS A REALLY CRITICAL ISSUE
MOVING FORWARD AND FOR THEM TO
EXERCISE THAT OPPORTUNITY OUR
RESEARCH COMMUNITY NEEDS TO
PROVIDE THE APPROPRIATE
EVIDENCE.
IMPROVING EFFICACY OF QUITTING
SMOKING.
WE FOLKED ON ADULTS BUT WE NEED
TO GET PEOPLE TO QUIT SOONER.
YOUTH AND TEENAGERS.
PEOPLE BECOME DEPENDENT QUICKLY.
CIGARETTE USE IN THE U.S. IS
LARGELY A RISK BEHAVIOR THAT IS
IN THE LESS EDUCATED AND
UNDERSERVED POPULATIONS AND THE
DEBATE AROUND ELECTRONIC
CIGARETTES IS STILL ONGOING.
I WANTED TO POINT OUT THIS.
THERE IS A LOT OF DISCUSSION ON
THIS TOPIC AND THAT IS OBESITY.
THIS ONE PARTICULAR PAPER THAT
HIGHLIGHTS THAT WHEN YOU LOOK AT
OVER-ALL CANCER TRENDS THE
MORTALITY REDUCTION HAVE BEEN IN
THE NONOBESITY ASSOCIATED
CANCERS.
IF YOU LOOK AT THE SUBSTANTIVE
CANCERS FOR OBESITY BEING A RISK
FACTOR YOU DON'T SEE THE SAME
PROGRESS.
AND THIS IS A TROUBLING SIGN
BECAUSE THESE MORTALITY RATES
ARE THE REPORT CARD ON THE WAR
ON CANCER.
THEY CHANGE SLOWLY AND
INFLUENCED OVER MANY YEARS.
SO THIS IS A RED FLAG FOR ALL OF
US MOVING FORWARD.
THE THREAT OF OBESITY AND
CHALLENGING OUR PROGRESS AGAINST
CANCER.
ONE OF THE AREAS OF MINE ARE MY
OWN FOCUS IS BUILDING UP AND
ENHANCING THE RESEARCH
INFRASTRUCTURE FOR POPULATION
SCIENCE IN THE U.S.
THE ESSENTIAL INFRASTRUCTURE FOR
POPULATION SCIENCE.
I COULD SPEND A WHOLE TALK JUST
TALKING ABOUT EPIDEMIOLOGY
CONSORTIA.
SEVERAL YEARS AGO -- THE
VISIONARIES IN THE FORMATION OF
MANY THESE CONSORTIA.
THEY'VE BEEN A MODEL OF
COLLABORATION AND DATA SHARING
AND ENABLING AND PROVIDING THE
STATISTICAL POWER FOR MOLECULAR
EPIDEMIOLOGY.
AND RISK FACTORS.
SO I WON'T GO INTO THIS IN
DETAIL.
WE COULD COME BACK TO THIS BUT
TWO OF THE PROGRAM ANNOUNCEMENTS
RELATE TO THE EPIDEMIOLOGY
COHORTS WHICH HAS BEEN AN
ESSENTIAL INFRASTRUCTURE AND
WILL BE ON -- AN ONGOING BASES
FOR CANCER RESEARCH.
CANCER SURVEILLANCE WE'VE MADE
REMARKABLE PROGRESS.
THERE WERE SOME UPDATES.
ONE OF MY OWN GOALS AS DIRECTOR
OF CANCER CONTROL WAS THAT BY
THE 50th ANNIVERSARY OF THE
NATIONAL CANCER ACT WOULD -- WE
WOULD EXPAND AND WE BARELY MADE
IT.
THAT IS IMPORTANT.
FROM A SCIENTIFIC PERSPECTIVE.
PARTICULARLY WITH ETHNIC
MINORITY POPULATIONS AND
SUBPOPULATIONS.
THIS IS IS A CURRENT MAP OF
SEER.
WE HAVE TWO TIERS OF CONTRACTS.
THESE ARE THE LIGHT BLUE REGIONS
ON THE MAP.
SMALL CONTRACTS BUT THAT PUT IN
PLACE A MECHANISM THAT THEN
ENABLE THESE SCIENTISTSES TO PAR
---- PETITION AND I HAVE TO GIVE
A SHOUT OUT TO THE CDC.
THEY'VE BEEN A GREAT
COLLABORATOR AND THEIR
PARTICIPATION.
SOME OF THE STATES ADDED
DIVERSIFY.
THE STATE OF TEXAS -- THIS
SUMMARIZES WHAT HAS BEEN
DISCUSSED AT PREVIOUS BOARD
MEMBERS.
BUT MANY OF THE SCIENTIFIC
REASONS WHY EXPANDING SEER IS SO
IMPORTANT.
THIS IS ONE.
7 AND I THINK -- THIS CONTINUES
TO BE UNDER A R -- APPRECIATED.
* AND THE SIGNIFICANT
DEMOGRAPHIC CHANGE HAPPENING IN
THE UNITED STATES TODAY AND THIS
EXAMPLE OF THE PERCENT OF GROWTH
OF THE U.S. LATINO POPULATION
DESERVES MORE ATTENTION FROM THE
SCIENTIFIC COMMUNITY.
WE ARE LAGGING BEHIND IN TERMS
OF GENERATING THE SUBPOPULATION
RELEVANT EVIDENCE.
NOT ONLY FOR THE LATINO
POPULATION AS A WHOLE BUT FOR
THE MANY SUBPOPULATIONS.
AND THE COMPLEXITIES OF
UNDERSTANDING THE GET NETTEDIC
EPIDEMIOLOGY.
*.
THIS SHOWS THE PROGRESS WE'VE
MADE IN FILLING IN THESE GAPS
AND THIS IS GOING TO BE A
CRITICAL PLATFORM FOR HEALTH
DISPARITY RESEARCH MOVING
FORWARD.
IF YOU LOOK IN THE BOTTOM RIGHT
WE'VE REALLY EXPANDED THE
HISPANIC REASON ROLEMENT.
ALSO IN THE ASIAN POPULATION.
IT'S UNDERGONE A SIGNIFICANT
CHANGE.
THIS IS NEW.
THIS IS JUST BEING BUILT AND
EXPANDED OVER THE NEXT YEAR.
THIS IS AN ENABLER FOR
POPULATION SCIENCE RESEARCH
MOVING FORWARD.
SURVEILLANCE IS JUST NOT ABOUT
CANCER INCIDENT SURVEILLANCE.
OUR SURVEILLANCE PROGRAM GOES
WELL BEYOND CANCER INCIDENTS.
FOR EXAMPLE WE LEAD OR COSPONSOR
MANY NATIONAL SURVEYS.
THESE ARE CRITICAL COMPONENTS.
AS WE'VE SEEN DURING THE COVID
EPIDEMIC.
WE'VE MONITORED AT A NATIONAL
LEVEL WHAT THE PUBLIC THINKS AND
KNOWS AND THEIR MYTHS ABOUT
CANCER.
AND THIS IS REALLY ESSENTIAL
INFORMATION AS WE MONITOR AND
DEVELOP STRATEGIES FOR CANCER
CONTROLLED INTERVENTION AND
COMMUNICATE WITH THE PUBLIC.
ONE OF MY OWN PRIORITIES AND
SOME PEOPLE HAVE ACCUSED ME OF
BIAS.
BECAUSE I COME FROM TWO CANCER
CENTERS PREVIOUSLY WORKING AT
HUNTSMAN CANCER INSTITUTE --
SEVERAL FOCUS ON LEVERAGING AND
ALSO FOR CANCER CONTROL AND
COMMUNITY ENGAGEMENT.
SO I WANT TO SPEND A FEW MINUTES
ON THAT ISSUE.
ONE OF THE THINGS THAT I CHOSE
TO DO -- IS TO REALLY FOCUS ON
THE OUTED SITUATION OF CANCER
CENTER SUPPLEMENTS AS A
MECHANISM TO CATALYZE NEW AREAS
OF RESEARCH.
AND I BELIEVE THAT THIS HAS BEEN
REALLY SUCCESSFUL.
OFTEN TIMES THESE ARE $100,000
VERY SMALL P30 SUPPLEMENTS.
THEY'VE HAD A TRANSFORMATIVE
IMPACT ON GROWING A NUMBER OF
AREAS OF CRITICAL RESEARCH.
THIS SLIDE SHOWS THE TOPIC AREAS
WHERE WE'VE DIN CANCER CENTER
SUPPLEMENT INITIATIVES.
AND SO THESE ARE ALL DESCRIBED
IN MUCH BETTER DETAIL ON OUR
WEBSITE AND YOU CAN GET MORE
INFORMATION ABOUT THESE SO I'M
GOING TO MENTION A COUPLE OF
THESE.
THEY REALLY ENERGIZED WORK AND
EFFORT AT CANCER CENTERS IN
THESE DOMAINS.
ONE EXAMPLE THAT WAS TIMED TO
COINCIDE WITH THE REQUIREMENT IN
THE CANCER CENTERS WHICH I ALSO
BELIEVE HAS BEEN HAS HAD A
TRANSFORMATIVE IMPACT IS ONE ON
HPV VACCINATIONS.
THIS ALSO LED TO A LOT OF MORE
COLLABORATION AND NATIONAL
CONSORTIA AND GENERATED PILOT
WORK THAT LED TO A NUMBER OF NEW
GRANT AWARDS AND GREATLY
EXPANDED OUR RESEARCH PORTFOLIO
RELATED TO HPV RELATED CANCERS
THESE ARE JUST SOME EXAMPLES OF
THINGS THAT GREW OUT OF THESE
SUPPLEMENTS INCLUDING THE FIRST
EVER NATIONAL STATEMENT CO-KIND
BY EVERY DIRECTOR.
THE IMPACT OFF PROGRAMS AT THE
STATE AND LOCAL LEVEL CANNOT BE
UNDERESTIMATED.
ADDING THAT LANGUAGE ON
COMMUNITY OUTREACH AND
ENGAGEMENT TO THE GUIDELINES WAS
CRITICAL.
BECAUSE OUR CANCER CENTERS ARE
STEP SOMETHING UP IN NEW WAYS IN
TERMS OF IMPACT ON THEIR LOCAL
COMMUNITIES IN A WAY THAT HAS
NEVER HAPPENED BEFORE.
ANOTHER EXAMPLE THAT DINA TALKED
ABOUT -- WAS THIS INITIATIVE.
AMONG THE ONES THAT WAS FUNDED
BY THE CANCER MOONSHOT.
IT'S MUCH LARGER IN SCALE IN
TERMS OF NUMBER OF AWARDS.
BUT ADDRESSING A HUGE PROBLEM
WHICH I THINK WAS A CHRONIC
EMBARRASSMENT TO THE NCI AND THE
CANCER COMMUNITY.
UNTIL RECENTLY MANY OUR CANCER
CENTERS WERE NOT ASSESSING OR
PROVIDING CESSATION SERVICES TO
THEIR CANCER PATIENTS.
AND I CAN GIVE SHOUT OUTS TO OUR
ADVISORY BOARDS FOR CATEGORIZING
THIS.
SAYING IF YOU WANT A MOONSHOT
HOW ABOUT MAKING SURE THE
SMOKERS WITH CANCER THAT WE'RE
TREATING GET SESSIONATION
SERVICES.
*.
THE MOONSHOT FUNDING HAS ENDED
AND NOW THE BALL SITS WITH THE
CANCER CENTERS AND IT'S UP TO
OUR DIRECTOR'S COMMUNITY TO
SUSTAIN THESE CLINICAL SERVICES
THAT WERE FIRST PILOTED THROUGH
RESEARCH FUNDS.
THIS SHOWS YOU JUST ONE MEASURE
OF THE IMPACT OF THIS SUPPLEMENT
INITIATIVE.
OVER 63,000 CANCER PATIENTS
REACHED THROUGH THE PROGRAMS.
A REMARKABLE ACCOMPLISHMENT OF
ALL OF THE CENTERS WHO
PARTICIPATED.
SO THINGS ARE CHANGING FOLKS.
BUT WE STILL HAVE A WAYS TO GO
BECAUSE NOW WE NEED TO
INSTITUTIONALIZE THESE IN THE
CLINICAL SERVICE LINES OF EVERY
CANCER CENTER.
AND THIS AGAIN HIGHLIGHTS THE
FACT THAT IN THIS LAST YEAR WE
HAVE PROVIDED FUNDING TO THE --
WISCONSIN -- THEY HAVE ONE YEAR
OF FUNDING LEFT TO A 'EM BELL
AND AGGREGATE AND DISSIM SENATE
THESE LESSONS * LEARNED AND THEY
WILL BE PROVIDING TOOLS FOR
EVERY CANCER CENTER.
FOR EVERY CANCER CENTER IN THE
NATION TO IMPLEMENT SIMILAR
PROGRAMS.
*.
AND HERE IS ONE THAT MAYBE YOU
WERE NOT EXPECTING.
A COUPLE OF TOPICS BEFORE
DISCUSSION.
I'M A COUPLE OF WEEKS AWAY FROM
RETIRING IN NIH.
WHAT IS THE BIG HANGING CHAD
RELATIVE TO CANCER.
THE FACT THAT WE'RE DOING WAY
WAY TOO LITTLE IN THE -- SCIENCE
OF UNDERSTANDING CANNABIS.
THE IMPACT IN CANCER PATIENTS SO
I'M GOING TO LEAVE WITH YOU A
PITCH HERE AND TELL YOU HOW
WE'RE JUST GETTING STARTED IN
THIS AREA AND RAMPING UP.
WE ARE UNDERGOING A MASSIVE
UNCONTROLLED HEALTH EXPERIENCE
IN THE UNITED STATES OF AMERICA
WITH THE CHANGE IN CANNABIS
POLICIES.
AND WE HARDLY HAVE A CLUE ABOUT
THE HEALTH IMPACT OF WHAT WE'RE
DOING.
THIS IS CHANGED AGAIN IN THE
LAST FALL ELECTIONS IN SOME
STATES BUT SHOWING YOU THE MAST
MASSIVE POLICY CHANGE THAT THE
NATION HAS UNDERGONE.
IN TERMS OF ACCESS TO CANNABIS.
NOT ONLY MEDICAL BUT BROAD
PUBLIC AND RECREATIONAL USE AND
A LOT OF STATE LEGISLATORS HAVE
BEEN FRUSTRATED WITH NIH BECAUSE
EVERY TIME A STATE LEGS TOUR
DEBATE THESE * POLICIES THEY SAY
SHOW US THE EVIDENCE.
WE HAVE TO SHRUG OUR SHOULDERS
AND SAY IT'S A WORK IN PROGRESS.
THERE IS A LOT THAT WE DON'T
KNOW.
SO WE'RE NOT DOING OUR DUTY IN
INFORMING POLICY MAKERS ABOUT
UNDERSTANDING THE IMPACT OF
CANNABIS USE.
THIS ILLUSTRATES IT FROM A
PUBLIC HEALTH PERSPECTIVE.
THIS IS FROM THE MONITORING THE
FUTURE STUDY THAT HNIDA RUNS:
THEY SURVEYED 12th GRADERS.
LOOK AT THE PROGRESS WE'VE MADE
IN TERMS OF REDUCTION OF
CIGARETTE USE.
A REMARKABLE ACCOMPLISHMENT.
BUT CANNABIS USING NOW DOUBLE
CIGARETTE USE IN HIGH SCHOOL
SENIORS.
THINK OF THE WEALTH OF EVIDENCE
WE HAVE ABOUT TOBACCO CONTROL IN
THE UNITED STATES AND ALL OF THE
AGENCIES WITH PROGRAMS FOCUSED
ON TOBACCO CONTROL AND MARIJUANA
USE IN SENIORS IS DOUBLE THAT OF
TOBACCO USE.
AND YOU LOOK AT VAPING --
RADICAL INCREASES IN VAPING.
YOU'VE HEARD BEFORE VAPING
CIGARETTES AND THE JULEP
DEMOCRATIC.
VAPING IS A * HUGE ISSUE.
SO WE DID A CANCER CENTER
SUPPLEMENT.
KIND OF PUSHING THE INVOLVEMENT
NUDGING OUR RESEARCH COMMUNITY
AND ONE OF THE REASONS I'VE DONE
THESE SUPPLEMENTS IS TO GRAB ALL
OF THE CANCER CENTER DIRECTORS
TOGETHER AND SAY PAY ATTENTION.
BECAUSE THIS IS SOMETHING THAT
WE ALSO MAY CONSIDER FOR FUTURE
NCI FUNDING
7 SO, ITS ALSO TRYING TO
INCREASE ATTENTION IN OUR
RESEARCH COMMUNITY TO AN ISSUE
AND SO WE AWARDED 12 CANCER
CENTER SUPPLEMENTS TO FOCUS ON
ONE SUBSET ISSUE AND THAT IS
CANNABIS USE AMONG CANCER
PATIENTS.
AND IN THE NEXT FEW MONTHS WE'RE
GOING TO GET A NEW WAVE OF DATA.
I'VE SEEN SOME OF THE DATA MUCH
IS NOT PUBLISHED.
SO TAKE THIS WITH A GRAIN OF
SALT BUT IN GENERAL I THINK WE
CAN SAY THAT ROUGHLY BASED ON
STUDIES THAT HAVE BEEN COMPLETED
SO FAR AS MANY AS 25% OF ALL OF
OUR CANCER PATIENTS IN THE
NATION WE THINK MAY BE USING
CANNABIS.
THAT IS A MASSIVE UNCONTROLLED
EXPOSURE FOR CANCER PATIENTS AND
AGAIN WE NEED TO UNDERSTAND THIS
A LOT BETTER.
SO NCI HELD ITS FIRST CANNABIS
WORKSHOP.
WE FUNDED THE SUPPLEMENTS TO TRY
TO DRAW ATTENTION TO THIS AREA
AND CATALYZE PLANNING AND
RESEARCH TEAMS.
WE ARE DISCUSSING THE
POSSIBILITY OF SOME TYPE OF
CONCEPT IN THE FUTURE BUT THAT
IS UP TO MY SUCCESSOR.
AS I STEP DOWN AND WE ARE REALLY
WORKING CLOSELY WITH OTHER
AGENCIES AND NIH AND HHS ON THIS
ISSUE BECAUSE OUR SURVEILLANCE
OF MARIJUANA USING VERY POOR
BECAUSE IT'S REALLY HARD TO GET
GOOD ACCURATE SELF-REPORT DATA.
YOU ASK PEOPLE WHAT PRODUCTS
THEY ARE USING.
WHAT IS THE THC CONTENT.
HALF THE TIME THEY DON'T KNOW.
USING SPORADIC.
I DON'T USE ANYTHING DURING THE
WORK.
BUT I DO ON THE WEEKEND.
REALLY TOUGH.
WHAT IS THE GREATEST CHALLENGE.
NOW I'M LEAVING I CAN TALK ABOUT
POLICY.
DEA SCHEDULING.
CANNABIS IS MARIJUANAS A
SCHEDULE ONE DRUG.
EQUIVALENT TO HEROIN AND
ECSTASY.
IT'S ABSOLUTELY INSANE AND THIS
IS A HUGE BARRIER TO RESEARCH
AND A BARRIER TO NIH BEING ABLE
TO FUND THE RESEARCH.
THIS IS BEING DEBATED IN
CONGRESS.
ALL OF THE ATTEMPTS TO OPEN THIS
UP LEGALLY THROUGH THE COURT
SYSTEM HAVE FAILED.
SITES UP TO CONGRESS.
THEY ARE RESCHEDULING BILLS IN
CONGRESS.
SENATOR SCHUMER CAME OUT AND
SAID HE SUPPORTED DESCHEDULING
WHICH IS IMPORTANT FOR OPENING
UP OPPORTUNITIES FOR OUR
INVESTIGATORS.
OUR INVESTIGATORS ARE
CONSTRAINED.
I WILL SAY A FEW WORDS ABOUT
HEALTH DISPARITIES.
ONE OF THE THINGS THAT I'M PROUD
OF IS THE SIGNIFICANT EXPANSION
OF OUR RESEARCH PORTFOLIO IN
HEALTH DISPARITIES AND THE FACT
THAT THE HEALTH DISPARITIES
RESEARCH THAT WE'RE FUNDING IS
ABSOLUTELY HIGH QUALITY
STATE-OF-THE-ART AND WE'RE IN
THIRD GENERATION HEALTH
DISPARITY RESEARCH.
THAT ARE LOOKING AT COMPLEXITY
THE INTERACTIONS IN A
SOPHISTICATED WAY THAT REALLY,
REALLY IS REMARKABLE AND IS
GOING TO INFORM US GOING
FORWARD.
WE HAVE OUR OWN CODING SYSTEM
FOR GRANTS IN THE DIVISION.
THIS IS NOT OFFICIAL.
WHAT NIH SAYS OR NCI SAYS.
WHEN SONIA PULLS TOGETHER THE
DATA SHE HAS TO FOLLOW THE RULES
WHICH IS NOR THE GREATEST CODING
SYSTEM.
AND I'M LEAVING SO I CAN SAY
THAT.
SONIA HAS HAD TO SUFFER UNDER
THIS ANTIQUATED CODING SYSTEM.
WE DO MUCH MORE FOCUSED ON
RESEARCH AIMS AND OUR HEALTH
DISPARITY RESEARCH PORTFOLIO
THAT IS ASKING HEALTH DISPARITY
RESEARCH QUESTIONS HAS DOUBLED.
AND PART OF THAT IS NOT JUST
RFAs AS SPECIAL INITIATIVES,
THE APPLICATIONS ARE SCORING
BETTER IN PEER REVIEW.
AND THAT IS A REALLY SHOUT OUT
TO ALL OF THE TRAINING PROGRAMS.
A LOT OF MONEY HAS BEEN INVESTED
OVER THE YEARS.
BUT ALSO THE FACT THAT WE'VE
GROWN THE ENTIRE INVESTIGATOR
BASE.
NOT JUST MINORITY INVESTIGATORS
BUT THOSE CONDUCTING RESEARCH IN
THIS DOMAIN.
SO SOME OF THE BIG OPPORTUNITIES
GOING FORWARD AND GAPS IN OUR
DISPARITY PORTFOLIO.
WE HAVE A TINY PORTFOLIO FOCUS
ON AMERICAN INDIAN ALASKA
NATIVES AND THIS IS A
SUBPOPULATION WHERE THE CANCER
BURDEN IS TREMENDOUS.
VERY DIFFICULT AND COMPLEX.
AND TRIBAL GOVERNANCE ISSUES.
THESE ARE INDEPENDENT ENTITIES
THAT HAVE A SPECIAL RELATIONSHIP
WITH THE U.S. GOVERNMENT.
THE HISTORY IS NOT PRETTY.
AND TRUST IS A HUGE ISSUE.
I'VE GOT TO GIVE A SHOUT OUT TO
-- WHO HAS DEVOTED THE LAST
SEVERAL YEARS TO OUTREACH AND
COLLABORATION OF THESE
COMMUNITIES.
HOPEFULLY YOU WILL BE HEARING
MORE ABOUT THIS.
SEXUAL GENDER MINORITY -- A VERY
SMALL PART OF OUR PORTFOLIO AND
I THINK THE TIME HAS COME TO RE
REGIGGER -- OUR EFFORTS MORE
SPECIFICALLY TARGETED.
JUST LIKE OUR MOLECULAR
TARGETING STRATEGY WE NEED MORE
SPECIFIC TARGETING TO THOSE
POPULATIONS IN THE GREATEST NEED
AND THEY ARE OFTEN TIMES THE
POPULATIONS WHO ARE NOT
PARTICIPATING IN OUR RESEARCH
STUDIES.
YOU WILL BE HEARING WHO ARE
THIS.
THE FOCUSING ON PERSISTENT
POVERTY.
LOOKING AT THE WHOLE PROBLEM IN
A VERY DIFFERENT WAY.
SOME OF THE CHALLENGES MOVING
FORWARD.
I THINK AN OPPORTUNITY TO
REVISIT OUR ENTIRE RELATIONSHIP
-- NOW IS THE TIME TO DO IT.
IT'S GREAT THAT KAREN HAS TAKEN
ON THE ROLE.
YOU HEARD ABOUT BREAST CANCER
AND THE ENVIRONMENT AND THE
STRONGER RELATIONSHIP.
WE'RE STRUGGLING IN THAT AREA.
THE GDPR -- IN EUROPE.
THIS IS HUGE.
IF YOU TRY TO COLLABORATE IT'S
BEEN INCREDIBLY DIFFICULT TO
SHARE DATA WITH COLLEAGUES IN
EUROPE.
WE HAVE NOT FIGURED THIS OUT.
NIH IS STRUGGLING WITH THIS
EUROPEAN UNION POLICY ON DATA
SHARING.
PRIVATE SECTOR BIG DATA. WE
BARELY TOUCHED THE SURFACE ON
THEIR MASSIVE COMMERCIAL
DATASETS.
NOT GENOMICS DATASETS BUT
COMMERCIAL DATASETS FOR
MARKETING DATABASE.
WE HAVE NOT LEVERAGED THAT.
AND I ALSO MENTIONED THE FUTURE.
WE NEED A NEW SUSTAINABLE
FUNDING MODEL FOR CoE IN THE
CANCER COMMUNITY.
MAYBE NOW THAT I'M LEAVING MAYBE
WE SHOULD RETHINK OUR CCSG AND
WHETHER OR NOT THERE SHOULD BE
DEDICATED FUNDING ON CoE
>> BOB WE WANT TO MAKE SURE WE
HAVE A COUPLE OF MINUTES FOR
QUESTIONS
>> THIS IS MY LAST SLIDE.
7 THE FUTURE IS BRIGHT.
BECAUSE OUR LEADERSHIP GROUP IS
TERRIFIC.
WE HAVE A NEW DIRECTOR
IT'S BEEN A GREAT TRANSITION.
AND THEY WILL BENEFIT FROM YOUR
ADVISE JUST AS I HAVE.
THANKS, JOHN.
>> WOW!
THIS IS A SPECIAL MOMENT, BOB
AND I WANT TO PROVIDE
DR. SHARPLESS THE PRIVILEGE OF
MAKING A FEW COMMENTS BEFORE WE
ENTERTAIN A FEW QUESTIONS.
NED.
>> I WILL BE BRIEF BECAUSE IT'S
SO HARD -- AND IMPOSSIBLE TO
SUMMARIZE BOB'S WORK.
THE TALK GAVE YOU A GREAT SENSE
OF HIS VISION AND CLARITY AND
PASSION.
I THINK HE IS WELL-KNOWN FOR
THAT.
HE IS LESS WELL-KNOWN FOR SOME
OTHER THINGS THAT I WOULD LIKE
TO POINT OUT.
HE IS A REAL SOURCE OF WISDOM AT
THE NCI.
I'VE GONE TO HIM MANY TIMES.
I'VE SEEN OTHER LEADERS GO TO
BOB AND GET ADVICE BECAUSE HE IS
SUCH AN EFFECTIVE MANAGER AND
LEADER.
HE HAS BEEN OUR WONDERFUL
CONDUIT TO OTHER PARTS OF THE
FEDERAL GOVERNMENT.
AND ONE OF THE REASONS IS
BECAUSE BOB IS A FANTASTIC
MENTOR.
YOU REALIZE HE TRAINED HALF OF
THESE PEOPLE.
HE IS SUCH A GREAT GUY.
AND LASTLY HE IS THAT DIAGRAM OF
COMPASSION AND INTELLECTUAL FIRE
POWER AND REALLY COMPETENT
FEDERAL EMPLOYEE.
BOB IS THAT.
AND WE SAW THAT CLEARLY AND HE
PROVIDED A WONDERFUL EXAMPLE OF
THAT IN THE CANCER CENTER
PROGRAM AND THAT IS ONE OF THE
MOST IMPORTANT AND EFFECTIVE.
AND IT WAS ADMINISTRATIVE
CHANGE.
IT WAS A ADVIS A VISIONARY IDEA.
8 WE'RE EXCITED ABOUT THE TEAM
HE LEAVES IN PLACE.
BOB IS IRREPLACEABLE.
CONGRATULATIONS.
>> I'M THINKING WE -- THANK YOU
SO MUCH NED AND BOB.
WE DO WANT TO ENTERTAIN AT LEAST
ONE QUESTION.
WE WANT TO HAVE AT LEAST A 10
MINUTE BREAK.
I SEE MARGARET DEFINITELY
RAISING HER HAND
>> I JUST WANTED TO USE ONE WORD
TO DESCRIBE HIS LEADERSHIP AND
THAT IS INSPIRATIONAL.
AND I ALSO WANTED TO SAY THAT I
AGREE THAT THE SUPPLEMENTS ARE A
CRITICAL COMPONENT THAT HE
DEVELOPED AND ESPECIALLY FOR
CANCER CENTERS WHERE THE
POPULATION SCIENCE PROGRAMS NEED
SOME BOOSTING SO I DO HOPE THAT
THAT PROGRAM WILL BE CONTINUED
AND I'M SURE YOU'RE NOT RETIRING
FULLY AND BEST OF LUCK IN ALL
FUTURE ENDEAVORS WHICH I'M SURE
WILL BE MANY AND SUCCESSFUL.
THANK YOU FOR ALLOWING ME TO SAY
THAT.
>> THANK YOU FOR THE COMMENTS.
THE VISION TO TACKLE CANNABIS IS
AMAZING.
I LOOK FORWARD TO SEEING HOW WE
GET AROUND THIS AND TACKLE THIS
COMPLEX ISSUE.
BOB, YOU DID A WONDERFUL JOB AT
REALLY PROVIDING THE PERSPECTIVE
AROUND HOW COMPLEX TACKLING THIS
JET HOW IMPORTANT IT IS FOR US
FOR UNDERSTAND THE LONG-TERM
IMPACTS.
SO WE'RE 12:50.
I WANT TO THANK THE PRESENTERS.
WE'LL TAKE A 10 MINUTE BREAK.
>> WE WILL NOW BEGIN REVIEWING
THE CONCEPTS.
BSA MEMBERS HAVE BEEN ASSIGNED
REVIEWERS TO EACH.
I WOULD LIKE TO THANK THE VAST
MAJORITY OF YOU FOR DOING DOUBLE
DUTY IN TERMS OF TAKING ON TWO
CONCEPT REVIEWS.
RECOGNIZE THAT THAT IS NOT EASY
TO FIT WITHIN YOUR DAY JOBS AND
SOME WAY SOMEHOW FIND A WAY TO
PAY YOU BACK.
MAYBE IN PERSON.
I'LL BRING DOUGHNUTS OR MAYBE
SOME GOOD COFFEE WHICH WOULD BE
A REAL GIFT AND MAYBE
PARTICULARLY APPRECIATED FOR
THOSE WHO HAVE BEEN IN PERSON
FOR BSA MEETINGS.
JUST TO REMIND YOU OF THE
PROCESS -- WE WILL REVIEW THESE
CONCEPTS, HAVE THEM PRESENTED
AND HAVE SUBCOMMITTEE MEMBERS
COMMENT.
BSA MEMBERS WILL BE THE ONES TO
VOTE TO APPROVE DISAPPROVE OR
DEFER A NEW CONCEPT FOR
REISSUANCE, BSA MEMBERS WILL
VOTE TO CONCUR, NONCONCUR OR
DEFER.
NCAB AND BSA MEMBERS MAY
PARTICIPATE IN DISCUSSION OF
EACH CONCEPT.
THIS ALLOWS NCI TO RECEIVE THE
BENEFIT OF YOUR EXPERTISE BUT
ONLY THE BSA MEMBERS WILL VOTE.
WE HAVE TO STAY ON SCHEDULE
TODAY AND TOMORROW.
SO LET'S GET STARTED WITH A
BRISK PACE.
DURING THE VOTING I WILL ASK HOW
MANY MEMBERS DISAPPROVE OR
NONCONCUR AND THEN HOW MANY
ABSTAIN.
THIS IS TO REINFORCE THE POINT
THAT IT'S CRITICAL FOR VOTING
MEMBERS TO STAY ON SCREEN AND
WITH US THE ENTIRE MEETING.
IF YOU HAVE TO STEP AWAY LET US
KNOW THROUGH THE CHAT.
THAT YOU NEED TO DO SO.
BECAUSE OTHERWISE WE TAKE YOUR
PRESENCE IN THE MEETING AS A YES
VOTE SINCE WE'RE COLLECTING
DISAPPROVALS OR NON.
PLEASE STATE YOUR NAME AND THEN
SEPARATELY ABSTAINING.
FIRST CONCEPT IS A COOPERATIVE
AGREEMENT FOR EQUITABLE CANCER
CONTROL.
IT WILL BE PRESENTED BY DR. NEAT
A.
>> THANK YOU FOR THE OPPORTUNITY
TO PRESENT OUR CONCEPT.
AS YOU KNOW GLOBAL INEQUITIES IN
CONCERT CONTROL ARE INCREASING.
ACCORDING TO THE 2020 COMPANY
REPORT ON CONCERT PROGRESS IS
SIGNIFICANTLY SLOWER IN
LOW-INCOME COUNTRIES.
THE GOOD NEWS IS THAT MANY
EFFECTIVE INTERVENTIONS
CONTINUUM CAN PREVENT PREMATURE
DEATH FROM CANCER.
HOWEVER IT'S BEEN SLOW AND
INCONSISTENT AND INCOMPLETE.
HERE YOU CAN SEE THE TIME IT
TAKES FOR A RANGE OF CANCER
CONTROL INTERVENTIONS TO REACH
JUST 50% OF THE TARGET
POPULATION AND THIS IS IN THE
U.S. ALONE.
FOR MOST THEY'VE YET TO REACH
50% UP TAKE.
SO WHY DOES IT TAKE SO LONG AND
HOW CAN WE ACCELERATE THE TIME
IT TAKES FOR THE EVIDENCE TO BE
IMPLEMENTED.
YOU CAN SEE EFFECTIVE CANCER
CONTROL INTERVENTIONS.
ON THE RIGHT YOU SEE OUR GOAL.
TO DECREASE THE BURDEN OF
CANCER.
IN THE MIDDLE YOU SEE REASONS
WHY THERE IS A GAP FROM THE
INTERVENTION TO THE INTENDED
EFFECT.
IT'S THE CHALLENGE OF
IMPLEMENTATION.
7 THEY ARE OFTEN UNDER AND OVER
USED.
THIS IS HIGHLIGHTED DURING THE
COVID PANDEMIC.
SOME REASONS FOR THAT GAP
INCLUDE INSUFFICIENT TRAINING,
INFRASTRUCTURE, GOVERNANCE AND
POLICIES.
THROUGH IMPLEMENTATION SCIENCE
WE CAN UNDERSTAND THE BARRIERS
AND DEVELOP AND TEST STRATEGIES
TO OVERCOME THOSE BARRIERS.
HOW DO WE KNOW IF THOSE
STRATEGIES ARE WORKING?
THOSE STRATEGIES SHOULD IMPROVE
THE FEASIBILITY AND
ACCEPTABILITY OF AN
INTERVENTION.
TO REACH AS MANY PEOPLE AS
POSSIBLE.
INSURE FIDELITY SO IT WORKS AS
IT IS INTENDED AND SUSTAIN THE
INTERVENTION OVER TIME.
WE'RE PROTECTING THE ADOPTION
AND INTEGRATION INTO PRACTICE BY
STUDYING THESE IMPLEMENTATION
OUTCOMES AND GENERATING EVIDENCE
ON STRATEGIES WHICH WILL IMPROVE
OUR ABILITY TO DECREASE THE
BURDEN OF CANCER THROUGH
EFFECTIVE DATA DRIVEN
IMPLEMENTATION.
AS YOU CAN SEE IMPLEMENTATION
SCIENCE BRIDGES THE DIVIDE.
THUS NCI RECOGNIZED THIS AS A
PRIORITY AREA.
SO TO SEE WHAT THE SCIENCE LOOKS
LIKE GIVEN THE FOCUS ON TESTING
STRATEGIES LET'S TAKE THE THE
EXAMPLE OF TASK SHIFTING.
IT'S A BROAD STRATEGY TO ENHANCE
ACCESS THROUGH DECENTRALIZATION
OF CARE.
TWO STUDIES TESTED SPECIFIC --S.
BOTH FOUND A THREEFOLD INCREASE
IN UP TAKE SUGGESTING THAT THE
STRATEGY CAN BE BROADLY
EFFECTIVE TO ADDRESS A REIGNS OF
GLOBAL CANCER CONTROL
IMPLEMENTATION CHALLENGES.
EFFORTS TO IMPLEMENT
INTERVENTIONS ARE NOT
NECESSARILY BEING CONDUCTED OR
CAPTURED IN A RIGOROUS WAY.
HERE YOU CAN SEE A GRAPHIC
DEPICTION OF THAT PROBLEM.
IN ASYMPTOMATIC REVIEW IN A
RANGE OF HEALTH INTERVENTIONS
ONLY A SMALL FRACTION CAPTURED
INFORMATION TO INFORM
IMPLEMENTATION EFFORTS AND EVEN
FEWER DOCUMENTED IMPLEMENTATION
OUTCOMES AT ALL.
THIS RELATES A CLEAR MISSED
OPPORTUNITY TO CAPTURE THE LARGE
RESERVOIR TO ACCUMULATE
KNOWLEDGE REGARDING
IMPLEMENTATION.
THIS WILL HELP ACHIEVE GREATER
EQUITY.
BUT THIS CANNOT BE FULLY
REALIZED WITHOUT SUPPORTING
TRAINING AND CAPACITY IN
LMICs.
TO DATE THROUGH OUR
DISSEMINATION AND IMPLEMENTATION
OPPORTUNITIES NCI HAS FUNDED 85
U.S. BASED INVESTIGATORS ABOUT A
DOZEN OF WHOM HAVE CONDUCTED
THESE STUDIES FROM DIVERSE
GEOGRAPHICAL LOCATIONS WHO ARE
WELL POSITIONED FOR FUTURE
COLLABORATIONS.
WE'RE ALSO SLATED TO FUND THESE
IN LMIC POPULATIONS.
THESE EFFORTS ARE FOCUSED ON
DOMESTIC CANCER CONTROL.
FOR THESE EXHIBITING INITIATIVES
-- THERE ARE NO EFFORTS IN
LMICs.
THE CONSORTIUM IS NEEDED TO
SIGNIFICANTLY NEEDED TO MOVE
THIS SCIENCE.
THUS WE PROPOSE TO BROADEN THE
SCOPE THROUGH A NEW GLOBAL
IMPLEMENTATION CONSORTIUM.
WE SEEK TO BUILD LMIC BASED
IMPLEMENTATION HUBS.
ALSO DEVELOP RESEARCH CAPACITY
FOR DEVELOPING ONGOING
IMPLEMENTATION STUDIES.
GIVEN THE CRITICAL ROLE OF
PRACTITIONERS AND OTHER
STAKEHOLDERS -- -- THUS WE HOPE
TO ENHANCE THE ABILITY TO SERVE
AS REGIONAL HUBS FOR
IMPLEMENTATION SCIENCE AND
TRAINING AND INDEPENDENT
RESEARCH CENTERS.
THIS INITIATIVE WOULD PROMOTE
THE MATURATION OF A READY
SCIENCE COMMUNITY THAT COULD
PROVIDE THE EVIDENCE BASED AND
FORM AND EXTEND EXISTING
EFFORTS.
WE PROPOSE A MECHANISM OVER FIVE
YEARS FOR FOUR AWARDS AT A COST
OF $4 MILLION PER YEAR.
EACH U54 APPLICANT WOULD DEVELOP
TWO PROJECTS.
THE RESEARCH CAPACITY BUILDING
CORE WOULD INCLUDE TRAINING AS
WELL AS STRUCTURED MENTORSHIP
FROM IMPLEMENTATION SCIENCE
EXPERTS ON THE DESIGN AND
CONTEXT OF THESE STUDIES.
ADDITIONALLY THIS CORE COULD
SUPPORT THE DEVELOPMENT OF
STANDARDIZED MEASURES.
THIS ENGAGES NCI TO COORDINATE
ACTIVITIES TO FACILITATE
HARMONIZED MEASURES AND
COLLABORATION.
ADDRESS KEY RESEARCH AREAS.
INCLUDING HOW TO ADAPT
INTERVENTIONS.
BUNDLE SERVICES.
INTEGRATE CANCER CONTROL INTO
PRIMARY CARE.
AND ENHANCE RETENSE OF CANCER
PATIENTS * ACROSS THE CONTINUUM
OF CARE.
SOME EXAMPLES INCLUDE STUDIES TO
UNDERSTAND BARRIERS AND
FACILITATORS TO EVALUATE
IMPLEMENTATION PROCESSES AND
CO-DESIGN STRATEGIES TO ENHANCE
INTEGRATION OF CANCER CONTROL
SERVICE OR TO TEST THE COST
EFFECTIVENESS OF STRATEGIES.
GREATLY APPRECIATE INPUT FROM
REVIEWERS.
WE HAVE ALSO CLARIFIED THAT THE
GOAL IS TO BUILD DEEP
IMPLEMENTATION SCIENCE AND
CAPACITY.
AND THE NEXT AND FINAL SLIDE WE
FURTHER CLARIFY ELIGIBILITY AND
REVIEW CRITERIA.
NONDOMESTIC INSTITUTIONS WILL BE
ELIGIBLE TO APPLY.
U.S. BASED INSTITUTIONS MUST
HAVE AN LMCI BASED MPI.
APPLICANTS SHOULD DEMONSTRATE A
HISTORY OF PARTNERSHIP.
THEY MUST ADDRESS HIGH PRIORITY
IMPLEMENTATION GAPS IN CANCER
CONTROL AND USE APPROPRIATE
APPROACHES IN THEIR RESEARCH
DESIGN.
THEY MUST DEMONSTRATE
INSTITUTIONAL SUPPORT FOR
IMPLEMENTATIONAL SCIENCE.
METRICS OF SUCCESS INCLUDE THE
NUMBER OF NEW LMIC
INVESTIGATORS.
NEW COLLABORATIONS ACROSS LMIC
BASED INSTITUTIONS.
PEER REVIEWED PUBLICATIONS.
AND IMPORTANTLY THE GENERATION
OF EVIDENCE THAT INFORMS
NATIONAL AND INTERNATIONAL
POLICIES AND PRACTICE.
THANK YOU FOR YOUR TIME AND
ATTENTION.
I WELCOME YOUR QUESTIONS.
>> OKAY.
FOR THIS ONE WE HAVE DR. BONDI.
PERHAPS -- WE CAN GET STARTED
>> I APPRECIATE SO MUCH THAT YOU
REALLY PAID ATTENTION TO THE
COMMENTS THAT WE HAD AFTER OUR
DISCUSSIONS AND NOW DR. FLAHERTY
SAID -- WE REALLY LIKE THE WORK
THAT YOU'VE PROPOSED AND NEED
NOR DOING IMPLEMENTATION SCIENCE
AND THE WORK THAT YOU PLAN TO DO
WITH TRYING TO INCORPORATE THE
---THE OTHER THE U.S. BASED
INSTITUTIONS TO WORK TOGETHER.
SOME OF THE CONCERNS THAT WE HAD
I BELIEVE YOU'VE ADDRESSED AND
OBVIOUSLY WE FELT LIKE FOR ONLY
HAVING FOUR APPLICATIONS THAT
WOULD BE AWARDED WAS PROBABLY
NOT ENOUGH AND ALSO YOU
DISCUSSED HAVING HUBS AROUND THE
WORLD AND HOW WOULD THOSE HUBS
STILL BE PLACED BECAUSE THE
WORLD IS VERY LARGE AND WE FELT
LIKE AND I KNOW THAT YOU HAVE
ALREADY EXPECTED THAT THERE
WOULD BE FOUR APPLICATIONS AND
$20 MILLION OVER FIVE YEARS AND
WE FELT LIKE MAYBE THAT WAS NOT
ENOUGH MONEY TO BE ABLE TO DO
THESE BUT THIS COULD BE A
DEMONSTRATION PROJECT BUT THAT
WAS SOME OF THE CONCERNS THAT
THERE WOULD NOT BE -- A SMALL
NUMBER OF CENTERS AROUND THE
WORLD AND HOW THE REGIONS WOULD
BE IDENTIFIED AND HOW THAT WOULD
BE DONE AND OBVIOUSLY THAT WAS
NOT UP TO YOU TO BE ABLE TO MAKE
THAT DECISION BUT WE FELT THAT
WAS IMPORTANT TO BRING THAT UP
-- AN OPPORTUNITY FOR US TO
BRING IT UP AT THIS VENUE AND
THE BSA TO DISCUSS THIS.
AND OBVIOUSLY IT'S IMPORTANT TO
HAVE AND CLARIFY THE BREADTH AND
DEPTH OF THESE APPLICATIONS AND
MAKING SURE THAT THESE
INSTITUTIONS WOULD BE ABLE TO
ADDRESS THAT AND MAKE A
DIFFERENCE AND I THINK THAT YOU
BROUGHT THAT UP WITH THE METRICS
AND THE SUCCESS METRICS OF EACH
OF THESE INITIATIVES AND HOW
THAT WOULD BE DONE.
I THINK YOU'VE ADDRESSED ALL OF
THE CONCERNS THAT WE HAD AND I
WANT TO ASK THE OTHERS IN OUR
REVIEW GROUP IF THEY HAVE ANY
ISSUES.
I KNOW DR. ROBESON AND DR. --
WERE ALSO MEMBERS.
SO I'LL PASS THAT ON TO THEM
>> I'LL REITERATE.
THE BSA NEEDS TO APPRECIATE THE
FACT THAT WITH THE DIVERSITY AND
LOW AND MIDDLE INCOME COUNTRIES
IN TERMS OF THE SETTING AND THE
COMPLEXITIES I REALLY THINK THIS
IS AN IMPORTANT INITIATIVE TO
START TO LEARN TO BRING THINGS
FORWARD AND FOUR CENTERS I JUST
REALLY URGE NCI LEADERSHIP TO
THINK ABOUT THE POTENTIAL TO
EXPAND THE NUMBER OF CENTERS TO
BE ABLE TO GET THAT BREADTH OF
DIFFERENCES THAT ONE SEES IN THE
COUNTRIES TO REALLY SORT OF
ACCELERATE OUR LEARNING IN TERMS
OF HOW FAR THESE BARRIERS WHICH
BARRIERS EXIST AND HOW THEY CAN
BE OVERCOME.
I JUST WANT TO ECHO THE
DISCUSSION THAT THE BSA
SUBCOMMITTEE HAD IS THAT A
DEMONSTRATION PROJECT, YES.
BUT THIS SHOULD BE MORE THAN A
DEMONSTRATION PROJECT.
IT SHOULD -- I CONSIDER
STRENGTHENING THE OUTPUT OF THE
INVESTMENT THAT IS GOING TO GO
INTO THIS.
>> I DON'T HAVE ANYTHING TO ADD
TO THE CONTINUES.
THE ONLY COMMENT I WILL ADD IS
TO CONSIDER SUSTAINABILITY
METRIC IN TERMS OF SUCCESS
METRICS.
I THINK -- IT WOULD BE IMPORTANT
TO HAVE THAT UP FRONT.
>> ANY OTHER QUESTIONS OR
COMMENTS FROM BSA MEMBERS
>> HI.
I GOT THE IMPRESSION THAT THE PI
OR THE MPI SHOULD BE IN COUNTRY
AND THAT IS TERRIFIC.
AND THAT THE TRAINING WOULD BE
TOWARDS THE IN COUNTRY PEOPLE
AGAIN THAT IS SMART.
BUT THIS IS -- THE
IMPLEMENTATION SCIENCE ITSELF IS
A SMALL FIELD AND THOSE THAT ARE
CANCER CENTERS AND INSTITUTIONS
THAT ARE KIND OF IMPLEMENTATION
SCIENTISTS AND GLOBAL I THINK
THAT THERE SHOULD BE PERHAPS
THERE IS MORE OF AN INTERCHANGES
THAT THE RESEARCH CAPACITY
BUILDING SHOULD BE BUILDING THE
TRAINEES HERE AND THERE AND BY
THAT I MEAN TRAINEES FROMth
U.S. THAT LIVE OR WORK IN THE
LMIC.
>> SURE AND ACTUALLY I'M NOT
SURE IF YOU'R YOUR -- YOU'RE AWARE --
WE HAVE ALREADY TRAINED A COHORT
OF HUNDREDS OF INVESTIGATORS IN
CANCER CONTROL MANY OF WHOM BUT
I DON'T KNOW THE SPECIFIC
STATISTICS WHO DO HAVE GLOBAL
COLLABORATIONS AND FOR SOME OF
OUR IMPLEMENTATION SCIENCE
CENTERS THAT ARE FUNDED THROUGH
THE MOONSHOT SOME HAVE STRONG
GLOBAL CONNECTIONS AS WELL AS I
MENTIONED OVER A DOES OF OUR
INVESTIGATORS HAVE PARTNERED
WITH LMICs.
IN TERMS OF THE TRAINING IT'S A
GREAT SUGGESTION AND ACTUALLY IT
WOULD BE ONE THING TO THINK
ABOUT HOW OUR TRAININGS CAN BE
MORE BROADLY RELEVANT BOTH TO
GLOBAL AND DOMESTIC AUDIENCES.
BUT I THINK ONE OF THE BIG
VALUES OF THIS INITIATIVE IS
THAT FOR MANY INVESTIGATORS THEY
WANT TRAINING IN THEIR LANGUAGE.
SO WE NEED THESE TRAININGS IN
FRENCH.
IN SPANISH AND THERE IS A GROUP
OF INVESTIGATORS ACROSS LATIN
AMERICA WHO ARE TRYING TO
ORGANIZE SOMETHING SIMILAR BUT
STRUGGLING TO FIND THE FUNDS --
I JUST LEARNED ABOUT THIS BUT
OBVIOUSLY COULD NOT SHARE THIS.
BUT I DO THINK THERE ARE MANY
INVESTIGATORS AROUND THE WORLD
WHO ARE INTERESTED IN DEVELOPING
THEIR OWN TRAINING PROGRAMS SO
THIS WOULD BE A REAL
OPPORTUNITY.
>> CONGRATULATIONS.
I THINK IT'S A GREAT INITIATIVE.
I WANTED TO FOLLOW-UP ON
DR. ROBESON COMMENTS.
FUNDING FOR CENTERS AND GIVEN
THE BREADTH OF NEEDS I WORRY
YOU'RE GOING TO HAVE A LOT OF
APPLICATIONS AND IT'S GOING TO
BE HARD TO DISTINGUISH BETWEEN
THE APPLICATIONS AND PRIORITIZE.
HAS THERE BEEN MORE THOUGHT
ABOUT WHAT THE METRICS WILL BE
FOR REVIEWERS IN TERMS OF HOW TO
PRIORITIZE AMONG THE MANY
APPLICATIONS.
7
>> SO I THINK THAT THAT QUESTION
MAY BE BEST ANSWERED BY THE
DIRECTOR OF THE CENTER FOR
GLOBAL HEALTH.
BUT MY HOPE WOULD BE THAT THERE
WOULD BE SOME CONSIDERATION FOR
GEOGRAPHICAL DIVERSITY AS WELL
AS DIVERSITY IN CANCER CONTROL
AREAS AND OTHER TYPES OF
SETTINGS WHETHER COMMUNITY OR
CLINICAL ETC.
SO WE DO HOPE TO SEE A DIVERSE
RANGE IN DIVERSITY NOT JUST
GEOGRAPHICALLY BUT IN OTHER
WAYS.
BUT I WONDER IF DR. -- OR OTHERS
MAY WANT TO FURTHER WEIGH IN ON
THE PROCESS WITH HOW WE MIGHT
WEIGHT THAT.
>> THANKS.
-- WE EXPECT A LOT OF STRONG
APPLICATIONS.
A NUMBER OF PEOPLE -- THERE IS A
RICH INVESTIGATOR COMMUNITY THAT
MAY END UP BEING A PROBLEM THAT
IS NOT DISSIMILAR TO WHAT SONIA
SPRINGFIELD DESCRIBED WITH THE
FIRST INITIATIVE.
WE WOULD LIKE TO SUPPORT KIND OF
STRONG IMPLEMENTATION SCIENCE
HUBS THAT CAN ADDRESS HIGHLY
RELEVANT CONTEXTUAL NEEDS.
WE'LL OF COURSE CONSIDER ISSUES
OF DISEASE.
GEOGRAPHIC HETEROGENEITY.
BUT WE'LL HAVE TO MAKE DECISIONS
AROUND THE SCIENCE.
THERE ARE OTHER RELATED
IMPLEMENTATION SCIENCE
ACTIVITIES BOTH DOMESTICALLY
INCLUDING AND INTERNATIONALLY
INCLUDING AN OPEN RFA THAT WE
HAVE THAT ARE FOCUSED ON HIV
POPULATIONS.
SO OUR HOPE IS THAT EVEN IF IT
IS JUST FOUR CENTERS AND OF
COURSE WE WOULD SUPPORT A LARGER
NUMBER IF THAT IS DOABLE THAT WE
CAN EFFECTIVELY COORDINATE AND
LEVERAGE THIS WITH OTHERS
INCLUDING THE TRAINING
ACTIVITIES TO HELP SUPPORT THE
COMMUNITY.
>> THANKS FOR THE DISCUSSION.
IF YOU ANSWER THE BRIEF QUESTION
IN THE CHAT WHILE WE MOVE TO
VOTING TO TRY TO KEEP ON
SCHEDULE.
THIS IS A NEW CONCEPT RFA.
SO DR. BON DEE CAN I ASK FOR A
MOTION.
>> I'D LIKE TO PROPOSE THAT WE
-- TO MAKE A MOTION THAT WE
ACCEPT THIS PROPOSAL.
>> A PROVAL.
*.
>> CAN I ASK FOR A SECOND?
>> SECOND.
>> THANK YOU.
ANY FURTHER DISCUSSION?
>> SORRY.
I HAD A QUICK QUESTION.
I FELT THAT WHEN HE SPOKE HE
FELT THAT THE CONCEPT DID NOT GO
FAR ENOUGH.
DID I MISS INTERPRET WHAT YOU
SAID?
>> I THINK IT DIDN'T GO FAR
ENOUGH IN TERMS OF ACCOMPLISHING
THE OBJECTIVE OF HUBS THAT CAN
HELP GENERATE INFORMATION THAT
WOULD HAVE A GREATER APPLICATION
GENERALIZABILITY WITHIN LOW AND
MIDDLE INCOME COUNTRIES.
MY VIEW IS I'M CONCERNED THAT
FOUR WOULD PROVIDE THAT LEVEL OF
BREADTH.
>> I THINK THE GROUP TALKED
ABOUT THE ISSUE OF BRE BREADTH AND
IN MANY WAYS THIS IS A PILOT.
ACROSS MANY AREAS ACROSS THE
WORLD
-- BUT AT THE SAME TIME PERHAPS
IT WILL ALLOW US TO SEE HOW TO
SET THEM UP AND THAT MAY BE A
WAY TO APPROACH IT WITH LIMITED
RESOURCES.
BUT ALSO THESE ARE GOING TO --
WITH EXISTING PROGRAMS.
THAT MAY ALLOW US TO BEGIN TO
LEARN HOW TO SET THIS UP IN AN
EFFECTIVE WAY.
>> THANK YOU VERY MUCH.
OKAY.
LET'S MOVE TO VOTING.
SO AGAIN THE DEFAULT IS A VOTE
OF APPROVAL.
SO PLEASE VOICE YOUR DISAPPROVAL
VOTES IF YOU DISAPPROVE THIS
CONCEPT OR DEFERRAL.
I DIDN'T HEAR ANY DISCUSSION OF
DEFERRAL SO I'M ASSUMING WE'RE
VOTING TO APPROVE OR DISAPPROVE.
ANY DISAPPROVALS, PLEASE.
PAULETTE, I DON'T SEE ANY OTHER
EITHER SCREEN
>> SO THE VOTE WAS UNANIMOUS
APPROVAL.
>> ANY ABSTENTIONS?
AGAIN I DO NOT SEE ANY.
SO UNANIMOUS APPROVAL.
NO ABSTENTIONS.
PAULETTE I'LL PROCEED.
>> YES.
>> THANK YOU.
THE MEXICAN SENT IS A REISSUE
RFP.
DR. SEI IS PRESENTING.
THE SUBCOMMITTEE IS INCLUDES
MYSELF AS CHAIR.
-- HAVE JOINED ME.
PLEASE PRESENT.
>> THANK YOU.
ON BEHALF OF THE DIVISION OF
CANCER PREVENTION I'M PLEASED TO
PRESENT WHAT PREVENT HAS BEEN
ABLE TO ACCOMPLISH SINCE THINGS
ACCEPTS.
-- THE -- INCEPTION.
* -- THE MISSION --
[ READING FROM SCREEN ]
>> --
[ READING FROM SCREEN ]
--PREVENT IS EXPECTED TO SUPPORT
DEVELOPMENT NEEDS COMING FROM
CAP IT AS WELL AS NONCAP IT
INVESTIGATORS.
PREVENT IMPLEMENTS --
COMPETITIVELY SELECTED.
WHEN THESE CONTRACTORS DO NOT --
HAVE A CERTAIN ASPECT THEY CAN
BRING IN SUBCONTRACTORS.
NOW APPROVED CONCEPTS CAN ENTER
AT ANY POINT WITHIN THE PREVENT
PIPELINE WHICH CONSISTS OF THREE
MAJOR DEVELOPMENT STAGES
PROOF OF CONCEPT, TESTING AND
ADVANCED PRECLINICAL
DEVELOPMENT.
7 EACH PROJECT GOES THROUGH THE
PIPELINE WITH GO NO GO DECISIONS
MADE WITH THE OVERSIGHT AND
APPROVAL OF THE INTERNAL -- WHEN
THEY ARE READY TO ADVANCE -- --
NOW TO DATE PREVENT HAS RECEIVED
390 APPLICATIONS AFTER THE PEER
REVIEW AND THE SECONDARY REVIEW.
101 APPLICATIONS HAVE BEEN
APPROVED.
SHOWN ON THE RIGHT IS THE
DISTRIBUTION OF PREVENTION.
SO FAR WE HAVE COMPLETED 74 OF
THOSE CONCEPT PROJECTS.
IT CAN BE SEEN WITH X MARKS.
THE SLIDE SHOWS THE BREAKDOWN OF
THE DECISIONS MADE ON THOSE
CLOSED OR COMPLETED PROJECTS.
45 HAVE BEEN CLOSED.
OF THOSE 27 PROJECTS WHICH IS
60% HAVE BEEN DEEMED NO GO.
SIMILARLY OF THE 21 CLOSED
PROJECTS, 17 WHICH IS 81% HAVE
BEEN DEEMED NO GO.
IN CONTRAST OF THE 8 CLOSED
PROJECTS IN ADVANCED DEVELOPMENT
STAGE ONLY ONE PROJECT HAS BEEN
DEEMED NO GO.
THIS BREAK DOWN ILLUSTRATES THAT
THE PREVENT STRIVES TO -- DROP
FAILING PROJECTS DURING
PRECLINICAL TESTING PHASE.
OF THE GO PROJECTS WE HAVE
ADVANCED -- AS CAN BE SEEN ...
INCLUDING SIX AGENTS SINCE 2016.
NOW THE -- -- PREVENT HAS BEEN
QUITE SUCCESSFUL.
ONE OF THE UNIQUE ASPECTS OF THE
DEVELOPMENT RESEARCH IS THE
OVER-ALL --
WE ESTABLISHED AREA SOLIZED -- WE
HAVE COMPLETED THE GLP STUDIES
AND FORMULATION HAS BEEN
DEVELOPED.
NOW WE'RE DISCUSSING -- FOR
CLINICAL STUDIES.
I APOLOGIZE FOR THE GLITZ.
IN SUM REAR OVER THE * PREVENT
HAS SHIFTED TO PREVENTION AND
TRANSFORMED THE PROGRAM
PORTFOLIO WITH INNOVATIVE
TARGETED AND IMMUNO TARGETED.
WE HAVE EXPANDED TECHNICAL
CAPABILITIES INCLUDING COMPLEX
MODELS AND BUILT THE PIPELINE
INFRASTRUCTURE WITH -- STEPS
EMBEDDED.
WE HAVE ADVANCED SEVEN AGENTS TO
FULLY -- DEVELOPMENT PHRASE.
MORE ARE EXPECTED IN 2022 AND
NEXT YEAR.
7 NOW AS FOR THE JUSTIFICATION
OF PROGRAM RENEWAL AND THE
BUDGET.
WE DO EXPECT AN INCREASE WHEN
AGENTS -- ENTER THE PIPELINE.
SO MEET THESE DEMANDS WE ARE
PROPOSING GRADUAL FUNDING
INCREASE FROM THE CURRENT
$11 MILLION TO $30 MILLION IN
FY23-24 FOLLOWED BY $50 MILLION
IN FY25.
WE WOULD LIKE TO THANK THE TEAM
MEMBERS -- FOR THEIR VERY
HELPFUL AND CRITICAL ADVISE AND
COMMENTS.
OUR RESPONSES AND CLARIFICATION
HAVE BEEN INCORPORATED IN
TODAY'S PRESENTATION.
7 THANK YOU FOR YOUR ATTENTION.
I WILL BE HAPPY TO TAKE
QUESTIONS.
>> THANK YOU DR. SEI.
OUR DISCUSSION WAS VERY NICELY
REFLECTED IN THIS PRESENTATION.
WE SPENT A FAIR LITTLE BIT OF
TIME REFLECTING FIRST AND
FOREMOST ON THE REALLY CRITICAL
ROLE THAT THIS PROGRAM PLAYS IN
THIS AREA OF DEVELOPMENT.
WHICH EVERYONE KNOWS AS NOT
ADDRESSED IN THE PRIVATE SECTOR.
IN TERMS OF DRIVING THIS TYPE OF
RESEARCH FORWARD.
THIS IS A UNIQUE PROGRAM IN ITS
PURVIEW IN TERMS OF SUPPORTING
THIS BROAD SPECTRUM OF CONTRACTS
AND WE HAD AN EXCELLENT
DISCUSSION AS WAS REFLECTED IN
THE PRESENTATION REGARDING WHAT
I CONSIDER TO BE EXCEPTIONABLE
PRODUCTIVITY BOTH WITH REGARD TO
THE NUMBER OF CONTRACTS
SUPPORTED AND THE SELECTION
PROCESS AND THE STRATEGY LOOKING
BACKWARD OVER THE PAST PERIOD
FUNDING PERIOD.
STRATEGY IN TERMS OF
PRIORITIZING THOSE CONCEPTS THAT
HAD THE GREATEST TRANSLATIONAL
POTENTIAL AND I THINK THE REALLY
EXCELLENT DISCIPLINE IN TERMS OF
MAKING THE GO NO GO DECISIONS AS
DESCRIBED AT EACH STAGE.
SO WE FELT AS A GROUP I THINK
THAT THIS PROGRAM IN ITS PAST
PERFORMANCE WAS QUITE
EXCEPTIONAL.
THE NEED REMAINS AS PRESSING IF
NOT MORE SO IN 2021 LOOKING
FORWARD.
SO OUR CONSENSUS AFTER EXTENSIVE
DISCUSSION WAS CONCURRENCE AS A
GROUP.
THAT SAID I'D LIKE TO ALLOW
OTHERS TO ADD THEIR COMMENTS.
>> I VERY MUCH AGREE WITH
DR. FLAHERTY.
THIS IS AN AREA OF UNMET NEED.
TO ADDRESS IT THROUGH THE
STRATEGY.
I THINK FOR ME ESPECIALLY HAVING
THAT CLARE OR PARTICULAR LACKS
OF THE ABILITY TO -- -- THAT
CLEAR ARTICULATION -- *.
--
>> OTHER COMMENTS OR QUESTIONS?
>> THERE IS A QUESTION IN THE
CHAT.
>> OH, GREAT.
>> LET ME SCROLL UP.
THERE ARE A COUPLE OF.
YES.
THE INVESTIGATORS -- ARE THEY ON
THE STEERING PANEL --
>> WHEN WE PULL EXTERNAL -- YOU
ARE PROBABLY REFERRING TO
EXTERNAL STEERING PANEL.
SO NO.
THEY ARE NOT.
THEY ARE NOT ON THE SPECIAL
EMPHASIS PANEL WHO REVIEW THE
APPLICATIONS BUT THEY ARE ON THE
INTERNAL DECISION MAKING
COMMITTEES.
THAT IS PROBABLY WHAT YOU MEANT
TO ASK.
AND YES WE'RE IN CONSTANT
COORDINATION AND COMMUNICATION
WITH THE CLINICAL TRIAL TEAMS
>> IF YOU WANT TO ANSWER THE
SECOND ONE KEEP YOUR RESPONSE
SHORT.
>> SORRY.
>> ANOTHER QUICK QUESTION.
MAYBE CLARIFICATION.
WHEN YOU TALK ABOUT PREVENTION
WOULD THAT INCLUDE AGENTS THAT
WOULD PREVENT LOW GRADE TUMORS
FROM PROGRESSING TO HIGH GRADE
TUMORS.
>> SO I COLLECT -- USE THE
CANCER PREVENTION.
AS WELL AS INTERCEPTS OF AGENTS.
WE DO SUPPORT AGING DEVELOPMENT
FOR CANCER --
[ INDISCERNIBLE ]
WHILE PREVENTION IS TO PREVENT.
THANK YOU FOR THE QUESTION.
>> THANK YOU.
>> FOR THE SAKE OF TIME LET'S
MOVE TOWARDS VOTING.
IF YOU WOULDN'T MIND TRYING TO
ANSWER THE QUESTIONS IN THE
CHAT.
PAUL LET, AM I ALLOWED TO CALL
FOR A MOTION.
>> YES.
YOU CAN.
YOU CAN ALSO CALL AND THEN HAVE
KAREN DO IT
>> LET'S DO THAT.
SO IT DOESN'T LOOK LIKE I'M
STEERING THE CONVERSATION
>> I'D LIKE TO CALL FOR A MOTION
>> I'M CALL FO -- CALLING FOR A
REISSUANCE.
>> CAN I GET A SECOND.
>> SECOND.
>> AND ANY FURTHER DISCUSSION?
AND HEARING NONE LET'S MOVE TO
FULL VOTING OF BSA MEMBERS.
THE MOTION IS FOR CONCURRENCE.
WE'RE GOING TO ASSUME THAT YOU
CONCUR.
ANY VOTES OF NONCONCURRENCE?
PAULETTE, I DO NOT SEE ANY.
>> ALL RIGHT.
>> ANY ABSTINENCES?
>> NO.
SO WE HAVE UNANIMOUS CONCURRENCE
AND NO ABSTINENCES.
GOOD.
THANK YOU ALL.
THANK YOU VERY MUCH DR. SEI.
EXCELLENT PRESENTATION.
>> THANK YOU.
>> NOW WE'RE MOVING TO A CONCEPT
TO REMIND YOU IN TERMS OF THE
TIME ALLOCATION FOR PARs.
10 MINUTES OF PRESENTATION AND
FIVE MINUTES OF DISCUSSION.
KEEP AN EYE ON THE CLOCK.
THIS IS A CANCER EPIDEMIOLOGY
COHORT STUDY.
DR. JOANNE ELENA IS PRESENTING
>> THANK YOU FOR THE OPPORTUNITY
TO PRESENT THIS PAR CONCEPT.
THIS PAR IS PART OF AN OVER-ALL
PLAN TO SUPPORT CANCER RESEARCH
AND COHORT STUDIES WHICH
INCLUDES TWO COMPLEMENTARY
PARs THAT YOU'LL HEAR ABOUT
TODAY.
THE PURPOSE OF THIS PAR IS TO
PROVIDE CONTINUED SUPPORT FOR
ESTABLISHED COHORT STUDIES THAT
ADDRESS NOVEL AND IMPORTANT
RESEARCH QUESTIONS ACROSS THE
CANCER CONTINUUM.
WE'RE DEFINING STUDIES.
THIS PAR WILL REPLACE PAR20-294
WHICH IS EXPIRING IN NOVEMBER OF
2022.
SEPARATED INFRASTRUCTURE FROM
RESEARCH BY PROVIDING SUPPORT
FOR BASIC MAINTENANCE ONLY.
THINGS LIKE PARTICIPANT
FOLLOW-UP.
CASE ASCERTAINMENT.
BIOSPECIMEN STORAGE BUT DID NOT
ALLOW FOR HYPOTHESIS RESEARCH.
THOSE WHO ARE CURRENTLY FUNDED
BY PAR TO-294 ARE NOT ELIGIBLE
TO RECEIVE FUNDING UNTIL AFTER
THE EXPIRATION OF THEIR CURRENT
GRANT.
THEY MAY SUBJECT THE GRANTS
INCLUDING --
>> WORKING MOTHERS.
IT NEVER ENDS
>> WE'VE ALL BEEN THERE.
I'LL TALK FAST TO MAKE UP FOR
IT.
AND DEVELOPING THIS PAR --
[ AUDIO DIFFICULTIES ]
WE WENT BACK TO THE JUNE --
[ AUDIO DIFFICULTIES ]
>> SOMETHING HAPPENED TO YOUR
MICROPHONE.
-- WE WENT BACK TO THE --
[ AUDIO DIFFICULTIES ]
UNLESS IT'S TOO DISTRACTING.
AND YOU TELL ME.
>> WE WENT TO THE AD HOC WORKING
GROUP -- PLEASE NEXT SLIDE.
WE'RE GOING TO GET THROUGH THIS.
WE WENT BACK TO THE AD HOC
WORKING GROUP ON POPULATION
SCIENCES REPORT FROM JUNE 2019
WHICH WAS CHAIRED BY LESS
ROBINSON AND JULIE PALMER AND
THIS PAR ADDRESSED MANY OF THEIR
RECOMMENDATIONS INCLUDING
CONTINUED SUPPORT FOR COHORTS TO
ADDRESS CRITICAL SCIENTIFIC GAPS
THAT PEER REVIEW SHOULD INCLUDE
JUSTIFICATION FOR CONTINUE
FOLLOW-UP BASED ON SCIENTIFIC
YIELD AND THAT COHORTS SHOULD
ADDRESS EMERGING FACTS AND
RESEARCH WITH APPROPRIATE
POPULATIONS.
FOR COHORTS OF CANCER SURVIVORS
THEY SHOULD ALSO ADDRESS CANCER
GAPS BY TREATMENTS.
AS DR. -- MENTIONED TODAY I
AGREE -- COHORT STUDIES HAVE LED
TO THE IDENTIFICATION OF A
MYRIAD OF ENVIRONMENTAL
BEHAVIORAL -- AND GENOMIC FACTOR
THES.
WE LEARNED OF THE LINKS AND
SOLIDIFIED EVIDENCE.
THEY'VE ALSO PROVIDED
INTERVENTIONS SUCH AS SUPPORT
FOR INTERVENTION SUCH AS SECOND
SCREENING -- SCREENING FOR
SECOND CANCERS
THEY ARE RICH RESOURCES OF DATA
-- THROUGH A WIDE VARIETY OF
RESEARCH.
MANY GROUPS ARE NOW COMBINING
DATA COLLECTED AND BIOSESSION
MENS AVAILABLE AMONG MANY OF THE
TOPICS.
REQUIRING SCIENTIFIC GAMES WITH
SPECIFIC RESEARCH QUESTIONS AND
ONE MECHANISM DESIGNED TO
SUPPORT WILL GUIDE STUDY DESIGN
AND SHORE UP APPROPRIATE USE OF
METHODS.
TO THIS AIM WE WILL A REQUIRE
APPLICANTS TO ADDRESS KEY GAPS.
THEY MUST INCLUDE HYPOTHESIS
BASED RESEARCH.
>> OKAY.
WE'RE HAVING PROBLEMS WITH THIS
PRESENTATION.
WHY DON'T WE -- AS NED SUGGESTED
WE MOVE TO THE NEXT ONE.
PERHAPS WE CAN DO IT TOMORROW AS
THE LAST ONE.
OKAY.
7 SO LET'S MOVE ON -- KEITH.
>> OKAY.
THANKS, PAULETTE.
SO THIS IS THE RELATED ALSO NEW
PAR -- COHORTS BUILDING THE NEXT
GENERATION OF RESEARCH COHORTS.
CLINICAL TRIALS NOT ALLOWED.
DR. LAM.
PLEASE PROCEED
>> THANK YOU.
WE'VE ALL BEEN THERE SO I
APPRECIATE -- THAT YOU'VE GONE
THROUGH.
GOOD AFTERNOON.
I'M PRESENTING A CONCEPT
PROPOSAL ENTITLED CANCER
EPIDEMIOLOGY COHORTS -- BUILDING
THE NEXT GENERATION OF RESEARCH
COHORTS.
THIS SEEKS TO SUPPORT OF
INITIATING AND BUILDING THE NEXT
GENERATION OF POPULATION BASED
CANCER EPIDEMIOLOGY.
AS WE LOOK FORWARD IN TIME NEW
CANCER EPIDEMIOLOGY COHORTS ARE
NEEDED TO ALIGN WITH FUTURE
NEEDS.
THE UNITED STATES IS RAPIDLY
EVOLVING WITH CHANGING
ENVIRONMENTAL AND DEMOGRAPHIC
LANDSCAPE THAT WILL DIFFER FROM
THE ONES OF PREVIOUS DECADES.
THIS CHANGING LANDSCAPE -- WOULD
HAVE SIGNIFICANT IMPLICATIONS ON
CANCER CONTROL AND PREVENTION IN
THE NEAR FUTURE.
AND AS SUCH NEW POPULATION BASED
CANCER EPIDEMIOLOGY COHORTS ARE
NEEDED IN ANTICIPATION OF
CHALLENGES THAT WILL FACE OUR
COUNTRY.
THESE NEXT GENERATION RESEARCH
COHORTS SHOULD ADDRESS CERTAIN
RESEARCH GAPS AND TO FOSTER
INCORPORATION AND ADAPTATION OF
NEW TECHNOLOGY AND APPROACHES.
THE WORLD IS RAPIDLY CHANGING AS
YOU KNOW.
OUR ENVIRONMENTAL EXPOSURE IS
EVOLVING AND THIS VISUALLY
SHOWCASES SOME KEY FACTORS.
CLIMATE CHANGE WILL INFLUENCE
POTENTIAL CANCER ASSOCIATED RISK
FACTORS SENSITIVE TO EXTREME
TEMPERATURES.
THERE ARE PRESENT AND EMERGING
ENVIRONMENTAL CHEMICALS AND
THERE ARE LIFESTYLE AND
BEHAVIORAL FACTORS SUCH AS
EXPOSURE FROM MULTIPLE I --
EXSPOUS--EXPOSURES.
AS YOU ALSO KNOW THERE IS A
DEMOGRAPHIC SHIFT IN THIS
COUNTRY.
THIS SHOWS THE PERCENTAGE
DISTRIBUTION OF RACE AND
HISPANIC ORIGIN BY AGE GROUP
FROM 2010 SHOWN IN THE LIGHT
BLUE AND 2020 SHOWN IN THE DARK
BLUE.
THE U.S. POPULATION IS BECOMING
MORE -- RACIAL AND NOTABLY IS
MORE DIVERSE THAN THE PAST
DECADE.
THIS IS MARKED IN PART BY A FAST
GROWING HISPANIC AND ASIAN
POPULATIONS.
AND THUS IN THE CONTEXT OF THESE
CHANGING LANDSCAPE THERE ARE
UNIQUE AND NEW EXPOSURES THAT WE
DO NOT KNOW THE INFLUENCE ON
CANCER RISK AND SURVIVORSHIP.
WE HAVE A DIVERSE POPULATION OF
AMERICANS MANY OF WHOM WHO ARE
NOT WELL REPRESENTED IN
BIOMEDICAL RESEARCH.
THESE FACTORS POSE NEW
CHALLENGES TO CANCER RESEARCH IN
HUMANS WITH SIGNIFICANT IMPACT
ON CANCER RISK AND OUTCOMES.
THESE NEW CHALLENGES REQUIRE
INNOVATIVE RESEARCH TO MEET THE
CHANGING NEEDS OF AN EVOLVING
MULTI-RACIAL AND ETHNIC NATION.
WITH THIS CONCEPT PROPOSAL WE
BELIEVE THAT NEW POPULATION
BASED CANCER COHORTS ARE NEEDED.
THEY SHOULD BE ABLE TO
INVESTIGATE THE
INTERSECTIONALITY AND INTERPLAY
THAT ARE RELEVANT ACROSS DIVERSE
POPULATIONS.
CANCER EPIDEMIOLOGY COHORTS ARE
COMPLEX ENTITIES AND THEIR
ESTABLISHMENT REQUIRES
METICULOUS PLANNING.
TO OPTIMIZE SUCCESS
METHODOLOGICAL WORK -- IS
REQUIRED FOR THIS CONCEPT.
TO ASK CONCRETE QUESTIONS.
AS WELL AS DEVELOP THE BASIC
INFRASTRUCTURE PRIOR TO FULL
SCALE INVESTMENT.
THESE ARE NOT LIMITED TO
APPROACHES TO OPTIMIZE
ENGAGEMENT, RECRUITMENT AND
RETENTION AS WELL AS ACCESSING
-- THE PROPOSED CONCEPT IS A
PRAGMATIC APPROACH TO MEET THE
CHALLENGES OF THE FUTURE.
THIS PAR SEEKS TO SUPPORT
METHODOLOGICAL WORK NECESSARY TO
INITIATE AND BUILD THE NEXT
GENERATION OF COHORTS.
APPEA.THEY WILL NEED TO JUSTIFY SAMPLE
SIZE.
STUDY POPULATIONS AND THE TYPE
OF DATA COLLECTION.
THERE ARE TWO OVER ARCHING KEY
FEATURES THAT APPLICATION MUST
ADDRESS.
CONCRETE PROPOSED METHODOLOGICAL
WORK AND COMMUNITY ENGAGEMENT.
THE COMMUNITY ENGAGEMENT IS
CRITICAL AND IT IS REQUIRED TO
REFLECT THE NEEDS OF LOCAL
CULTURE AND BELIEF SYSTEMS OF A
STUDY POPULATION PARTICULARLY
FOR MINORITY AND HARD TO REACH
POPULATIONS.
THE PROPOSED -- MAY TEST
QUESTIONS AS WELL AS SHORT-TERM
RESEARCH QUESTIONS THAT CUTS
ACROSS THE CANCER CONTINUUM AND
WE'VE HIGHLIGHTED A FEW HERE AND
LASTLY APPLICATIONS OF ALREADY
ESTABLISHED COHORTS ARE NOT
APPROPRIATE FOR THIS FOA.
WE ARE PROPOSING A PAR USING A
COOPERATIVE AGREEMENT MECHANISM.
IT SHOULD HAVE TWO RECEIPT DATES
PER YEAR FOR THREE YEARS.
UP TO FIVE YEARS OF FUNDING OUT.
THERE IS NO SET ASIDE REQUESTED
AND NO BUDGET CAP.
FOR APPLICATION WITH LARGE
BUDGETS THERE WILL BE A REVIEW
PROCESS TO ASSESS AND SCOPE THE
APPROPRIATENESS OF THE PROPOSE
ENDS BUDGET.
THE CURRENT CANCER EPIDEMIOLOGY
COHORT'S PORTFOLIO IS WELL
REPRESENTED OF APPROXIMATELY 31
COHORTS WITH OVER A MILLION
PARTICIPANTS.
THERE ARE SLIGHTLY MORE WOMEN
THAN MEN AND THE RACIAL
DISTRIBUTION IS 66% WHITE, 16%
BLACK AND 7% ASIANS AND 6%
HISPANICS.
THE HISPANIC POPULATION
REPRESENTED IN THESE COHORTS
THAT YOU'VE SEEN IS
SIGNIFICANTLY LOWER THAN THE
CURRENT PROPORTION OF HISPANICS
IN THE UNITED STATES.
THERE ARE TWO KEY POINTS THAT I
WOULD LIKE TO HIGHLIGHT ALSO IS
THAT 75% OF THE ASIAN AND
HISPANICS IN THE CURRENT FUNDED
-- DCCPS COHORTS -- AND
ESTABLISH A WELL-KNOWN COHORT.
WITH THE MEDIAN AGE OF
APPROXIMATELY GREATER THAN 75
YEARS OR OLDER AND AS WE PROJECT
INTO THE FUTURE WE'RE FACING ANN
ANTICIPATED RESOURCE GAP THAT'S
WILL LIMIT OUR CAPACITY TO
CONDUCT THE TYPE OF RESEARCH IN
HUMANS THAT WILL BE ABLE TO
ELIMINATE THE ROLE OF
ENVIRONMENTAL LIFESTYLE GENETIC
DETERMINANTS OF CANCER RELATED
RISK AND OUTCOMES RELEVANT TO
AMERICANS.
THE PROPOSED NEXT GENERATION
COHORT PAR IS FORWARD THINKING.
IT COMPLIMENTS THE RESEARCH
COHORT PAR BY AUGMENTING FUNDING
OPPORTUNITIES FOR INVESTIGATORS
IN THE ACTUAL -- COMMUNITY TO
INNOVATE.
IT PROVIDES A STRATEGIC LONGVIEW
OPTION TO ADDRESS SCIENTIFIC AND
RESEARCH GAPS TAKE INTO ACCOUNT
MULTIPLE IT WILL DOMAINS ACROSS
THE CONCERT CONTINUUM AND WILL
DEFINE THE NEXT GENERATION OF
COHORTS.
WE ENVISION THAT A DIVERSE
PORTFOLIO -- THAT COMES FROM
THESE TWO AND LED BY ACTUAL
RESEARCHERS WILL COMPLIMENT THE
COHORTS THAT ARE SPEARHEADED BY
INTRAMURAL INVESTIGATORS SUCH AS
CONNECT AND ALL OF US.
I WOULD LIKE TO THANK
DR. THOMPSON -- AND KNUDSEN FOR
THEIR FEEDBACK.
WE APPRECIATE THEIR SUPPORT
PARTICULARLY IN THE CONCLUSION
OF THE COMMUNITY ENGAGEMENT AND
LONG-TERM GOMES.
THE COMMITTEE ALSO ASKED US TO
CLARIFY HOW THEY WOULD EVALUATE
PROGRESS AND WE'LL CLARIFY THIS
EXPECTATION -- THIS INCLUDES THE
ABILITY TO RECRUIT AND THE
COMPLETION OF ENROLLMENT WITHIN
FIVE YEARS AS WELL AS THE
COMPLETION OF THE PROPOSED
SPECIFIC AIMS.
WE WANT OUR GRANTEES TO BE
SUCCESSFUL AND THE PROPOSED
MECHANISM WILL PERMIT MORE
INVOLVEMENT TO ADDRESS ANY
ISSUES EARLY ON AND WE WOULD
ALSO LIKE TO -- CONFIRM THAT THE
CONCEPT WILL INCORPORATE
INNOVATIVE APPROACHES.
TO TEST AND VALIDATE METHODS FOR
EXPOSURE AND OUTCOME ASSESSMENT.
LINKAGES TO EXISTING DATA -- AND
TO ASSESS SHORT-TERM EFFECTS.
THIS CONCLUDES MY PRESENTATION
AND I THANK YOU FOR YOUR TIME
AND I'M HAPPY TO ANSWER ANY
QUESTIONS THAT YOU MAY HAVE.
THANK YOU.
>> GREAT.
THANK YOU DR. LAM.
DR. THOMPSON
>> THANK YOU, KEITH.
WE WOULD LIKE TO -- THE
REVIEWERS -- AN EXCELLENT
CONVERSATION AND FOLLOW-UP WITH
DR. LAM AND ELENA.
THERE WAS SIGNIFICANT ENTHUSIASM
FOR THIS CONCEPT AND THE
PREVIOUS COHORTS OVER SO MANY
DECADES HAVE PROVIDED TREMENDOUS
INCITE INTO A BROAD RANGE OF
ISSUES RELATED TO CARCINOGEN
EXPOSURE AND WE'VE SEEN AN
IMPACT.
THE COHORTS OF THE PAST EXAMINED
POPULATIONS OF THAT TIME AND
ADDRESSED SOME OF THE ASPECTS OF
VERY DIFFERENT POPULATIONS OF
THE FUTURE NOR EXPOSURES AND
OTHER MEASURES THAT WE THINK
WILL PLAY A ROLE IN AND CANCER
CORE CERTAIN AGAIN SURVIVORSHIP
*.
ALL OF US FELT IT WAS EXTREMELY
IMPORTANT THAT THE CONCEPT BE
TESTS NEW METHODS -- THAT HAVE
NOT PREVIOUSLY BEEN ENROLLED AND
UNDER ASSESSED AS WELL AS
MEASURES IN BIOLOGICS FOR WHICH
THEY WILL NEED TO BUILD SYSTEMS
TO CAPTURE THE INFORMATION.
AS THE PROPOSALS WILL BE EXPECT
TO PROVIDE NOVEL METHODOLOGIES
AND SUCCESSFULLY RECRUIT BOTH OF
THOSE THE REVIEWERS FELT IT WAS
NECESSARY TO CAREFULLY CRAFT
MILESTONES AND MONITOR.
MUST BE COMPLETED IN FIVE YEARS
THERE WILL BE A NEED FOR
SUCCESSFUL INVESTIGATORS TO
PROVIDE A TRACK RECORD OF
ACCRUAL OF THESE POPULATIONS OF
INTEREST AND WE FELT THE
EXPECTATION OF COMMUNITY
ENGAGEMENT WAS CRITICALLY
IMPORTANT TO THE CONCEPT'S
SUCCESS.
THIS CONCEPT WILL INTERFACE WELL
WITH THE PLAN FOR THE OTHER
COHORTS THAT WE'LL HEAR ABOUT
LATER.
AND ULTIMATELY ALL OF THESE
COHORTS WILL NEED TO IN
CORPORATE THESE LESSONS LEARNED.
AGAIN THERE WAS TREMENDOUS
ENTHUSIASM BY THE REVIEWERS AND
I'LL LET MY COLLEAGUES MAKE
ADDITIONAL COMMENTS.
>> YEAH.
NO.
7 I DON'T REALLY HAVE VERY MUCH
TO ADD.
IT IS VERY FORWARD THINKING.
TAPPING INTO DAY VERSE
POPULATIONS AND -- DIVERSE
POPULATIONS.
AND THE ENVIRONMENT.
NOT ONLY CAPTURING DIFFERENT
EXPOSURES AND ALSO SOME
LIFESTYLE CHANGES BUT ALSO
PSYCHOSOCIAL CHANGES THAT ARE
OCCURRING AS WELL.
SO AGAIN I'M VERY SUPPORTIVE OF
THIS EFFORT.
>> I COMPLETELY AGREE WITH BOTH
OF MY COLLEAGUES AND ALSO THANK
DR. LAM FOR BEING SO RESPONSIVE
TO US.
IT'S THE CASE THAT THOSE COHORTS
IF YOU LOOK AT THE AGES THAT ARE
CURRENTLY IN ARE AGING OUT.
IT'S TIME TO BE BOLD AND LAUNCH
NEW COHORTS AND WE'RE ASKING
THIS NEW YOUNG OF INVESTIGATORS
TO -- OF COHORTS TO COME IN AND
DO SOMETHING DIFFICULT.
SO THE CONCEPT ARE REALLY
ENSURING THAT THEY ARE
SUCCESSFUL IN SETTING MILESTONES
WAS IMPORTANT TO US AND THE
RESPONSIVENESS IS IMPORTANT.
>> I SEE YOUR HAND DR. ROBSON SO
ASK YOUR QUESTION AND WHEN WE DO
MOVE TO VOTING DR. LAM IF YOU
COULD RESPOND TO THE CONTINUES
THAT APPEARED IN THE CHAT.
>> I THINK THIS IS A FANTASTIC
PAR THAT IS GOING TO MEET THE
NEEDS.
TWO QUICK QUESTIONS FOR
CLARIFICATION.
YOU MENTIONED MULTIPLE TIMES
POPULATION BASED.
IS THIS TRULY GOING TO BE
RESTRICT ONLY TO POPULATION
BASED COHORTS WHICH I FEEL IS
LIMITATION BECAUSE SOME OF THE
RESEARCH QUESTIONS MAY BEST BE
CARRIED OUT IN SELECTED
POPULATIONS THAT THAT DON'T NEED
THAT SPECIFIC CRITERIA.
ESPECIALLY WHEN WE TALK ABOUT
THE SURVIVOR COHORTS
>> TO ANSWER YOUR QUESTION I
BELIEVE THE SCIENCE THE
SCIENTIFIC GAPS WILL BE DRIVING
MUCH OF THE DECISIONS.
WE WOULD LIKE THE INTENSE IS TO
-- HAVE COHORTS THAT MEET THE
SCIENTIFIC GAPS.
AND AS SUCH WE WILL ENCOURAGE
INVESTIGATORS TO TOUCH BASE WITH
PROGRAM TO DISCUSS THE
APPROPRIATENESS OF THE STUDY
POPULATIONS SO WHILE WE SEEK FOR
POPULATION BASED COHORTS WE ARE
ALSO VERY OPEN TO ANY OTHER
POPULATIONS THAT WOULD ADDRESS
SOME OF THE SCIENTIFIC GAPS.
>> EXCELLENT.
THAT IS EXACTLY HOW I FEEL IT
SHOULD BE HANDLED.
THE SCIENCE SHOULD DRIVE THE
COMPOSITION OF THE COHORT.
THE SECOND POINT YOU SAID THIS
WOULD NOT BE RESPONSIVE TO
ESTABLISHED COHORTS AND I'M
REALLY SORT OF QUESTIONING WHAT
THE DEFINITION OF AN ESTABLISHED
COHORT WOULD BE.
BECAUSE SOME SMALL COHORTS THAT
MIGHT NOT BE NCI FUNDED MIGHT
ACTUALLY HAVE DEVELOPED SOME OF
THE METHODS, SHOWN THE METHODS
AND ACTUALLY BE FURTHER ALONG IN
TERMS OF MOVING FORWARD TO THE
OBJECTIVE.
SO I JUST ENCOURAGE YOU TO HAVE
A VERY CLEAR DEFINITION OF WHAT
YOU CAN BE AN ESTABLISHED
COHORT.
YOU MIGHT BE CUTTING OUT SOME
VERY IMPORTANT OPPORTUNITIES TO
ESTABLISH MORE EXPANDED COHORTS
THAT CAN MOST EFFECTIVELY
ADDRESS THE ISSUES
>> THANK YOU FOR THAT COMMENT.
IT IS PART OF OUR INTERNAL
DISCUSSION AS WELL TO HAVE
CLARITY ON WHAT WE MEAN BY
ESTABLISHED COHORTS.
AND -- THOSE THAT HAVE FINISHED
ENROLLMENT ALREADY.
WE'RE SEEKING FOR NEW COHORTS
THAT WILL ALLOW US TO CAPTURE
SOME OF THE -- ADDRESS SOME OF
THE SCIENTIFIC GAPS AND I WANT
TO UNDERSCORE AGAIN IS THAT THE
SCIENCE WILL BE DRIVING MUCH OF
THE DISCUSSION AND WHAT IS
QUALIFIED OR LEGIBLE FOR THIS
PAR.
THANK YOU FOR THE COMMENT
>> THANK YOU.
>> AND --
>> THANK YOU DR. LAM.
AS YOU KNOW ONE OF THE
CHALLENGES OF THE NEW COHORTS IS
FOLLOW-UP TIME AND HAVING ENOUGH
EVENTS FOR WELL POWERED STUDIES.
IS THERE A THOUGHT ABOUT
ENCOURAGING INTERMEDIATE
BIOMARKERS AS END POINTS.
>> ABSOLUTELY.
AND THAT IS PART OF THE
SHORT-TERM RESEARCH STUDIES THAT
WE HAVE INCLUDED WITHIN THE
CONCEPT THAT WILL ALLOW THOSE
ASSESSMENT OF SHORT-TERM
RESEARCH QUESTIONS INCLUDING
BIOMARKERS.
I BELIEVE ONE OF MY SLIDES
HIGHLIGHTED THAT AND THAT IS
SOMETHING THAT THE REVIEWERS OF
THE BSA SUBCOMMITTEE ALSO
THOUGHT WAS A GREAT FEATURE OF
THIS PAR.
>> THANK YOU.
>> OKAY.
LET'S MOVE TO VOTING IF NO ONE
OBJECTS.
DR. THOMPSON
>> I MOVE FOR APPROVAL
>> CAN I GET A SECOND?
>> SECOND.
>> ANY FURTHER DISCUSSION?
>> OKAY.
HEARING NONE THIS IS A NEW
CONCEPT.
SOth MOTION IS TO APPROVE.
IF ANYONE DISAPPROVES PLEASE
VOICE THAT VOTE.
I DO NOT SEE ANY.
INDICATIONS OF SUCH.
ANY ABSTINENCES.
NO ABSTINENCES.
SO * CALL IT UNANIMOUS AND NO
ABSTINENCES.
>> GOT IT.
>> APOLOGIES FOR THE SHIFTING
SCHEDULE BUT WE WOULD LIKE TO
TRY TO KEEP FOCUS AND MOMENTUM.
>> WE REGISTERED THESE COMMENTS
IN THE CHAT.
THANK YOU FOR POINTING THAT OUT
AND IT'S NOTED.
>> DR. ELENA I THINK YOU ARE
TEED UP AND BACK ON-LINE.
WE WOULD LIKE TO RESUME YOUR
PRESENTATION AND KEEP OUR FOCUS
ON THIS.
>> WOULD YOU LIKE ME TO START
FROM THE TOP OR FROM WHERE YOU
LEFT OFF.
>> A BRIEF REMINDER WOULD BE
USEFUL AND THEN --
>> I WILL BE BRIEF AT THE
BEGINNING.
I WANT TO PUT A PLUG IN FOR
WORKING AT NCI.
WHAT A GREAT PLACE AND GREAT
PEOPLE.
THANK YOU.
LET'S GO -- WITH THE SLIDES UP.
THANK YOU VERY MUCH.
VERY VERY BEGINNING.
7 OKAY.
YOU KNOW WHO WE ARE AND WHY
WE'RE HERE.
SO THE PURPOSE OF THIS PAR IS TO
PROVIDE CONTINUED SUPPORT FOR
ESTABLISHED COHORT STUDIES AND
DR. ROBSON JUST ASKED WHERE
DEFINING ESTABLISHED STUDIES AND
WE'RE DEFINING ESTABLISHED
STUDIES IS THOSE WHO HAVE
ACHIEVED THEIR INITIAL PLANNED
RECRUITMENT GOAL.
THIS PAR WILL BE REPLACED
PAR20-2694.
IT SEPARATED INFRASTRUCTURE FROM
RESEARCH BY PROVIDING SUPPORT
FOR BASIC MAINTENANCE ONLY.
THINGS LIKE PARTICIPANT
FOLLOW-UP.
CASE ASCERTAINMENT AND
BIOSPECIMEN STORAGE
THIS PAR IS BRINGING RESEARCH
AND INFRASTRUCTURE BACK
TOGETHER.
NEXT SLIDE.
IN DEVELOPING THIS PAR WE WENT
BACK TO THE JUNE 2019 -- AND
THIS PAR IS ADDRESSING MANY OF
THEIR RECOMMENDATIONS INCLUDING
CONTINUED SUPPORT FOR COHORTS TO
ADDRESS CRITICAL SCIENTIFIC GAPS
THAT PEER REVIEW SHOULD INCLUDE
JUSTIFICATION FOR CONTINUED
FOLLOW-UP AND THAT COHORTS
SHOULD ADDRESS EMERGING GAPS
WITH APPROPRIATE POPULATIONS.
ALSO RESEARCH GAPS BY CANCER
TYPE AND TREATMENT.
COHORTS STUDIES HAVE LED TO THE
IDENTIFICATION OF A MYRIAD OF
FACTORS ASSOCIATED WITH CANCER
INCIDENTS.
MORBIDITY AND MORTALITY.
WE'VE LEARNED THAT THE LINK OF
OBESITY AND CANCER MORTALITY AND
PESTICIDES AND SOLIDIFIED
EVIDENCE FOR ASSOCIATIONS WITH
SMOKING AND ALCOHOL INTAKE AMONG
MANY OTHERS.
THEY'VE ALSO PROVIDED SUPPORT
FOR INTERVENTIONS SUCH AS
SCREENING FOR SECOND CANCERS AND
HEALTH CONDITIONS AND CHILDHOOD
CANCER SURVIVORS.
THERE ARE RICH RESOURCES FOR A
WIDE VARIETY OF FUTURE RESEARCH.
MANY GROUPS ARE NOW COMBINING
COLLECTED DATA AND BIOSPECIMENS
TO DEVELOP RISK SCORES AND MANY
OTHER TOPICS.
REQUIRING SCIENTIFIC AIMS WITH
SPECIFIC RESEARCH QUESTIONS AND
ONE MECHANISM DESIGNED TO
SUPPORT ESTABLISHED CANCER EPPIE
COHORTS WILL GUIDE DESIGN AND
ASSURE APPROPRIATE METHODS WHICH
BRINGS US CLOSE TO OUR GOAL OF
ADVANCING SCIENTIFIC KNOWLEDGE
AND THE HEALTH OF THE
POPULATION.
* TO THIS AIM WE'LL REQUIRE
APPLICANTS TO ADDRESS KEY
SCIENTIFIC GAPS.
WE EXPECT THE INFRASTRUCTURE
NEEDS WILL BE INCLUDED.
THE JUSTIFICATION AND ADD ANY
PROPOSED ASSAYS WILL BE BASED ON
THE RESEARCH PROPOSED IN THE
SCIENTIFIC GAINS.
INTERNALLY PRIORITY WILL BE
GIVEN TO RESEARCH THAT INCLUDES
UNDERSTUDIED POPULATIONS.
AS WELL AS STUDIES THAT DIRECTLY
INFORM INTERVENTIONS AND
GUIDELINES.
WE WILL CLEARLY DEFINE WHO'S
ELIGIBLE.
THOSE APPLICATION THAT'S PROPOSE
NEW COHORTS OR DO NOT INCLUDE
RESEARCH FROM AN ESTABLISHED
COHORT STUDY IN THE AIM WILL BE
DEEMED NONRESPONSIVE BECAUSE WE
WANT TO MAXIMIZE THE
PRODUCTIVITY OF THESE STUDIES
WE'LL REQUIRE THAT THEY HAVE
DATA AND RESOURCE SHARING PLANS
THAT COMPLY WITH THE NIH POLICY
AND ADHERE TO FAIR PRINCIPLES.
WHILE THERE IS NO SPECIFIED
BUDGET GAP THE BUDGET MUST
REFLECT THE SCIENCE PROPOSED.
WE'LL FOLLOW THE POLICY FOR
GRANTS ABOVE $500,000 AND
BECAUSE WE COULD IMAGINE THAT
SOME OF THESE GRANTS MIGHT BE
QUITE COSTLY WE'LL REQUIRE A
PRESUBMISSION MEETING FOR GRANTS
ABOVE $700,000 DISTRICT COST
ANNUALLY APPROXIMATELY 12 WEEKS
BEFORE SUBMISSION TO ASSURE
APPROPRIATE SCOPE OF THE PROJECT
AND REASONABLENESS OF THE
PROJECT.
NCI HAS MADE A CONSIDERABLE
INVESTMENT IN COHORTS.
THERE ARE CURRENTLY YOU'VE HEARD
ABOUT THIS.
HAVE 31.
ABOUT THREE QUARTERS ARE WOMEN.
THE RACIAL AND ETHNIC
DISTRIBUTION PROBS MATES THE
U.S. POPULATION WITH THE
EXCEPTION OF THE HISPANIC
POPULATION CLASS 6% IN OUR
COHORTS YET 18% OF THE U.S.
POPULATION BASED ON RECENT
CENSUS DATA. WITH THE
LONG-STANDING SUPPORT MANY HAVE
OLDER POPULATIONS WHICH
TRANSLATES TO A CRITICAL NUMBER
OF EVENT.
THE MEDIAN AGE FOR SEVERAL RISK
COHORTS IS APPROACHING 80 YEARS.
SOME OF THE STUDIES HAVE FAIRLY
NARROW RANGES OF AGE OTHERS HAVE
A VAST RANGE OF AGES FROM LATE
40s TO OVER 100.
WE FOCUS ENDS ON ESTABLISHED
COHORTS BECAUSE THEY HAVE THE
NECESSARY DATA COLLECTED AND
NUMBER OF EVENTS TO PRODUCE
IMPORTANT RESEARCH.
NEXT SLIDE.
I THOUGHT IT MIGHT BE HELPFUL TO
GO THROUGH A TYPICAL TIME LINE.
ALTHOUGH THERE WILL BE
DIFFERENCES IN LENGTHS.
TYPICALLY THERE IS A PERIOD WHEN
THE STUDY TEAM IS PILOTING AND
THEY PROCEED TO ENROLLMENT AND
BEGIN COLLECTING DATA. THEY
WILL CONTINUE TO ACCRUE CASES
AND THEY HAVE A NUMBER OF WAYS
OF DATA COLLECTION.
THEY CONTINUE TO ACCRUE CASES
AND IT TRANSITIONS FROM ACTIVE
DATA COLLECTION TO MORE PASSIVE
FOLLOW-UP AND THEN ARCHIVES THE
DATA FOR FUTURE RESEARCH.
THIS PAR -- THIS IS AN
ANIMATEDDED SLIDE SO IF YOU'LL
HIT FORWARD ONCE.
THIS COVERS THE TIME PERIOD FROM
COMPLETED ENROLLMENT AND THE
NEXT PAR -- THE PREVIOUS PAR
COVERS THE INITIAL PERIOD THAT
IS CRITICAL FOR ESTABLISHING NEW
COHORTS.
TOGETHER THESE PARs WILL HELP
TO CONTINUE THE SUPPORT FOR
THESE IMPORTANT CONTRIBUTIONS.
I'VE SUMMARIZED THE MAIN
COMMENTS.
CURRENT GRANTEES FROM PAR20-294
ARE NOT ELIGIBLE FOR FUNDING BUT
ARE WELCOME TO SUBMIT
INVESTIGATOR INITIATED RESEARCH
GRANTS AT ANY POINT.
WE'VE CLARIFIED THE
NONRESPONSIVE CRITERIA.
AND THIS IS A GOOD PLACE TO END.
DIVERSITY AND INNOVATION ARE
IMPORTANT FOR OUR PORTFOLIO OF
CANCER EPIDEMIOLOGY COHORTS.
OF COURSE WE'RE TALKING ABOUT
RACIAL AND ETHNIC DIVERSITY BUT
ALSO AGE, CANCER SITE, URBAN AND
RURAL AND SOCIOECONOMIC STATUS
AND BEYOND.
AND I'M HAPPY TO ANSWER ANY
QUESTIONS.
>> DR. ROBSON.
DO YOU WANT TO START US WITH THE
DISCUSSION.
>> YES.
FIRST I WANT TO THANK DR. ELANA
AND LAM FOR THEIR TWO
PRESENTATIONS THAT ARE VERY MUCH
IN LINE WITH THE NCAB WORKING
GROUP REPORT.
THAT WAS GENERATED ADDRESSING
THE ISSUES OF COHORTS.
SO I REALLY CONGRATULATE THE NCI
AND REALLY THINKING ABOUT THE
FUTURE OF THE COHORTS WHICH WE
OBVIOUSLY THROUGH THESE
DISCUSSIONS HAVE REALLY
EMPHASIZED ARE AN IMPORTANT PART
OF THE NCI PORTFOLIO.
AND DOES REPRESENT A VERY
SPECIFIC METHODOLOGIC STUDY
DESIGN TO INFORM A NUMBER OF
IMPORTANT ISSUES RELATING TO
BOTH CANCER RISK AS WELL AS
CANCER OUTCOMES WITHIN THE
GROUP.
AS A WORKING GROUP WE WERE
INCREDIBLY POSITIVE ABOUT THIS
REVISED PAR THAT WOULD TAKE THE
PLACE OF THE EXISTING
INFRASTRUCTURE APPROACH.
WE THINK THIS IS A VERY POSITIVE
MODIFICATION THAT AGAIN STARTS
TO REINTEGRATE HYPOTHESIS DRIVEN
RESEARCH.
AROUND THE SUPPORT OF THE
INFRASTRUCTURE AND THE SPECIFIC
INFRA STRUCTURE BEING BUILT FOR
THE EXISTING COHORTS THAT ARE
GOING FORWARD.
SO I THINK WE CAN KEEP THE
DISCUSSIONS.
THERE IS A NUMBER OF OTHER
POSITIVE THINGS THAT HAVE BEEN
BROUGHT OUT IN SOME OF THE
PREVIOUS DISCUSSIONS.
SO I THINK IN GENERAL WE THINK
THAT THIS IS A VERY RESPONSIVE
-- TO THE NEEDS OF THE PORTFOLIO
FOR ITS COHORTS OF THE NCI AND
THAT IT WILL VERY MUCH HAVE THE
LIKELIHOOD OF ENHANCING THE
EXISTING INVESTMENT THAT NCI HAS
PUT IN THE CURRENT COHORTS.
7 I WANT TO RESPOND ABOUT
CLARIFYING TRANSITION -- AND WE
THINK THAT THE CRITERIA THAT
WILL BE APPLIED IS REALLY
ADEQUATELY DRESSED THROUGH OUR
PREVIOUS QUESTIONS AND YOUR
CURRENT PRESENTATION.
THE ONE THING THAT WE WANT TO
REEMPHASIZE IS THAT REVIEW OF
THESE PROPOSALS SUBMITTED
ABSOLUTELY NEED TO BE REVIEWED
THROUGH A SPECIAL EMPHASIS PANEL
THAT BRINGS TOGETHER THE RIGHT
EXPERTISE.
THAT IS SOMETHING THAT IS
ESSENTIAL FOREIGN SURING THAT
THE BEST SCIENCE AND THE BEST
APPROACHES GO FORWARD.
SO AGAIN I THINK THE WORKING
GROUP WAS INCREDIBLY SUPPORTIVE
AND I'LL STOP THERE AND OPEN IT
UP TO EITHER MELISSA AND KIM FOR
ADDITIONAL COMMENTS
>> I JUST WANT TO SAY JOANNE
WE'VE ALL BEEN THERE WITH OUR
KIDS AND WILL CONTINUE TO BE
THERE WITH OUR KIDS.
BUT ANYHOW WE ALL SYMPATHIZE
WITH YOU AND UNDERSTAND.
I DEFINITELY CONCUR AND I WAS
THINKING ABOUT HOW THE GRANTS
WOULD BE REVIEWED.
I'M REALLY GLAD THAT YOU ADDED
IT.
AND WE KNOW HOW STUDY SECTIONS
REVIEW THESE AND WHEN THEY ARE
HUGE GRANTS THAT WITHOUT THEM
BEING REVIEWED THEY WOULD FAIL.
SO THANK YOU FOR INCORPORATING
THAT POINT.
WE NEED TO KEEP THESE -- SOME OF
THESE GRANTS THE INFRASTRUCTURE
OF THESE COHORTS HAVE BEEN
REALLY IMPORTANT AND HAVE BEEN
TRANSFORMATIONAL IN TERMS OF
WHAT WE'VE LEARNED FROM THEM AND
WE WANT TO MAKE SURE THAT THE
INFRASTRUCTURE AND I THINK I
WROTE YOU THIS TOO OVER THE
WEEKEND AND INCLUDED THE OTHERS
THE IMPORTANCE OF THE
INFRASTRUCTURE THAT WHEN YOU ADD
IN HYPOTHESIS TO MAKE SURE THAT
THE INFRASTRUCTURE IS CONTINUED.
BECAUSE IT DOES HELP WITH THE
RO1s BECAUSE THE
INFRASTRUCTURE IS MAINTAINED IN
A LARGER GRANT SO I JUST WANT TO
MAKE SURE THAT THAT WOULD HELP
THE PI OF THE MAIN PARENT GRANT.
SO THANK YOU.
I DON'T HAVE ANY MORE COMMENTS.
I THINK YOU'VE ADDRESSED THEM
ALL AND DR. ROBISON MENTIONED
THEM AS WELL.
>> GREAT.
I JUST WANT TO SAY I'M GLAD THAT
WE COULD REVIEW THIS IN PARALLEL
WITH THE OTHER ONE BECAUSE THEY
GO TOGETHER NICELY.
THAT IS GREAT.
THIS IS AN INCREDIBLE RESOURCE
TO BE ABLE TO CARRY FORWARD NOT
JUST FEEDING AND WATERING BUT
PUTTING HYPOTHESIS GOVERNMENT
RESEARCH INTO IT.
AGREE WITH THE OTHER MEMBERS OF
THE COMMITTEE.
>> GREAT.
THANK YOU ALL.
ANY BRIEF SUCCINCT QUESTIONS OR
COMMENTS?
OKAY.
VERY GOOD.
LET'S MOVE TO VOTING.
DR. ROBSON.
>> I MAKE THE MOTION TO APPROVE
THIS CONCEPT.
>> A SECOND.
>> SECOND.
>> ANY FURTHER DISCUSSION?
OKAY.
THE MOTION IS FOR APPROVAL.
LOOKING FOR ANYONE WHO WOULD
LIKE TO VOTE TO DISAPPROVE?
I SEE NONE.
ANY ABSTENTIONS?
AND NO ABSTENTIONS SO UNANIMOUS
APPROVAL.
NO ABSTENTIONS.
>> OKAY.
SO WE'RE GOOD.
MEMBERS STAY WITH US.
WE HAVE ONLY ONE MORE AND WE
HAVE TO HAVE A QUORUM.
OKAY.
>> AS LONG AS WE CAN KEEP NINE
PEOPLE FROM THE BSA WE'RE GOING
TO MOTOR THROUGH THE LAST ONE.
THANK YOU ALL FOR YOUR
ENDURANCE.
WE HAVE ANOTHER NEW RFA FINAL
CONCEPT FOR THE DAY.
THE CANCER CONTROL RESEARCH IN
PERSISTENT POVERTY AREAS
CONCEPT.
DR. SRINIVASAN IS PRESENTING.
PLEASE PROCEED
>> THANK YOU ALL FOR STAYING ON
TO THE VERY END AND THANK YOU
FOR THE OPPORTUNITY TO SPEAK
WITH YOU TODAY.
THIS IS A REQUEST FOR THE U54RFA
ON CANCER CONTROL RESEARCH IN
POVERTY AREAS.
POVERTY IS DEFINED AS COUNTIES
WHERE 20% OR MORE OF THE
POPULATION IS BELOW THE POVERTY
LINE FOR THE PAST 20 YEARS.
FOPS LOOK AT THIS MAP WE SEE
THERE ARE ONLY A FEW STATES WITH
PERSISTENT POVERTY DEPICTED.
IN THE STUDY WE PUBLISHED IN
2020 WE FOUND THAT PEOPLE IN
PERSISTENT POVERTY AREAS HAVE
HIGHER CANCER MORTALITY THAN
THOSE IN -- AND EVEN HIGHER AS
COMPARED TO --
[ AUDIO DIFFICULTIES ]
FOR SCREENABLE AND PREVENTABLE
CANCERS.
NEXT SLIDE PLEASE.
SO THIS ACTUALLY IS PART OF THE
STUDY WHICH WAS PUBLISHED WHERE
WE FOUND THAT PEOPLE WHO LIVED
IN THESE COUNTIES ARE MORE
LIKELY TO DIE FROM CANCER THAN
OTHER AREAS.
NEXT SLIDE, PLEASE.
SO PERSISTENT POVERTY IS AN
IMPORTANT CONTEXT TO ADDRESS
HIGH MORTALITY RATES FOR CANCER.
BUT THERE ARE LIMITATIONS TO
COUNTY LEVEL DEFINITIONS WHEREBY
SMALLER AREAS IN EXTREME POVERTY
ARE EXCLUDED FROM THIS
DEFINITION SUCH AS INNER CITIES.
SO IN CONJUNCTION WITH TRACY --
AT THE U.S.D.A -- THEY EXTENDED
THE DEFINITION TO THE CENSUS
TRACK LEVEL AND WE MAKE THIS
INFORMATION AVAILABLE WITH THE
RFA.
DEFINING PERSISTENT POVERTY
LOUSE US TO DOUBLE THE
POPULATION FROM 16.5 MILLION TO
29 MILLION.
SO THIS IS A DEPICTION THAT
SHOWS THAT IN THE NEW DEFINITION
AT THE CENSUS TRACK LEVEL WE
HAVE REPRESENTATION ACROSS ALL
STATES AND THAT IT IS PERVASIVE
ACROSS THE U.S.
WHAT ARE THE THE UNIQUE
CHARACTERISTICS.
LACK OF ADEQUATE HOUSING.
GREATER ENVIRONMENTAL
DEGRADATION.
HIGHER RATES OF OBESITY, SMOKING
AND LOWER LEVELS OF EDUCATION
AND INADEQUATE ACCESS TO HEALTH
CARRA AMONG OTHER THINGS.
* THIS IS DATA REPORTED BY THE
U.S.D.A WHERE THEY TALK ABOUT
EFFECTS OF PERSISTENT POVERTY
AREAS AND PEOPLE LIVING IN THOSE
AREAS.
NOT ONLY THOSE IN POVERTY BUT
EVERYBODY LIVING IN THOSE AREAS.
THEY SAY THAT IT'S A GREATER
LIKELIHOOD FOR LACK OF ADEQUATE
SUPPORT OF SERVICES.
ALSO EXPOSURE TO PERSISTENTLY
POOR AREAS.
AND LASTLY THERE IS DOUBLE
POVERTY EXPOSURE.
PEOPLE WHO ARE IN POVERTY AND
ALSO THOSE WHO LIVE IN THESE
POVERTY AREAS HAVE LIMITED
OPPORTUNITIES FOR EVERYTHING
INCLUDING AFFORDABILITY.
SO THE AIM OF THIS INITIATIVE IS
TO CONDUCT CANCER CONTROL AND
PREVENTION RESEARCH IN
PARTNERSHIP WITH COMMUNITIES AND
CLINICS IN PERSISTENT POVERTY
AREAS BY LEVERAGING EXISTING
DATA RESOURCES AND CONDUCTING
PRELIMINARY DATA COLLECTION.
CONDUCTING MULTI-LEVEL
INTERVENTION AND IMPLEMENTING
TRAINING OF TRANSDISCIPLINARY --
FOR JUNIOR INVESTIGATORS.
SOME EXAMPLE AREAS OF RESEARCH
ACROSS THE CANCER CONTINUUM --
THE EFFECTS OF PERSISTENT
POVERTY --
[ INDISCERNIBLE ]
WOULD LEAD TO TARGETED OUTCOMES
SUCH AS INCREASE IN CANCER
SCREENING.
PREVENTION STRATEGIES.
INCREASE VACCINATION RATES AND
IMPROVE SURVIVORSHIP CARE.
SO THE PROPOSED FUNDING
OPPORTUNITIES --
[ INDISCERNIBLE ]
SPECIALIZED CENTERS AND WE'RE
SAYING THAT THESE CENTERS WOULD
HAVE THESE CODES.
ADMINISTRATIVE CORE.
A RESEARCH AND INFRASTRUCTURE
CORE.
7 ONE TO BE AN INTERVENTION.
PILOT PROJECTS.
DECIDED ON AFTER THE FUNDING TO
BE FLEXIBLE AND RESPONSIVE.
AND AGAIN WE'RE ASKING FOR A
MINIMUM OF TWO PILOT PROJECTS
AND ONE BEING AN INTERVENTION
AND AN INVESTIGATOR DEVELOPMENT
CORE.
7
[ INDISCERNIBLE ]
AND FOCUS ON COMMUNITY AND
INSTITUTIONAL AND STRUCTURAL
LEVELS AND BE MULTI-LEVEL AND
MULTI-FACTORIAL.
ADDITIONALLY THEY SHOULD ALSO
ADDRESS ISSUES OF SUSTAINABILITY
-- AS SUGGESTED BY THE BSA
REVIEWERS.
THE PROPOSED BUDGET IS FOR
$10 MILLION FOR YEAR.
FOR A TOTAL COST OF UP TO
$50 MILLION OVER FIVE YEARS WITH
FUNDING BEGINNING IN 2023.
WE'RE CAPPING EACH CENTER AT
$1.5 MILLION A YEAR.
WE'RE ASKING APPLICANTS TO SET
ASIDE 1.5% OF THEIR DIRECT COST
FOR THE ENTIRE FUNDING PERIOD TO
FUND TWO PILOT PROJECTS.
ONE AS I NOTED EARLIER WOULD BE
AN INTERVENTION STUDY.
WE WOULD LIKE TO ENCOURAGE
MULTI-CULTURAL PROJECTS --
PILOTS AND DECIDED BY THE
STEERING COMMITTEE.
THE STEERING COMMITTEE WILL
COMPLY OF NCI STAFF AND
COLLABORATORS TO ASSESS.
AND WHICH WILL ALSO HELP PROVIDE
FEEDBACK TO THE STEERING
COMMITTEE.
WE'LL HOLD ANNUAL MEETINGS AND
MONTHLY CALLS WHICH WILL ALLOW
US TO ASSESS THE PROGRESS.
AND WE WILL BE ABLE TO ADDRESS
ANY CHALLENGE.
CHALLENGE.CAME UP WITH FIVE PROJECTS THAT
FOCUSED ON PEOPLE LIVING IN
PERSISTENT POVERTY AREAS.
WE ALSO DID A CANCER CENTER --
IN THE SPRING OF 2021.
AND WE RECEIVED APPLICATIONS OF
WHICH WE FUNDED FIVE.
[ INDISCERNIBLE ]
WE HAVE NOT RECEIVED ANY
APPLICATIONS YET.
IT WAS PUBLISHED LATE SUMMER.
THE BSA REVIEWERS GAVE VERY GOOD
FEEDBACK AND THESE WERE THE
POINTS THAT THEY HIGHLIGHTED.
THEY ASKED US TO ENCOURAGE
SUSTAINABILITY OF TRAINING IN
THE OVER-ALL PROGRAM.
INCLUDE LANGUAGE AND ADOPTION OF
INNOVATIVE TECHNOLOGIES IN THE
RFA AND ALSO INCLUDE LANGUAGE
AND TRAINING ACROSS ALL PROJECTS
AND PILOTS AND ESPECIALLY CROSS
CENTER PROJECTS.
THANK YOU VERY MUCH FOR YOUR
TIME.
>> GREAT.
THANK YOU VERY MUCH.
DO YOU WANT TO START THE
DISCUSSION
>> THANK YOU DR. SRINIVASAN AND
DR. KENNEDY FOR PUTTING THIS
GREAT CONCEPT TOGETHER AND FOR
YOUR GREAT PRESENTATION.
WE WERE HIGHLY ENTHUSIASTIC
ABOUT THIS CONCEPT.
IT'S VERY TIMELY AND AS YOU
HEARD IT REALLY ADDRESSES A HIGH
UNMET NEED.
THERE IS AS YOU HEARD IN THE
LAST SLIDE THERE IS VERY LIMITED
RESEARCH IN THIS AREA.
IN THE NIH AND NCI PORTFOLIO AND
WE FELT IN ORDER TO IMPLEMENT
INTERVENTIONS IT'S GOING TO
REQUIRE A MUCH BETTER
UNDERSTANDING OF PERSISTENT
POVERTY AND OTHER HEALTH FACTORS
AT THE STRUCTURAL AND
INSTITUTIONAL LEVELS.
WE WERE REALLY PLEASED WITH THE
USE OF CENSUS TRACTS AS OPPOSED
TO COUNTY DATA BECAUSE TO DEFINE
THE AREAS OF PERSISTENT POVERTY
AND THOUGHT THIS WAS HIGHLY
BENEFICIAL BECAUSE IT ALLOWS THE
INCLUSIVENESS OF THE URBAN
POPULATION.
THERE WERE ANOTHER STRENGTH WAS
THE SUSTAINABILITY.
BECAUSE IT FOCUSES ON DEVELOPING
PROVENCE AND CONTROL STRATEGIES
IN PARTNERSHIP WITH LOCAL
COMMUNITIES AND COMMUNITY-BASED
ORGANIZATIONS AND PRIMARY AND
LOCAL CLINICS AND HOSPITALS.
IT HAS A STRONG EMPHASIS ON
BUILDING A NETWORK OF
RESEARCHERS FOR CONTINUITY OF
RESEARCH AND THIS IS THROUGH THE
DEVELOPMENT OF JUNIOR FACULTY
WITH CAREER DEVELOPMENT OF
RESEARCHERS VIA THE CORE
FACILITIES, THE INVESTIGATOR
DEVELOPMENT PROJECTS AND THE
MAIN PROJECTS THEMSELVES.
WE FELT THERE WERE VERY STRONG
-- AS YOU HEARD WE ASKED TO
EMPHASIZE BUILDING ON TECHNOLOGY
BUT ALSO DEVELOPING NEW
TECHNOLOGIES AS AN EMPHASIS OF
THIS MECHANISM.
WE FELT THAT THE EVALUATION
CRITERIA WAS VERY ROBUST AND
APPROPRIATE AND THAT ONE OF THE
STRENGTHS WAS THE STEERING
COMMITTEE.
DR. SRINIVASAN WAS ABLE TO
ADDRESS ALL OF OUR CONCERNS AND
OUR ONLY RECOMMENDATION IS WHATS
TO ADDRESS SUSTAINABILITY AND
DISCUSS THE USE AND DEVELOPMENT
OF ENOUGH TECHNOLOGIES AND I
WILL TURN IT OVER TO DR. -- --
FOR THEIR COMMENTS.
7
>> I'LL JUST SAY VERY QUICKLY --
THANK YOU AND A CONGRATULATIONS
TO DR. SRINIVASAN.
SHE AND BOB AND SOME PEOPLE FROM
THE DIVISION OF CANCER CONTROL
PUBLISHED THE PAPER WHICH SHE
REFERENCED IN HER TALK WHICH IS
ONE OF THE MOST IMPORTANT PAPERS
IN THE AREA OF HEALTH
DISPARITIES AND REALLY DOES HELP
LAUNCH THIS WHOLE ERA WHERE
WE'RE LOOKING AT ENVIRONMENTAL
INFLUENCES ON GENETIC AND
GENOMIC AND EPIGENETICS IN
CANCER AND I WANT TO SAY THANK
YOU NUMBER ONE FOR SOME GREAT
WORK AND I ENDORSE THIS CONCEPT
WHOLEHEARTEDLY.
>> I DON'T HAVE ANYTHING TO ADD.
I THINK THE CONTINUES THAT HAVE
BEEN MADE HAVE CAPTURED OUR
REACTIONS TO THIS HIGHLY
SUPPORTIVE.
I THINK IT SHINES A LIGHT IN AN
AREA THAT REALLY NEEDS TO BE
ADDRESSED.
>> GREAT.
THANK YOU.
DR. SRINIVASAN.
THERE ARE A COUPLE OF QUICK
QUESTIONS.
SPECIFICALLY ARE NCI
COMPREHENSIVE CANCER CENTERS WHO
DO NOT ACCEPT MEDICAID EXCLUDED?
NO.
NOT AT ALL.
WE WOULD ENCOURAGE -- TO GO OUT
INTO AREAS OF PERSISTENT POVERTY
AND CREATE THOSE PARTNERSHIPS TO
HELP DO THIS KIND OF WORK.
>> AND THEN WHITE BE ESSENTIAL
FOR INVESTIGATORS TO KNOW AS
SOON AS POSSIBLE THE RELEVANT
CENSUS TRACTS PRIOR TO THE FOA
IS PUBLICALLY ANNOUNCED.
>> S WE COULD MAKE IT PUBLICLY
AVAILABLE IN PROBABLY JANUARY OR
LATER IN FEBRUARY.
WE ARE TESTING THE DATA OUT AS
WE SPEAK.
TO SEE HOW IT WORKS OUT AND SEE
WHETHER THE DATA PROS ANY SMALL
CATEGORIES.
-- WE WANT TO MAKE SURE THE DATA
IS ROBUST ENOUGH.
WE HAVE THE CENSUS TRACT.
8 * AND WE WILL MAKE IT
AVAILABLE AS SOON AS POSSIBLE.
>> I HAVE A COMMENT AND MAYBE A
QUESTION.
VERY TIMELY STUDY.
THE CHARACTERISTICS OF
PERSISTENT POVERTY -- THAT YOU
HAD ON YOUR SLIDE WOULD BE ALSO
CHARACTERISTICS THAT WOULD
INCREASE INCIDENTS OF OTHER
TYPES OF CONDITIONS.
CARD OHIO VASCULAR DISEASE.
METABOLIC DISEASE.
DIABETES.
WONDER TO WHAT EXTENT HAS THIS
BEEN FACTORED THAT WOULD BE *
PROPOSED.
WHETHER OR NOT THE INTERACTION
BETWEEN THESE CONDITIONS AND
CANCER -- I'M NOT SURE THAT IS
BEYOND THE SCOPE OF THE PROGRAM
OR NOT.
>> I THINK THAT IS THE FEATURE
OF PEOPLE WHO LIVE WITH
PERSISTENT POVERTY -- IT'S A
HIGH DISEASE OCCURRENCES OF
DIABETES AND HEART DISEASE.
TO SAY IT'S ONLY CANCER IT'S
GOING TO BE DETRIMENTAL TO THE
WHOLE BEING RESPONSIVE TO THE
POPULATION AND THE NEEDS OF THE
POPULATION.
SO WE'RE NOT EXCLUDING ANY
POPULATION.
BUT ALSO TRY TO DEVELOP CANCER
SCREENING AND CANCER PREVENTION
TECHNIQUES ALONG WITH THE
CURRENT CONDITIONS THAT THEY
FACE.
>> THANK YOU.
ANY MORE QUESTIONS OR COMMENTS?
>> I THINK TO THAT POINT I'M
JUST WONDERING -- AN OPPORTUNITY
TO PARTNER WITH OTHER ICs OR
THINK ABOUT WAYS TO CREATE
RELATIONSHIPS TO BE ABLE TO
LEVERAGE THESE CENTERS.
7
>> WE ARE OPEN TO PARTNERSHIPS.
AS YOU KNOW ABSOLUTELY IF OTHER
ICs ARE WILLING TO JOIN US WE
WOULD SURELY BE OPEN TO IT.
WE WOULD ENCOURAGE IT.
WE WOULD LOVE IT.
BUT YOU HAVE TO UNDERSTAND THAT
IT HAS TAKEN US FOUR YEARS TO
GET TO UNDERSTAND THIS COMMUNITY
AND UNDERSTAND THE CHALLENGES
AND EVEN PUT OUT A PAPER AND
WE'RE IN THE PROCESS OF WRITING
A SECOND PAPER ON LOOKING AT THE
INTERSECTIONALITY.
THAT IS A BIGGER EYEOPENER FOR
PEOPLE.
IF WE GO -- I WILL APPROACH
NHLBI WE'LL ASK THEM TO PARTNER
WITH US AND ANY OTHER INSTITUTE
WHO'S WILLING TO DO SO.
>> I JUST WANT TO THANK YOU FOR
THE WORK YOU'VE DONE.
KNOWING THAT YOU'VE STUCK WITH
THIS AND THANK YOU SO MUCH FOR
THE PROGRESS YOU'VE MADE.
>> THANK YOU.
>> DR. FREES JUST ADDED ADDING
THE PARTNERSHIP -- WOULD BE --
[ INDISCERNIBLE ]
ANY FURTHER COMMENTS OR
QUESTIONS.
>> I ENTHUSIASTICALLY MOVE TO
APPROVE
>> CAN I GET A SECOND
>> SECOND.
>> THANK YOU.
ANY FURTHER DISCUSSION?
OKAY.
THIS IS A NEW CONCEPT.
SO APPROVAL OR DISAPPROVAL.
MOTION IS TO APPROVE.
ANYONE DISAPPROVE?
JAKE YOU HAVE YOUR HAND UP BUT
I'M ASSUMING THAT IS FROM YOUR
LAST QUESTION.
GREAT.
JUST CONFIRMING.
ANYONE ABSTAINING?
NO.
SO UNANIMOUS APPROVAL AND NO
ABSTENTIONS.
>> OKAY.
7 OKAY.
THAT CLOSES OUR BUSINESS FOR
TODAY.
18 MINUTES BEHIND SCHEDULE.
MY APOLOGIES BUT REALLY ROBUST
DISCUSSION.
EXCELLENT PRESENTATIONS AND
DISCUSSION.
WE RESUME TOMORROW WITH OPENING
UP THE SESSION AT 1:00 TOMORROW
AND WE ASSUME CONCEPT REVIEWS
AFTER.
>> GREAT JOB BY THE NEW CHAIRS.
>> AGAIN TOMORROW, SAME TIME
SAME STATION.
>> 10:00 A.M. ON THE WEST COAST.
>> BYE ALL.